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ABSTRACT
Characterization of a gene expressed during human myeloid cell 
differentiation
Previous work using differential screening of a cDNA library- 
representing poly A+ RNA from the peripheral blood leukocytes of a 
chronic phase CGL patient had led to the isolation of cDNA clones 
representing mRNAs found at high abundance in this leukaemia compared 
to ANLL, CLL or normal peripheral blood leukocytes. The gene 
encoding one clone, pCG14, was also found to be expressed during 
normal human myelopoiesis in the neutrophilic myelocyte, a 
bone-marrow restricted neutrophil progenitor.
In this work the pCG14 cDNA was completely sequenced and shown to 
encode HNP3, one of a group of three closely homologous peptides 
called defensins. These peptides are found in abundance in the 
granules of neutrophils and are involved in destruction of 
micro-organisms. The human defensin peptides HNPl and HNP3 were 
shown to be encoded by two mRNAs differing at only one coding 
position that could be distinguished by PCR, and the regulation of 
the abundance of these mRNAs during myelopoiesis was investigated 
using induced differentiation of HL60 cells as a model system.
Four different genes, two encoding HNPl and two encoding HNP3, were 
isolated and one gene encoding HNPl was characterized in detail. It 
was shown to be comprised of three exons and its 5 ’-regulatory region 
shown to contain two functional promoters. Using the presence of a 
single nucleotide change which distinguishes the coding regions of 
HNPl and 3 genes, giving rise to a polymorphic Hae3 restriction 
enzyme site, individuals were shown to contain variable relative 
amounts of HNPl and HNP3 genes.
To explain these results it was hypothesized that individuals contain 
four defensin genes per diploid cell, one tandem pair on each 
chromosome 8. This model was tested using DNAs from a family where 
it was shown that defensin genes were inherited as a pair.
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1. INTRODUCTION
1.1 NORMAL HEMATOPOIESIS
Active hematopoiesis in humans begins extraerabryonically 
early in development in the embryonic yolk sac with cells 
subsequently migrating to the foetal liver. By birth,
however, the major site of hematopoietic stem cell 
differentiation has shifted to the bone marrow and lymphoid 
organs (Metcalf, 1971). The regulated production of blood 
cells is one of the most complex examples of multilineage 
differentiation in man. Essentially the process consists of 
a common set of highly proliferative pluripotent stem cells, 
residing mostly in the bone marrow, giving rise to large 
numbers of non-dividing red cells, neutrophils, basophils, 
eosinophils, monocytes, platelets and lymphocytes in the 
circulation. As many of these blood elements are short lived 
(for example, a few hours for neutrophils, a few weeks for 
erythrocytes), they must be continually replenished. 
Moreover, the levels of mature cells can respond dramatically 
to environmental stress. For example, in cases of severe 
infection, granulocyte counts can increase from the normal 
'-5000/ml to more than 50,000/ml, a variation corresponding to 
the production of 2 x 10" cells which can occur wfthic a 
matter of a few days (Williams et al„ 1933)..
13
1.1.1 Stem cells
It is thought that hematopoiesis originates from a 
multipotential stem cell, the main source of which by birth is 
the bone marrow. The stem cells are relatively few in
number, but can persist throughout life by undergoing 
proliferation to produce daughter stem cells. This process 
of self-renewal is the distinguishing feature of hematopoietic 
stem cells and is a characteristic shared by stem cells in 
other regenerating systems (Potten, 1983). The assay in
vivo for this type of cell was first developed by Till and 
McCulloch (1961) after it was recognised in the murine system 
that animals given lethal doses of irradiation (and thereby 
suffering bone marrow failure) could be saved by injection of 
unirradiated bone marrow cells (Ford et al, 1956) and that
these animals were restored in all hemato-lymphoid cell types 
by cells of bone marrow donor origin. Till and McCulloch 
(1961) performed the first quantitative experiments on bone
marrow restoration of lethally irradiated mice, showing that 
limiting numbers of bone marrow cells called CFU-S (colony 
forming units - spleen) gave rise to clonal colonies of
myeloid-erythroid cells in the spleen and bone marrow of the 
irradiated hosts. Subsequent studies using chromosomal
markers showed that each spleen colony was unlike any other 
and that certain distinguishing chromosomal markers in 
reconstitution experiments .could- be shared by cells of 
lymphoid as well as the myeloid lineages (V'u gt _ al , 1967 ;
14
Abramson et al, 1977). Recently, Lemiska et al, (1986)
confirmed and expended this finding using retroviruses as 
insertion markers to follow the progeny of single stem cells.
The spleen colonies in the irradiated mice also contained 
stem cells, moreover, since injection of cells from the spleen 
colonies into another lethally irradiated mouse also led to 
secondary spleen colonies in the recipient, shown by 
chromosomal markers to have been derived from the injected 
cells (Till and McCulloch, 1980). The vast self-renewal
capacity of these stem cells can in fact allow repopulation of 
the entire hematopoietic system of one animal from a single 
stem cell (Till and McCulloch, 1980). In may respects then, 
spleen colony forming cells (CFU-S) posses the charateristics 
of stem cells. However, more recent work by Magli et al,
(1982) has shown that CFU-S are heterogeneous; they include 
not only multipotent stem cells, but also more mature cells 
that have lost their capacity to fully re-establish 
hematopoiesis, although they often retain a multipotential 
na t u re.
Circulating blood itself has a low number of stem cells, 
although it characteristically lacks proliferative cells 
between the blast and mature cells in the developmental 
lineages (Metcalf, 1971). One implication of this
observation is that committed cells must mature elsewhere, act 
indeed there is impressive evidence that only in rue
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appropriate hematopoietic inducing microenvironment (HIM) in 
hematopoietic tissue will stem cells proliferate and 
differentiate.
The question as to what proportion of bone marrow cells 
are stem cells has been answered using the irradiated mouse 
system. Boggs et al, (1982) have shown that infusion of as 
few as lO^-lO^ marrow cells into an irradiated mouse is 
sufficient to restore hematopoiesis. Since a normal mouse 
has 3 x 10^ marrow cells, the infused amount represents only 
0.01% of this total. Since these transplant recipients have 
a normal lifespan and their hematopoietic system shows no 
evidence of decline with age (Schofield et al , 1986), this
implies that there must be a vast proliferative reserve built
into the hematopoietic system that would be sufficient to last
several times the normal lifespan.
1.1.2 Committed cells
Like stem cells, the committed progenitor cells are 
distinguished by the progeny they produce. This distinction 
is generally made on the basis of an in vitro analysis in 
clonogenic soft-gel culture systems (Metcalf, 1977). For
example, certain cells undergo proliferation and
differentiation in' vitro to produce colonies containing cells 
of several different lineages: neutrophils, megakaryocytes,
macrophages, ' basophils and erythroid Ceils (Johnson, .'.980. 
Such colonies can be obtained from all mammalian species sc
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far examined (mouse, rat, cat, dog, sheep, cows) including 
man. Since the colonies are clonal, the mature cells must be 
derived from a raultipotent cell called colony-forming cell 
(mixed) or CFC-MIX. Moreover, some of the colonies contain 
cells that can be plated in soft gels to produce more mixed 
colonies, which means that some of the CFC-MIX can themselves 
undergo self-renewal. In fact, some of the colonies derived 
from CFC-MIX may contain CFU-S, which would indicate a 
considerable overlap between these two populations (Metcalf 
and Burgess, 1982). Not all colonies undergo self-renewal, 
however, perhaps indicating the likelihood of heterogeneity in 
self-renewal capacity of CFC-MIX.
Lineage - restricted progenitor cells are also classified 
on the basis of the progeny they produce in clonogenic 
soft-gel systems. Granulocy te-macropliage colony — forming
cells, GM-CFC, undergo proliferation and development to 
produce netrophils and/or macrophages, depending on the growth 
stimulus used. The most primitive erythroid progenitor
cells, BFU-E (burst— forming units - erythroid) can also 
undergo proliferation in vitro. The cells thus produced,
CFTJ-E (colony-forming units - erythroid) migrate through the 
soft—gel system where they begin to synthesize hemoglobin 
thereby generating typical erythroid "bursts". 
Megakaryocyte, eosinophil and basophil colony-forming cells 
(Meg-CFC, Eos-CFC and Bas-CFC, respectively) can also be 
recognized by their ability to. undergo proliferation and 
differentiation in vitro to -p.ro duee mature progeny (Metcalf,
17
1977). All of these lineage-restricted progenitor cells are 
continuously generated from the multipotent stem cells and, in 
this way, a constant supply of mature cells is ensured and a 
balance is maintained throughout the different cell 
compartments. The central question of hematopoiesis, i.e. 
how this controlled process of self-renewal, commitment, 
proliferation and maturation is regulated, has been 
investigated in two main in vitro assay systems. These
systems are the in vitro soft-gel culture system of Metcalf 
(Bradley and Metcalf, 1966) and the long-term bone marrow 
culture system of Dexter et al (1977). The first system has 
strongly underscored the importance of colony-stimulating 
factors (CSFs) in the regulation of hematopoiesis and will now 
be discussed.
1.1.3 Growth factors in hematopoiesis
The development of semisolid culture systems supporting 
the clonal growth of hematopoietic cultures independently by 
Metcalf (Bradley and Metcalf, 1966) and Sachs (Ichikawa et al, 
1966) and the recognition that hematopoietic precursor cells 
are unable to survive or proliferate in vitro unless 
specifically stimulated (Metcalf, 1984), led to the discovery 
of a group of specific regulatory glycoproteins, the 
colony-stimulating factors, that stimulate cell proliferation 
and at least some aspects of the functional activity of 
various hematopoietic sub-populations iMetcall, 198*;« These
colony-stimulating factors were initially discovered to be
18
Fig.l Schematic views of hematopoiesis.
A: Interaction of colony stimulating factors (CSFs) with 
hematopoietic cells. The different progenitor cells 
shown are those identified by in vitro culture systems 
(see Section 1.1.3). CFU-GEMVl (colony-forming-unit
granulocyte-erythrocyte-monocyte-megakaryocyte), CFU- 
Meg (CFU-megakaryocyte), CFU-Eo (CFU-eosinophil), CFU- 
GM (CFU-granulocyte/monocyte), CFU-E (CFU-erythroid), 
and BFU-E (burst-forming unit-erythroid) . The abbrev­
iations for the hematopoietic lineages are : n, neutro­
phil; b, basophil; m, monocyte/macrophage; E, erythro­
cyte; e, eosinophil; M, megakaryocyte. The interactions 
of the different CSFs with the various lineages are as 
indicated. These interactions are based on analysis of 
mature cells found in colonies grown in the presence of 
CSFs. The sites of action are intended to indicate that 
at least some, but not all, progenitors of that lineage 
are responsive to the indicated CSF (Figure from Clark 
and Kamen, 1987) .
B: This is a simplified model of hematopoiesis in which 
various stages of normal development are represented 
by leukaemic cell lines (where available) which re­
semble the normal cell stage, using a number of cri­
teria such as reactivity with a panel of monoclonal 
antibodies, morphology, ultrastructure and histochem­
istry (see Section 1.2 ) . Considering the myeloid 
cell lineage, HL60 cells resemble immature myeloid 
cells (promyelocytes) although they are bipotent in 
vitro (ie they can be induced to differentiate along 
both the granulocytic and the monocytic lineages) 
unlike normal promyelocytes present in bone marrow.
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present in the conditioned media from a variety of normal and 
leukaemic cell lines, or from various tissues or activated T- 
lymphocyte cell clones (Metcalf, 1984). Several different 
colony-stimulating factors have been distinguished through 
careful analysis of the cell types found in hematopoietic 
colonies grown with various sources of growth factor activity 
(Bradley and Metcalf, 1966; Metcalf, 1984; Pluznik and 
Sachs, 1965). In the best characterized murine system, four 
major types have been identified. Two of these have proven 
to be relatively lineage-specific; that is, colonies grown in 
the presence of granulocyte-CSF (G-CSF) consist largely of 
neutrophilic granulocytes and their precursor cells (Metcalf 
and Nicola, 1983), whereas those grown in the presence of 
raacrophage-CSF (M-CSF, CSF-1) consist largely of macrophages 
(Stanley and Heard, 1977). In contrast, the colonies grown 
in the presence of multi-CSF (IL3) are generally found to 
contain many different lineages (Shrader, 1986; Ihle et al,
1983), whereas those found in cultures grown in the presence 
of granulocyte-macrophage-CSF (GM-CSF) are found to contain 
neutrophilic granulocytes, macrophages, eosinophils and other 
cell types. These results, in a model proposed by Metcalf 
and Nicola (1983), define a hierarchy of progenitor cells 
along the various lineages. In this model, G-CSF and M-CSF 
are postulated to support growth and proliferation of only 
relatively late progenitors already committed to their 
respective lineages. In contrast, GM-CSF is presumed to
interact additionally with somewhat earlier progenitor cells 
that are still capable of differentiating into neutrophils,
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eosinophils and monocytes. The multiplicity of activities 
attributable to IL3 is believed to be a consequence of its 
ability to support the growth of cells from relatively early 
pluripotent progenitors to mature cells of multiple 
lineages. In humans a set of four analogous factors have
been described each having properties similar to those of the 
corresponding murine G-, M - , GM- or Multi-CSFs (Metcalf, 1984, 
1985; Yang et al, 1986).
Before considering the role of these polypetides in vitro 
and in vivo in more detail, it is worthwhile mentioning that 
analogous regulatory proteins exist for hematopoietic cells in 
other lineages. For example erythropoietin has the general 
properites of a CSF (Miyake et al. 1977 ; Jacobs et al,
1985). This molecule is thought to act in a classical
hormonal fashion to promote proliferation and 
hemoglobinization of fairly mature erythroid progenitor cells 
(CFU-E). Production of this hormone occurs in the kidney and 
is regulated by the number of mature erythrocytes in the 
circulating blood and their oxygen-carrying capacity (Adamson 
et al , 1978) i.e. via a classical feedback loop control
system. Other less well characterised polypeptides with the 
general properties of CSFs include T-cell regulator (IL2) 
(Taniguchi et al, 1983)j B-cell growth factor (Yoshizaki et 
al, 1983) and a factor stimulating eosinophil differentiation 
in vitro (Sanderson et al, 1985).
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The most extensively characterised growth factors, G-CSF, 
M-CSF, GM-CSF and IL3 not only commit progenitors to 
differentiate, they are also required for cell survival in 
vitro in the absence of bone marrow stromal cells. This is 
not, however, a withdrawal into a quiescent state as can be 
seen in other growth factor systems such as PDGF and EGF 
stimulation of cultured fibroblast cell lines; hematopoietic 
cells cultured in the absence of growth factors die. Thus, 
in vitro these growth factors subserve several functions; 
survival, proliferation and differentiation, which are perhaps 
not mutally exclusive events. How then do these factors 
exert their pleiotropic effects in vitro? cDNAs encoding all 
the above factors from mice and humans have been cloned and 
have been found to be unrelated in nucleotide or amino acid 
sequence. By analogy with other growth factor systems, one 
would expect there to be specific receptors for the 
colony-stimulating factors and, since each factor is unrelated 
to any of the others, one prediction would be that there would 
be at least four such receptors. This prediction is indeed 
borne out. A single class of specific membrane receptor for 
M-CSF exists of mol.wt. 165KD (Morgan and Stanley, 1984; 
Guilbert and Stanley, 1980) with receptor numbers highest on 
cells of the moncyte-macrophage lineage (Byrne et al, 1981;
Chen et al, 1984). This receptor is structurally related,
and possibly identical tc, the c-fms proto-oncogene product 
that is expressed at high levels in mature macrophages (Sherr 
et al, 1985). M-CSF can sometimes support the proliferation
of granulocyte clones. (Metcalf onu Burgess, and m
accord with this is the finding that some cells of the 
granulocyte series also contain the 165KD M-CSF receptor 
(Shaddock et al , 1983). Interestingly, receptor numbers are 
relatively high (up to 50,000/cell) on some macrophage tumour 
cell lines, whilst lower numbers (3,000-15,000/cell) are found 
on mature monocyte-macrophages from various normal sources 
(Byrne et al, 1981; Stanley and Guilbert, 1981). The reason 
for this is unknown, but may represent an adaptation to cell 
culture.
A similar situation occurs with G-CSF. There exists a 
single receptor for this growth factor on the membranes of all 
murine granulocytic cells, receptor density increasing as the 
cells mature to postmitotic polymorphs (Nicola and Metcalf, 
1985). Receptors are however demonstrable on some cells of 
the monocytic lineage, but not on eosinophil, erythroid or 
lymphoid cells. Average receptor numbers for this growth
factor are low (5-500/cell), with an apparent dissociation 
constant for binding of 60-80 pmol/L. These two observations 
may be significant, since they imply that G-CSF is able to 
exert half-maximal proliferative effects on responding cells 
at low receptor occupancy.
For GM-CSF a slightly different situation exists. It 
appears that normal marrow cells have both high and 
low-aff inity receptors (average number 70/eell and 350/cell 
respectively) (Walker ard Burgess-, 1 v o ,<. Ail granulocytes,
numbers decreasing with increasing maturation and with mature 
eosinophils exhibiting half the receptor numbers of 
neutrophils. Significantly, no receptors are found on
lymphoid or erythroid cells. Despite the high and low
affinity types, it appears that there exists a single receptor 
of mol. wt. 51KD (Metcalf, 1986).
For IL3, high numbers of receptors of a single class have 
been observed on continuous hematopoietic cells lines 
dependent on this growth factor (Palaszynski and Ihle,
1984). Lower receptor numbers are observed on normal marrow 
cells (receptor numbers being ^50-1 ,000/cell) with all 
granulocytic, monocytic and eosinophilic cells containing the 
receptor. Similar to the situation with the GM-CSF receptor, 
receptor numbers decrease with increasing maturation although 
in this case eosinophils exhibit twice the number as mature 
neutrophils. Lymphoid or nucleated erythroid cells, moreover, 
do not contain the receptor.
It appears then that most murine granulocyte-macrophage 
cells simulatenously exhibit receptors for three or four 
CSFs. The function of this redundancy is not known, but 
clearly has some bearing on notions of lineage commitment. 
Perhaps, for example, the binding of cue factor to its cognate 
receptor somehow commits the cell to a particular lineage and 
also ensures that other lineage choices are obviated. There 
is some evidence from Walker et al (1985) that there exists a 
hierarchical decrease in abundance of growth factor receptors
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in response to factor binding. They have found that although 
there is no direct competition for receptor binding between 
the CSFs, binding of IL3 to its receptor can lead to 
down-raodulation of receptors for all other CSFs. Binding of 
GM-CSF to its receptor, furthermore, does not influence IL3 
receptor binding but can down-modulate receptors for G-CSF and 
M-CSF. Finally, high concentrations of M-CSF down-modulates 
GM-CSF receptors and high concentrations of G-CSF 
down-modulate receptors for M-CSF. The mechanism of this 
down-modulation is unknown, but could clearly operate at a 
number of levels of control, transcriptional or 
post-transcriptional. Elucidating exactly what controls are 
operating in such an in vitro system is of paramount 
importance in understanding the molecular basis of commitment, 
but will clearly be a difficult task simply due to the small 
numbers of pluripotent stem cells that can be isolated and 
characterised biochemically. Model systems consisting of one 
cell type which can grow in cell culture in sufficient numbers 
for molecular analysis may provide some insight as to genetic 
changes underlying commitment and development and will be 
discussed later.
It is apparent, then, that IL-3, GM-CSF, G-CSF and M-CSF 
can support the survival,. proliferation and development of the 
appropriate target cell in vitro. This does not, however,
prove that they exert the same influence in vivo. Both M—CSF 
and GM-CSF have been detected in the serum and urine of 
animals and man (Metcalf, 1986). In terms of roles for these
26
molecules in vivo, it may be significant that substantial 
increases in the circulating concentrations of both GM-CSF and 
M-CSF are observed in animals treated with bacterial 
lipopolysaccharides, and this correlates with GM progenitor 
cell proliferations (Whetton and Dexter, 1986). 
Additionally, the CSFs can stimulate a number of functional 
aspects of mature granulocytes, eosinophils and macrophages. 
These effects include survival, cell mobility, shape, 
phagocytic activity, synthesis of biologically active 
molecules, antibody-dependent cytotoxicity, autofluorescence 
and expression of various membrane markers (Metcalf, 1984).
The accumulated evidence suggests that in vivo the role of 
the colony-stimulating factors is to protect the body from 
infective organisms (helminths, protozoa and bacteria) and to 
stimulate accessory cells in the immune response. Thus high 
local or circulating levels of these growth factors may 
represent the outcome of a peripheral immune response rather 
than having a bearing on marrow myeloporesis.
1.1.4 Growth factors and commitment
It is clear that hematopoietic differentiation in 
Metcalf’s in vitro1 system requires the presence of growth 
factors that are progressively restricted in their biological 
activities and target cells. '■ uowever, as pieviously 
mentioned, one of the fundamental unanswered cues Lions 
concerns the process by which cells re th*g. capacity to
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respond to growth factors and just how the commitment process 
operates. For example, multipotential stem cells can respond 
to IL3, but not to M- or G-CSF. Presumably this means that 
stem cells hve receptors that respond to IL3 but not to M- or 
G-CSF. It is possible, then, that commitment involves
activation for the gene coding for the M- or G-CSF receptor, or 
it may be that c o n t r o l  o p e r a t e s  at the 
t ranslat ional/post-translational level.
Whichever is the case, the expectation would be that IL3 
could then initiate the production of all the subsequent 
lineages. In the ideal situation, one would wish to isolate 
such IL3-responsive pluripotent stem cells and determine 
whether they are indeed expressing each of the receptor genes 
at the mRNA. and protein levels and also whether they are
expressing each receptor in a correct membrane orientation 
suitable for interaction with growth factor. If such a
system were avqrlable, one would be able to test directly
whether simple non-expresion of growth factor receptor genes 
was involved in commitment. Such systems, however, are as 
yet not available.
Some recent studies on a particular effector of 
hematopoiesis, a molecule known as hematopoiet m — 1 (Hi ) may, 
however, be shedding ligbt. on the nature of commitment i_n
vitro. This factor, first described by. Bradley and Hodgson 
(1979) acts synergistically with gikQC growth kb
recruit more colony—forming celiS by Hciy
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no growth stimulatory effect. Using fluorenscence-activated 
cell sorting (FACS) to obtain marrow cells enriched for CFU-S,
Lord and Spooncer (1986) have shown that in the absence of HI,
4-40% of cells produce multilineage colonies in vitro when
cultured in the presence of IL3, i.e. this proportion has the 
receptor for, and can respond to IL3. When this stem
cell—enriched fraction is cultured in vitro in the presence of 
only Hi they die, but when IL3 and HI are combined, however, 
50-100% more colonies are produced than in the presence of IL3 
alone. Therefore, it seems that HI acts to recruit more
stem cells to an IL3-responsive state. Most interesting, 
however, is the interaction between M-CSF and HI. With M-CSF 
alone no colonies are produced from the CFU-S-enriched 
fraction and the stem cells die as would be expected if they
did not express receptors for M-CSF. However, in the
presence of M-CSF and HI, as many colonies develop as in the 
presence of IL-3 and HI. One interpretation of this is that
HI facilitates the development of multipotent stem cells to a
stage at which they can respond to M-CSF, i.e. HI commits the 
cells to an M-CSF-responsive state. An immediate possibility 
then would be that HI and possibly other as yet unidentified 
hematopoietic regulators may act by inducing the expression of 
parti cular growth factor receptors on pluripotent stem 
cells. Perhaps by allowing these cells to express the
receptors for all the growth factors., the particular lineage 
finally chosen could be decided by..#Mchs growfli f i a t f f r r  i s  
present and can actively bind to its r«teffor. Th #
hypothesis cannot be totally . corre&fh howeVetV sifU-®- cindf
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Spooncer (1986) have also shown that preincubation of enriched 
stem cells with HI followed by its removal and addition of 
M-CSF alone leads to stem cell death; both must be present
simulatenously to show the enhanced colony development 
effect. This would seem to imply that M-CSF receptor
expression per se is not sufficient to maintain a response to
M-CSF. If, then, the role of HI is indeed to induce
expression of growth factor receptors, as this work implies,
the question of how this is accomplished is a fundamental, but 
as yet unresolved, one.
1.1.5 Role of the hematopoietic microenvironemnt
The extreme complexity of hematopoiesis is further 
exemplified by the results from another in vitro sytem, the 
long-term bone marrow culture system of Dexter et al (1977). 
The development of this system, in which hematopoiesis can be 
maintained, not just for a few days as in the soft-gel in. 
vitro system, but for several months, arose from experiments 
and observations on the importance of the hematopoietic 
microenvironment in hematopoietic development.
Initial experiments indicating the role of the 
hematopoietic microenvironment were on mice with congenital 
genetically determined macrocytic anaemias, termed Steer iSL) 
and W, and used the 'irradiation/spleen colony-Ccrming assay 
previously described. CFU-S are greatly reduced ar absent in 
W anaemic mice, but' are present in 'normal •Lumbers. 5L M.C& 
(Russel and Bernstein, 1966), cons is ten:: Vtf rth Vfe* th a t
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lesions in W mice are due to intrinsic defects in 
hematopoietic stem cells, whereas in SL mice the defect 
resides in the hematopoietic microenvironment into which these 
cells migrate (Russel and Bernstein, 1966; Bernstein et al, 
1968; Bennett et al, 1968; Sutherland et al, 1970). Thus, 
W mice, both irradiated or unirradiated, support spleen-colony 
formation after in oculation of bone marrow from non-anaeraic 
1itter-mates or from SL mice, whereas spleen-colony formation 
does not occur in SL mice after normal marrow in oculation.
The hematological defects in W mice can, thereore, be 
cured by an inoculum of marrow cells from SL mice, and the 
macrocytic anaemia of SL mice can be reversed after grafting 
of neonatal spleen or whole bone marrow from W anaemic mice as 
a source of non-defective hematopoietic microenvironment.
In Dexter’s in vitro system, stem cells and committed 
progenitor cells can be shown to be present in culture, 
indicating that the system supports both self-renewal and 
commitment to differentiation. Bone marrow stromal cells, in. 
the form of an adherent multilayer, are the crucial feature of 
this in vitro system, forming a mechanical and functional 
support in a similar manner to that occurring in vivo (Dexter 
and Allen, 1983). Moreover, specific hematopoietic
cell/stromal cell interactions seem to be reproduced in this 
system. Thus when adherent layers cf stromal cells prepared 
from the bone marrow of SL mice are used to support 
hematopoiesis in these cultures the he.matopo.i.etic sleir. cej..s
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do not survive. However, when marrow cells from SL mice are 
added to normal adherent layer bone marrow stromal cells, 
survival of stem cells and hematopoiesis can take place 
(Dexter and Moore, 1977). This result proves that the
hematopoietic microenvironment is located in the bone marrow 
and also that the hematopoietic defect in the SL mice is in 
the stromal cells of the bone marrow.
A second feature of these long-term cultures is that 
hematopoiesis is sustained in the absence of added growth 
factors. Since it is known that isolated hematopoietic cells 
(grown in soft-gel clonogenic systems) die in the absence of 
growth factor, this would imply that the marrow stromal cells 
provide the necessary extracellular matrix and growth factors 
essential for establishment of hematopoiesis. Furthermore, 
the production of these regulatory molecules is obviously 
stringently controlled in these long-term cultures, since
homeostasis is maintained for many months, i.e. a balance is 
maintained between stem cells self-renewal/differentiation and 
growth and development of the committed progenitor cells.
How then is this exquisite regulation acheived? Several
points have emerged concerning the interactions of stromal 
cells (which comprise a heterogeneous collection of various 
cell types such as endothelial cells, fibroblasts, adipocytes 
and macrophages) with hematopoietic cells (Dexter et al , 1977
and 1984). Firstly, the hematopoietic cells must be in
direct contact with the stromal cel. xs to permit rnei-
survival, growth and development: ir tuey are preventt c
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attaching to tne stroma, they die. Secondly, discrete
stromal elements show characteristic interactions with the 
different maturing myeloid cells and with each other. Dexter 
has suggested (Dexter and Spooncer, 1987) that this might be 
indicative of different environmental 'niches' existing that 
could specifically modulate lineage development. In this 
regard, it may be significant that extracellular proteoglycans 
produced by stromal cells have been found to bind GM-CSF and 
in this way possibly mediate stromal cell/hematopoietic cell 
interactions (Gordon et al, 1987; Roberts et al, 1987). How 
might such niches (better described as hematopoietic inducing 
microenvironments (HIMs)) ensure that cells of only one 
lineage type are retained? An immGdf S.ate possibility is that 
cells of a particular lineage might somehow bind to HIMs 
through specific adhesion molecules in the extracellular 
matrix (ECM). A possible candidate for such a molecule, 
haemonectin, has been described by Campbell et al (1987). 
This protein, of approximately 60KD relative molecular mass, 
is a lineage-specific attachment molecule for granulocyte 
lineage cells and is found only in bone marrow ECM. Lastly, 
stromal cells from drug-treated animals or congenitally 
anaemic mice may be compromised in their ability to support 
hematopoiesis, which indicates that some myeloproliferative 
disorders may in fact represent a defect in the stromal cell 
environment rather than the hematopoietic target celis*
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1. 1 •6 Role o£ growth factors in long—term marrow cultures and in 
vivo
The expectation that marrow stromal cells will themselves 
produce growth factors is a strong one. However, if they do 
produce growth factors, these are not normally released as 
diffusible regulatory molecules since both Dexter et al (1977)
and Quesenberry et al (1984) have shown that, not only is
direct contact of the hematopoietic cells with the stroma 
required to stimulate hematopoiesis, but that media 
conditioned by the growth of marrow stromal cells contains 
little or no colony-stimulating factor activity. The
implication of this is that growth factors, presumably produced 
by stromal cells, represent surface-bound molecules that exert 
their effects through direct cell-to-cell contact. In this 
respect, it is worthwhile to note that Gough et al (1986) have 
suggested that a variant cDNA clone of IL3 with an upstream 
exon 14kb from the main body of the gene may encode a larger 
IL3 present on the cell surface. This could conceivably be 
produced by differential splicing of the IL3 raRNA in stromal 
cell s.
One immediate question is whether the growth factor 
stimuli operating in long term cultures are the same factors 
defined in the soft-gel clonogenic assays. Initial
(unpublished) in situ hybridisation studies by Dexter have 
failed to detect mRNAs for IL3, GM-CSF or G-CSF in marr.ou 
stromal cells of hematopoietieaily active cultures (Dexter and
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Spooncer, 1987). Thus, either these particular factors are 
not synthesized by stromal cells (and as a corollary, they are 
not essential for stromal cell—associated hematopoiesis) or 
they are produced at levels below the limit of detection by 
present molecular techniques but in biologically active 
amounts. This latter possibility is not as unlikely as it 
appears when it is borne in mind that receptors for 
hematopoietic cell growth factors on target cells are few in 
number (100-1000) and that relatively few receptors (5-10%) 
have to bind a growth factor to elicit a maximal response 
(Nicola and Metcalf, 1985; Park et al, 1986). Dexter has 
also found, perhaps significantly, that one of the factors 
secreted in appreciable amounts by stromal cells is 
hematopoietin-1 (Hi ). This factor may act in helping
progenitor cells to be growth factor-responsive in situations 
where growth factor alone initiates no response.
These results, showing that stromal cells by themselves 
are capable of stimulating hematopoiesis in the absence of 
detectable growth factors, could be interpreted as implying 
that some of the growth factors previously described (IL3, 
GM-CSF, G-CSF, M-CSF) may in fact represent in vitro artifacts 
rather than in vivo biological response-inducers or modifiers 
of hematopoiesis. Recent results using recombinant factors, 
however, are not in agreement with this inteipretation. 
Iniection of IL3 into the mouse can cause a rapid recruitment 
of quiescent stem cells (CFU-S) into the cell cycle (Lord et 
al, 1986). Continued administration of 1L3, moreover, leans
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to a major disturbance in the kinetic behaviour of stem and 
progenitor cells in the bone marrow; it also causes the mouse
spleen (normally a lymphoid organ) to increase in size and
cellularity, become actively myelopoietic, and show a dramatic 
increase in the numbers of CFU-S and committed progenitor 
cells (Metcalf et al, 1986; Kinder et al, 1986). The
response to G-CSF is also dramatic in the mouse, inducing a 
10-20 fold increase in circulating blood leukocyte levels and 
increasing the total number of multipotent stem cells. 
Studies in primates treated with GM-CSF have reported effects
similar to those in mice. Donahue et al (1986) have shown,
for example, that administration of GM-CSF to normal macaque 
monkeys leads to a tenfold rise in circulating leukocyte 
levels. The evidence is clear, therefore, that growth
factors can have some role in hematopoiesis, although whether 
they do under normal circumstances is unclear.
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1.2 NORMAL MYELOPOIESIS
Three major compartments of differentation during normal 
myelopoiesis have been distinguished. As previously
described (Section 1.1.1) the most primitive compartment is 
characterized by pluripotent stem cells. These stem cells 
have a large proliferative potential including the potential
for self—renewal, and serve as the cellular basis for a 
self-maintaining hematopoietic clone containing multiple 
lineages. The second major compartment of differentiation
in the marrow consists of progenitor cells committed to a 
single hematopoietic lineage. Although these cells have
great proliferative potential and have acquired sensitivity to 
the regulatory mechanisms of their lineage, they are not
self-renewing. When triggered by specific stimuli, they
undergo terminal differentiation and become effector cells 
with various functions. The third and most familiar stage of 
myelopoiesis consists in cells identifiable by morphologic 
features e.g. a characteristic nuclear configuration and the 
presence of obvious cytoplasmic granules. These cells are
either fully mature PMN or those undergoing the last few
divisions leading to maturity.
1.2.1 Cell biology of myelopoiesis
Myeloid, cells are located in humans in three main 
locations: bone marrow, peripheral blood and tissues. Bone
marrow is the. .site of the importoflt processes of proliferation
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and terminal maturation of neutrophilic granulocytes (from 
committed cells, myeloblasts, to mature PMN). Proliferation, 
consisting in approximately 5 divisions (Bainton, 1977), takes 
place only through the first three stages of neutrophil 
maturation (myeloblast, promyelocyte and myelocyte). At the 
myelocyte stage, the cells become 'end cells' (cells no longer 
capable of mitosis) and enter a large storage pool. About 5 
days later they are released into the blood where they 
generally circulate for about 10 hours. Their fate after 
they have migrated to tissues is generally senescence and they 
generally live for only 1-2 days (Bainton, 1977).
Prior to the development of clonogenic soft-gel culture 
systems and the culturing of primitive hematopoietic cells and 
their differentiation in response to colony-stimulating 
factors (Section 1.1.3), the main descriptions of the cell 
biology of myelopoiesis came from examination of suitably 
stained smears of bone marrow material by microscopy. This 
approach has been instructive and has led to the 
identification of distinctive stages of myeloid development 
during which immature ■ committed cells (myeloblasts) 
differentiate to mature PMN.
The immediate precursor of mature granulocytes is a cell 
called the metamyelocyte. Morphologically this cell contains 
an Indented .or .horseshoe-shaped HaclettJ w ith  e x te n s iv e  
clumping of chromatin. The ifieuamje.1 ocyie dees  not d iv ide  end 
it not normally , found in peripheral blood
Preceding the metamyelocyte is the myelocyte. The
myelocyte stage begins with the formation of the first 
specific granules (the sites of strorage of a number of 
proteins involved in PMN function including lysozyme, 
collagenase, lactoferrin and alkaline phosphatase) and ends 
when the cell has a full complement. Late myelocytes can be 
firmly classified as neutrophilic, eosinophilic or basophilic 
because of the characteristic staining of the granules, 
classification is more difficult in earlier stages. All
myelocytes can be readily distinguished from precursors of 
monocytes, lymphocytes and megakaryocytes. The myelocyte is 
a fairly large cell, 16-25 um in diameter with a rounded 
nucleus. The chromatin is mostly loose, though some clumping 
appears late in this stage, and one or two nucleoli are 
usually present. Myelocytes do divide and 1-2% of cells are 
typically in mitosis. Early myelocytes have deeply
basophilic cytoplasm, but this is lost during the stage and 
late myelocytes have faintly pink cytoplasm. The specific 
granules synthesized during this stage of myeloid development 
are formed by the Golgi complex. They vary in size and shape 
and are typically spherical ( 200 nm) or rod-shaped (1j0 x
1000 nm). Kinetic studies on human cells indicate that
about three divisions occur at this stage of maturation 
(Cronkite and Vincent, 1969).
The earliest cell that can bo identified with eertaxuty 
as a neutrophil precursor is the •promyexocyut. This stag- of 
maturation is characterized by the £ to duct art*! acc^mu^at ion
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of a large population of peroxidase-positive granules that 
vary in contour and size; most are spherical ( ~  500 nm), but 
there are also ellipsoid, crystalline forms as well as small 
granules connected by filaments. Morphologically,
promyelocytes are of rather variable size (15-20 um) with a 
large, rounded central nucleus, usually containing one or two 
nucleoli, and a small amount of deeply basophilic cytoplasm.
Overall, granulocyte precursors constitute about 60% of 
all the cells in bone marrow. Of this about 5% are
promyelocytes, 12% myelocytes, 22% metamyelocytes and 20% 
mature PMN. These figures are, in fact, averages with a very 
considerable variance from individual to individual. They 
also vary within an individual in response to infection.
1.2.2 Neutrophils: cellular and functional aspects
Neutrophils, the terminally differentiated end-cells of 
myelopoiesis are the most abundant human white blood cell 
(typically 50—60%) in peripheral blood. These cells are 
involved in a number of body processes including inflammation
and destruction of invading microorganisms. These cells show 
a variety of behaviours, the most important of which, 
chemotaxis, allows the cells to cross two
boundaries (to leave bone marrow and enter tissues,) to reach
sites of tissue damage and infection. The totax amount ol 
neutrophils can be regulated suc.i tiex..- t.jinbc.. -.1
peripheral blood can vary more than tt-n-fola. Infection,
inflammation, and stress have been s h o w n  ..nen .c i t . ' - h e
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rate of production of neutrophils from precursors. 
Additionally, such conditions can shorten the time usually 
required for each stage of neutrophil maturation, decrease the 
time mature neutrophils reside in the bone marrow and result 
in the release of immature neutrophil precursors into the 
circulation.
Neutrophils are equipped with a variety of specific 
proteins and reactive compounds which allow their specific 
responses to infection. The most prominent cytoplasmic
constituents of neutrophils are the granules, which are 
visible by light microscopy and have given the cell its 
alternative name of 'granulocyte*. There is considerable 
variation in granule morphology among species, but at least in 
the rabbit and in man there are two main types.
The azurophil granules constitute 10-20% of the total 
population. In electron micrographs these granules are
dense, with a diameter of about 0.5 um and are surrounded by a 
unit membrane. The specific granules, the other main granule 
type, are smaller (0.2 um), stain faintly pink with Wright's 
stain, and are also surrounded by a unit membrane. The two 
granule types can be separated by ultracentrifugation and 
their constituents have been analyzed. Many of the
constituents of azurophil (primary) and specific (secondary) 
granules have been identified. Primary granules contain, two 
of the cell's most' abundant proteins, deiensins arid 
myeloperoxidase, involve* in oxygen™i/t<5teffcncgnt and -dependent
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microbial killing, respectively. The secondary granules also 
contain antimicrobial proteins including lactoferrin (involved 
in sequestration of iron, required for bacterial growth) and 
various collagenases.
Both primary and secondary granules are enveloped, thus 
protecting the cell from intracellular damage. The envelope 
surrounding granules is also vital to the processes of 
phagocytosis and degranulation whereby micro-organisms are 
ingested by neutrophils into phagocytic vescicles which fuse 
with granule membranes allowing direct contact of granule 
constituents with microorganisms. The molecular nature of 
this phenomenon is complex and only partially understood. 
The initial recognition process involves a number of specific 
proteins covering the microorganism and receptors on the 
neutrophil surface. Wright and Douglas (1903) first showed 
that human serum contains both heat-stable and heat-labile 
factors that dramatically enhance the ability of blood 
neutrophils to ingest Staphylococci. These factors, which 
include IgCJ and complement C3, were later shown to act by 
binding to bacteria. Neutrophils recognize the coated
bacteria via specific receptors for IgQ and C 3 , and 
phagocytosis follows. Phenomenclogically, phagocytosis is a 
process whereby, opce a microorganism is attached to the PMN, 
pseudopods pass around each side of it, meet, and then ruse 
together. The microorganism is enclosed in a pouch of ce.>.i 
membrane, the inner layer of wnico 0 r.L-,a.’. . - h e  outej.
layer of the cell membrane. Ibf. voucicle ?s
&
originally connected to the cell surface by two opposed layers 
of cell membrane but these soon disappear freeing the vescicle 
with its contained microorganism.
It was first observed by Hirsch and Cohn (1960) that, 
following phagocytosis in vitro, there occured a loss of 
neutrophil granules and that the extent of loss varied with 
the number of microorganisms phagocytosed. Careful electron 
microscopy studies have shown that engulfment of particles is 
accompanied by the assembly of contractile elements around the 
developing vescicle which are sequentially removed starting at 
the apex of the vescicle as it moves towards the apex of the 
cell (Stossel, 1988). Granules then fuse with the vescicle 
and discharge their contents (Zucker-Franklin and Hirsch, 
1964; Weissmann et al, 1971).
There is evidence that degranulation is an ordered 
process. The neutrophil contains at least two and probably 
three morphologically distinct populations of granules and 
there is evidence that secretion from them may be under 
separate control (Lew et al, 1986). Specific granules, then, 
seem to interact with the phagosome earlier uhan do the 
azurophil granules and perhaps contribute the first events cn. 
microbial killing such as removal of iron (by i.nctui.ei'rii.'.1 c.nd 
breakdown of the outer envelope of oaCterLa (cy > su/-.y mo> •»
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1.2.3 Neut rophil anti imicrobial ms ch. a. n is ms
One of the main functions of neutrophils is their 
capacity to ingest and destroy organisms, both bacterial and 
fungal (Klebanoff and Clarke, 1978; Spitznagel, 1977). 
Neutrophils destroy invading microorganisms by two principal 
mechanisms. One of these depends on production of reactive 
oxygen intermediates (ROI) by stimulated phagocytes. These 
ROI such as H2O2 (hydrogen peroxide) and OH* (hydroxyl 
radical) can act directly or in concert with other granulocyte 
components, such as myeloperoxidose, to damage or kill 
ingested microbes (Klebanoff and Clarke, 1978; Root and 
Cohen, 1981). In addition to such oxidative and
peroxidative microbicidal mechanisms, neutrophils are equipped 
with antimicrobial mechanisms that can operate independently 
of ROI (Spitznagel, 1984; Elsbach and Weiss, 1983). Thus 
neutrophils obtained from patients with chronic granulomatous 
disease (defective in production of ROI), or neutrophils 
tested under anaerobic conditions, retain substantial efficacy 
against certain bacteria and fungi (Spitznagel and Okamura, 
1983; Vel et al, 1984).
Studies of oxygen-independent microbicidal mechanisms, 
have shown that broken cell preparations from neutrophils can 
be fractionated, and that certain cell fractions are ^apabJe 
of killing a range of both Gram-positive arm iT.rar,i-iiegci.j.ve
bacterial species. Hirsch (1956) was the .  •
a protein-rich fraction from acid-exui.dti.au' ..eu.,
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’phagocytin* had potent bacteriocidal activity. The
discovery of the degranulation phenomenon whereby membranes of 
the granules and the phagocytic vacuole of neutrophils fuse 
covering phagocytosed bacteria with granular contents (Hirsch 
and Cohn, 1960; Section 1.2.3) further implicated granular 
substances in microbicidal activity. A more detailed
dissection of neutrophil granule constituents with 
bactericidal activity by Zeya and Spitznagel (1968) led to the 
partial resolution of a phagocytin-1 ike fraction into a series 
of apparently low molecular weight (3-8 KD) proteins with
overlapping microbicidal activity towards a spectrum of both 
Gram-negative and Gram-positive bacterial species. 
Mechanistically, these (^“independent activities appeared to 
be relatively fast-acting, with killing of microorganisms
accompanied by little structural disorganisation of the 
organism (Elsbach and Weiss, 1988). Thus E.coli treated with 
crude neutrophil extracts, for example, have been shown to 
incur subtle envelope alterations involving the outer membrane 
(in less than one minute) after treatment, despite continued
protein and nucleic acid metabolism for at least one hour 
(Elsbach et al, 1973).
A number of distinct microbicidal proteins have now been 
identified and some partially characterised. These proteins 
are found in both primary (azurophilic) and secondary 
(specific) granules. Some are typical lysosomal hydrolases
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capable of degrading microbial macromolecules, such as 
elastase, collagenases, lysozyme, chymotrypsin-1ike protease 
(Cathepsin G), lipases, sulphatases and phosphatases. 
Others, amongst which include bacteri cidal permeability 
increasing protein (BPI), defensins (see Section 1.2.4) 
lactoferrin, Bj2-binding proteins and major basic protein have 
no known catalytic activity.
Two of the best-studied microbicidal proteins involved in 
02-independent killing are defensins and BPI. BPI is
present in primary granules of both human and rabbit 
neutrophils (Weiss et al, 1978; Elsbach et al, 1979) and is a 
possible candidate for the previously described activity that 
kills E.coli with minimal apparent initial damage to bacterial 
stru cture.
Human and rabbit BPI are similar in their biological 
effects and show identical target specificity. The protein 
is potently bactericidal toward a broad range of enteric 
Gram—negative bacterial species and strains. However, even 
at concentrations of up to 100-fold higher it is non-toxic to 
all of the Gram-positive bacteria and eukaryotic cells tested 
(Elsbach and Weiss, 1988).
Studies on BPI have addressed the question of how the 
molecule acts in such a way as to increase permeability within 
one minute despite . continued metabolic activity oi une 
microorganism for at least one houi,. Mt-.ch<aui,.t^  c.c....l> , -i'ar
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elements have been identified in the interaction of BPI with 
susceptible bacteria; (i), insertion into the outer membrane 
of the Gram-negative bacterial envelope through electrostatic 
and hydrophobic forces; (ii), irreversible loss of 
colony-forming ability of the cells within 30 seconds of 
exposure to BPI; (iii), a reversible increase in the 
permeability of the outer membrane for normally impermeable 
hydrophobic substances; and (iv), a reversible and highly 
selective activation of enzymes degrading bacterial 
phospholipids and peptidoglycans (Elsbach and Weiss, 1988).
The specificity of BPI for Gram-negative bacteria and the 
highly discrete envelope alterations that are associated with 
its actions appears to be explained by the unique composition 
and organisation of the Gram-negative bacterial outer membrane 
with its negatively-charged 1ipopolysaccharides (LPS) which 
allow homing-in of the highly-basic BPI (Weiss et al, 1983).
Although binding is necessary for the effects of BPI on 
bacterial multiplication and outer envelope it is not 
sufficient. Post-binding steps apparently involving
hydrophobic interactions must follow (Weiss et al, 1983).
This dependence on post-binding steps can be demonstrated by 
creating conditions that impede hydrophobic interactions 
without preventing protein binding. Under such conditions, 
the bacteria can be rescued from the bactericidal effect. 
(Weiss et al, 1983). However, the primary irreversible
event that leads to bacterial death is unknown.
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Defensins, small peptides or Mr. 4000 present in secondary 
granules of PMN from several species, are one of the main 
effectors of oxygen—independent bactericidal activity of 
neutrophils. These peptides were first described by Zeya and 
Spitznagel (1968) as bactericidal components of an arginine- 
and cysteine-rich cationic protein fraction from granules of 
rabbit PMN. Acid extraction of granule-rich cell fractions 
solubilizes large quantities of these cysteine-rich peptides 
that can be separated by preparative electrophoresis and HPLC 
into several closely homologous single peptides (Selsted e£ 
al, 1984; 1985a). Two have been purified to homogeneity
from rabbit alveolar macrophages (MCP1 and MCP2, Selsted et_ 
al, 1983), six from rabbit peritoneal neutrophils (MCP1, MCP2, 
NP3a, NP3b, NP4, NP5, Selsted et al, 1985a) and three from
human neutrophils (HNPl-3, Ganz et al, 1985; Selsted et al, 
1985b). The primary structures of all eleven of these
defensins have been determined and both the rabbit NP2 and the 
human HNP1 have been crystallized (Westbrook et al , 1984;
Stanfield et al, 1988). All defens in. peptides isolated thus 
far contain between 28 and 32 amino acids and share at least 
11 residues, including six cysteines without apparent free S3, 
groups.
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A number of roles have now been ascribed to these 
peptides including tumour cell cytolysis (Lichtenstein et al, 
1986 and 1988) and macrophage chemotaxis (Territo et al, 
1989). The most studied role of these peptides however is 
that of inactivation of bacteria, fungi and enveloped 
viruses. A large body of evidence now exists that these 
peptides can inactivate bacteria (Selsted et al, 1985b; Ganz
et al > 1985; Viljanen et al, 1988; Lehrer et al, 1988a)
certain fungi (Selsted et al, 1985c; Lehrer et al, 1985;
Lehrer et al, 1988b) and enveloped viruses (Lehrer et al,
1985b, Daher et al, 1986).
1.2.5 Activities of human defensins against microorganisms
Three human defensin peptides have been isolated and 
characterized. As shown in Figure 12., HNP1 and HNP3 are 
identical in amino acid sequence apart fro/y* their N-terrainal 
amino acid (alanine in HNP1, aspartic acid in HNP3, whilst 
HNP2 lacks this N-terrainal residue (Selsted et al, 1985b).
All three peptides can be isolated from PMN where they are 
present in large amounts (30-40% of total granule protein, 
Ganz et al, 1988). Ultrastructural iramunochemistry has
localized these peptides to the azurophilic granules \.Ganz et 
al, 1985). Ganz et al (1985) have purified defensins HNP1, 
HNP2 and HNP3 and investigated their relative capacity to 
inactivate various bacteria. Interestingly, they round th<i^  
a mixture of HNP1 and HNP2 were iust as active as a mixture of
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all three peptides. HNP3 was less microbicidal against four 
out of five of the bacterial strains tested, although against 
one strain it had similar activity to HNPsl and 2.
Daher et al (1986) have also addressed the question of 
the relative activities of HNP1-3. Since it was already 
wel 1~established that neutrophils could inhibit viral 
replication (Rouse, 1981; Allison, 1974) they tested the 
three defensins’ capacity to inactivate the enveloped human 
virus, HSV-1. In an in vito plaque-reduction assay, all 3 
defensins had equal activity. Additionally, HNP1 was found to 
inactivate several other enveloped viruses such as 
cytomegalovirus, vesicular stomatitis virus and influenza 
virus. However two non-enveloped viruses, echovirus and
reovirus were resistant to inactivation. Interestingly, a
similar study has been performed with rabbit defensins (Lehrer
et al, 1985b) and a functional homology shown between the
human defensins HNP1, 2 and 3 and MCP1 and 2, two rabbit
defensins expressed in both alveolar macrophages and 
neutrophils. MCP1 and 2 are identical in sequence except
for an amino acid substitution (arginine in MCP1 for leucine 
in MCP2) (Selsted et al, 1983). In this respect they are
similar to HNP1 and 3 which are also identical in primary 
sequence except for one residue Iff. nine in. HMP1, aspartic 
acid in HNP3; Selsted et al , 1985b), bike HHPl and 3, MCP1 
and 2 are potent in activating O th er  rabbit
defensins NP3a, NP3b, NP4 Qf\d NfVS whrch Qrt f M f :  -more
divergent in sequence than MCP I 1 haV€ , confcras-.. f <16
HSV-l-inactivating capacity (LehflSf
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The three human defensins have also been tested in vitro 
for their ability to inactivate certain fungi (e.g.
albicansy Lehrer et al, 1988b). The relative activities of 
HNP1, 2 and 3 when the peptides were tested against C. albicans 
were similar to that obtained with bacteria. Thus, both HNP1 
and HNP2 had significant activity against fungi, whilst HNP3 
had no detectable activity. Thus the single amino acid
difference between HNP1 and HNP3 results in a marked 
difference in the capacity of the two peptides to inactivate 
both bacteria and fungi, though interestingly not enveloped 
viruses.
1.2.6 Other activities of defensin peptides
As well as their capacity for inactivating phagocytosed 
microorganisms, there is evidence that human defensins secreted 
from neutrophils might contribute to inflammatory lesions.
Thus, in vitro HNP1-3 have been 
purified PMN are stimulated with 
coated) zymosan (Ganz, 1987). 
peptides in vitro indicates that 
at effective concentrations 
inflammation, though this has nc 
What role might these peptides ha> 
is that they may contribute to cvt 
al (1986), using a chromium- re 1<S 
lysis, have shown that in vitro ai 
the capacity to lyse a number o.
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shown to be secreted when 
PMA or opsonized (antibody 
The secretion of these 
they may be present in vivo 
at sites of infection/
• t yet been directly shown. 
,-e there? One possibility
:otoxicity. Lichtenstein et 
base assay 'fo measure cell. 
1 three hyjfcfZj} deleftx (fkr havfe
i: euka ryoi ic ceif* f
WIL 2, IM 4, Raji, K562), target lysis occuring after a lag 
period of to 3-4 hours. They further showed (Lichtenstein et 
— ’ 1988) that binding of defensins to target membranes was a 
necessary precondition for lysis. However, subsequent
internalization was then required before lysis could occur. 
Such internalization was mediated by the target cell and could 
be antagonized by agents that interfered with target cell 
energy metabolism, the cytoskeletal apparatus, lysosomal 
function or calmodulin-mediated activities. Okrent et al
(1990) have addressed the possibility that such cell lysis by 
defensins might be involved in neutrophil-mediated 
cytotoxicity of the lung by showing that a crude fraction from 
neutrophils containing mainly defensins was cytotoxic to three 
lung-derived cell lines. They showed, moreover, that the 
cytotoxicity of this extract could be completely accounted for 
by its defensin content. Thus there is a strong possibility 
that the defensins play a role in tissue damage in the 
extracellular raillieu. What defensins might be doing once
bound to lipid bilayers is unknown. However, Kagan et al, 
(1990) have shown that, at least in artificial lipid bilayers, 
MCPl, a rabbit defensin similar in many respects to the human 
defensins, can integrate into the membrane and form 
voltage-dependent, weakly anion-selective channels. This
MCPl—conductance was found to be moderately selective for 
monovalent anions such as Cl compared to Na , , La and
SO4 . This may be one way in which defensins cause membrane 
damage during lysis, but precisely how !_hio xo Cxto-^ed i.„ 
unknown.
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Lastly, another role in the extracellular raillieu has 
recently been ascribed to defensins. Territo et al (1989)
have shown that in vitro the defensins show significant 
chemotactic activity for monocytes. Purified preparations of 
each of the three human defensins have all been tested and
H.NP1 shown to have significant chemotactic activity 
(approximately 50% of that elicited by chemotactic agent, 
FMLP). HNP2, on the other hand, showed somewhat less
activity (20% of FMLP), whilst HNP3 showed no activity.
Again then, in common with their activities against bacteria 
and fungi, HNP3 has least activity; HNP2 more and HNP1
highest. Since this chemotactic effect is shown at very low 
defensin concentrations (10"^M), the possibility is clear that 
defensins secreted by neutrophils may play a role in the 
recruitment of monocytes by neutrophils into sites of 
infection/inflammation.
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1.3 THE HL60 CELL LINE AS A MODEL SYSTEM FOR MYELOPOIESIS
The human promyelocytic cell line HL60 was established 
from the peripheral blood leukocytes of a patient with acute
promyelocytic leukaemia (FAB class M2) (Collins et al, 1977). 
The ability of these growth-factor independent cells to be 
induced to differentiate in vitro make this cell line a useful 
model for human myeloid differentiation. The majority of 
HL60 cells are promyelocytic in morphology and histochemistry 
but 4-15% can display morphological characteristics of more 
mature myeloid cells such as myelocytes, metamyelocytes and 
PMN (Collins et al, 1977). Promyelocytes are normally found 
in bone marrow of humans and comprise immature
granulocyte-committed cells (Fig. IB). Fig. IB indicates the 
position of HL60 cells and some other myeloid and non-myeloid 
cell lines in hematopoietic lineages used in this study.
1.3.1 HL60 cells are karyotypically abnormal transformed cells
HL60 cells are a suspension cell line and grow with a 
doubling time of 20-45 hours, depending on the subline.
Morphologically, the cells are, large, with characteristic 
large rounded nuclei containing typically 2-4 nucleoli and a 
basophilic cytoplasm with •azurophilic granules. Most cells 
in a culture carry a variety of cell sun. ace antigens
characteristic of immature myeloid, ceils ss shown by their 
reaction with an extensive panel of monoclonal antibodies 
(Graham et al, 1985). Amo-.gsf thsse p  ricers M u *
myeloperoxidase and acid pho h., i. l a t e .. as
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neutrophil antimicrobial function as well as receptors for 
insulin, transferrin and complement (Tsiftsoglou and Robinson, 
1985; Collins, 1987).
Cytc genetically, HL60 cells show many karyotypic
abnormalities. A variety of such abnormalities have been 
described, including monosomy, polyploidy and a variety of 
chromosomal translocations (Wolman et al, 1985; Donti et al, 
1988). Moreover, a number of specific genetic lesions have 
been described. For example, the p53 gene on chromosome 
17pl3 has been largely deleted (Wolf and Rotter, 1985) and one 
allele of the GM-CSF gene on chromosome 5q21-q23 is rearranged 
and partly deleted (Huebner et al, 1985). Additionally,
N-ras contains an activating codon 61 mutation in HL60 cells 
(Bos et al, 1984) responsible for the transforming activity of 
HL60 DNA in an NIH3T3 transformation assay (Murray et al,
1983).
Amplification of the c-myc oncogene has also been found 
in HL60 cells (Collins and Groudine, 1982) as well as in Che 
primary leukaeraic cells from which the cell line was
established. The extent of amplification of c.—myc Vcir^es
from 4-30 fold in different HL60 sublines (Graham et el.
1985; Donti et al, 1988), with a concomitant variation in
c~my c  mRNA abundance (Graham et a j . .  j . ^ 8 5 ) .  ! > -
possible that this overexpression of o~mvc may nave j.m
cooperation with a mutated N-ras gene ■■■>'•*■ c-
the HL60 line.
1.3.2 Induction of differentiation
From the viewpoint of understanding how myeloid genes 
such as those encoding defensins are controlled during
differentiation, the most important property of HL60 cells is 
their capacity to differentiate in vitro to mature cells of 
the granulocytic or monocytic lineages. HL60 cells are
capable of induced differentiation when treated with a number 
°f different agents. They are not unique in this respect. 
A number of other established hematopoietic cell lines also 
posess this capacity. U937 cells, for example, a human 
monoblastic cell line, can be induced to monocytes by various 
agents; Friend murine erythroleukaeraia cells can be induced
to mature erythrocytes under appropriate stimulatory 
conditions (Olsson and Breitman, 1982; Rifkind et al,
1984). However, HL60 cells can be induced to differentiate
along either of two distinct lineages, depending on the
inducing agent used. If, as seems to be the case, the
neoplastic transformation of HL60 cells is due to an 
uncoupling of the processes oF proliferation and
differentiation resulting in a 'maturation arrest' at a stage 
similar to that which occurs in the course of normal 
hematopoietic differentiation, the effect of agents which 
induce HL60 cells to differentiate may be to enable the cells 
to overcome this block in differentiation with the restoration 
of the differentiation programme.
56
HL60 cells can be induced to differentiate to both
granulocytic and monocytic cell types. The most commonly
used granulocytic inducing agents are retinoic acid (RA) and 
dimethyl sulphoxide (DMSO). HL60 cells, when cultured for 5 
days in the presence of retinoic acid or DMSO, differentiate 
to mature myeloid cells with many of the characteristics 
attributed to mature granulocytes (Collins et al, 1978;
Breitman et al, 1980). The HL60 cell line can also be
induced to differentiate to monocyte/macrophage-like cells by 
exposure to other agents such as phorbol ester (TPA) or
1,25-dihydroxyvitamin D3. Following the period of induction, 
the terminally differentiated cells possess many of the 
characteristics attributed to monocyte/macrophages (Rovera et 
al, 1979; McCarthy et al, 1982).
1.3.3 Morphological and functional changes during HL60 cell 
differentiation
The course of terminal differentiation of HL60 cells is 
accompanied by striking morphological, histochemical and 
immunological changes. These changes have been described by
Collins et al ( 1977) and are characteristic of terminally
differentiated myeloid cells. Thus incubation with DMSO or 
retinoic acid leads to a progressive decrease in the size of 
HL60 cells, a condensation of nuclear material and the 
appearance of kidney-shaped nuclei or ten. with a reduction or 
disappearance of nucleoli characteristic of banded and 
segmented neutrophils. The nuc-eaw cy. op-^ .tn’ic r^ti^
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decreases and the cytoplasm becomes more diffuse. The
process of differentiation can be followed by analysis of 
these changes in cell morphology. It has been demonstrated 
that 24 hours of induction is required before the first 
morphological changes are observed, but by 4 days of treatment 
with either retinoic acid or DMSO cells displaying terminally 
differentiated cell morphology are present in culture 
(Breitman et al, 1980).
Concomitant with these morphological changes, there occur 
marked changes in histochemistry, including decreased 
myeloperoxidase activity and the appearance in culture of 
cells capable of reducing nitroblue tetrazolium, a marker for 
functionally mature granulocytes. Following treatment with 
agents which induce HL60 cells to differentiate to 
monocyte/macrophages, the cells settle out of suspension and 
clump together on the surface of the tissue culture flask and 
attach to the plastic. These adherent cells have a
spindle-like morphology. Ruffling of the cell membrane is 
apparent and the cells possess blunt pseudopods characteristic 
of macrophages (Fibach et al, 1982).
A number of functional changes can also be detected in 
differentiating HL60 cells which reflect the functions of 
normal PMN and macrophages. For example, HL60 cells
terminally differentiated to granulocytes have the ability to 
phagocytose fungi (C.albicans) and opso .--.a e c i t i d e s  
(Collins et al, 1978), as well as the ability 1.0 res.xm.
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chemo tact ically to FMT P in ay LU niur in a manner similar to mature
granulocytes (Tsiftsoglou and Robinson, 1985). Similarly,
HL60 cells induced to differentiate to monocyte/macrophages 
also show characteristics of mature cells of this lineage. 
Thus, following HL60 induction by phorbol ester, an induction 
of cR napthol esterase, a histochemical marker for mature 
macrophages is detected (Daniel et al, 1987). These cells
are also capable of phagocytosis, show increased synthesis of 
lysozyme and express a number of monocyte surface antigens 
(Monroe et al, 1984; Polansky et al, 1985).
1.3.4 Changes in HL60 gene expression during differentiation
The large number of morphological, functional and 
biochemical changes seen when HL60 cells are induced to 
differentiate are accompanied by large qualitative and 
quantitative changes in gene expression. This was first
indicated from results of experiments comparing the 
translation products detected following in vitro translation 
of polysomal polyA+ RNA extracted from uninduced and induced 
HL60 cells. No gross change in the total amount of polyA+ 
RNA was detected following induction of differentiation, but 
different sets of proteins were translated (Colbert et al, 
1983; Reyland et al, 1986). This relatively insensitive
method still detected large differences in mRNA populations 
between induced and uninduced cells and between HI, SO 
granulocytes and HL60 macrophages.
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Another approach to detecting changes in gene expression 
occaring during HL60 differentiation is that of isolation of 
genes whose abundance is related to differentiation of the 
cells by screening cDNA libraries derived from induced and 
uninduced HL60 cells. This approach has identified a number 
of recombinant clones homologous to a large number of mRNAs 
that change in abundance during differentiation (Davis et al, 
1987; rlitchell, 1987). Interestingly, a large number of
these clones contained highly repeated sequences (including 
Alu sequences) or belonged to members of extensive gene
families (Davis et al, 1987)
For genes for which cloned probes are available, the HL60 
differentiation system has proven useful for a number of
reasons. It provides a system in which the relationship
between gene expression and both proliferation and
differentiation can be investigated. One much-studied
example is the c-myc proto-oncogene, the cellular homologue of 
the transforming avian retrovirus MC29. There is much
evidence that c-myc proteins are involved in both 
proliferation and differentiation in many diverse cell
types. Briefly, evidence for an involvement of c-myc
proteins in proliferation was initially proposed from the 
observation that c—myc expression was induced following serum 
or growth factor stimulation of quiescent fibroblasts or 
following mitogenic stimulation of lymphocytes (Kelly £t__al,
1983, Reed et al, 1985). Armelin et_ul \ i9d4) snoweo,
moreover, that DNA synthesis could be inuuced when o n  mouse
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fibroblasts were transfected with a construct containing c-myc 
under the control of an MMTV promoter and the cells stimulated 
with glucocorticoids to induce expression.
A link between c-myc expression and differentiation has 
also been inferred from work on a number of inducible cell
lines including HL60, Friend erythroleukaemia and F9 cells 
(Lachman and Skoultchi, 1984; Dean et al, 1986; Collins,
1987). Thus a marked decrease in c-myc RNA and protein levels 
occur in HL60 cells in response to initiation of
differentiation. This decrease has been shown to be due to a 
two-phase down-regulation of transcription. In uninduced
HL60 cells there is a partial block to transcript elongation 
at the end of exon 1 of the c-myc gene that is rapidly and
greatly enhanced by induction of differentiation with DMSO 
(Bentley and Groudine, 1986; Kick and Bornkamm, 1986;
Siebenlist et al, 1988). A later event which serves to
consolidate this down-regulation is a decrease in the rate of 
initiation of transcription (Siebenlist et al, 1988). This
is correlated with changes in chromatin structure 5* of exon 1 
as shown by changes in DNAase I hypersensitive sites.
For a number of other genes expressed in the myeloid
lineages (granulocytic and monocytic) the HL60 cell line has 
been of value in understanding if and how the expression of 
particular genes is related to differentiation. This system 
is especially useful for proteins expressed during normal 
granulopoiesis, since almost all synthesis and processing of
individual mRNAs and proteins begins and is completed in 
relatively immature myeloid cells such as the promyelocyte and 
myelocyte which are normally confined to the bone marrow and 
therefore physically difficult to study. Thus the HL60 cell 
line can help serve as a model for the synthesis and 
processing of normal myeloid proteins since it is active in 
transcription and translation during its terminal 
differentiation.
One such protein which has been investigated is 
myeloperoxidase. This protein is a major constituent of 
azurophilic granules and contributes to oxygen-dependent 
bactericidal functions. Myeloperoxidase mRNA is confined to 
cells of the granulocytic lineage and is found at highest 
abundance in immature myeloid cells (promyelocytes and 
myelocytes) (Koeffler et al, 1985; Jaffe et al, 1988) but
not in mature granulocytes. Induction of HL60 cells to
differentiate to granulocytes, moreover, leads to a similar 
down-regulation of myeloperoxidase gene expression implying 
that the types of controls operating during normal 
myelopoiesis on myeloperoxidase mRNA levels may be conserved 
during HL60 cell differentiation. (Yamada and Kurahashi,
1984; Weil et al, 1984; Tobler et al, 1988).
The mRNAs encoding defensins KN'Pl and KNPj are similar in
. 1  « c ' 1 1  G O  Til 0  reSpeCtS il Otheir range or express iou - ^  --Mu- t
myeloperoxidase. They coo are expi.e-;sed o<-> -n ire m\e-oid 
lineage although in a smaller wiiidoi-- of d i f f e r e n t i a t i o n  (the
neutrophilic myelocyte) than myeloperoxidase (Weidemann et al, 
1989). In common with myeloperoxidase mRNA, defensin mRNAs 
are not detected in mature PMN, although their corresponding 
proteins are found at high abundance. For an analysis of the 
fine details of how defensin gene expression might be 
controlled during myelopoiesis, inddCed differentiation of 
HL60 cells would seem to provide a useful model system.
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1.4 LEUKAEMIA. ABNORMAL REGULATION OF HEMATOPOIESIS
1.4.1 Maturation arrest
The normal process of multi-lineage hematopoiesis, 
involving as it does intricate control of both highly 
proliferative pluripotent cells and very long-lived 
self renewing stem cells, is an obvious target for neoplastic 
transformation. Most evidence supports the notion of a
unicellular (monoclonal) origin of most leukaemias and 
lymphomas with the original transforming event(s) in 
leukaemogenesis taking place in the hematopoietic stem cell 
compartment in the bone marrow (and thus giving rise to a 
number of transformed stem cells) and an apparent uncoupling 
of proliferation and differentiation known as maturation 
arrest (Greaves and Janossy, 1978). It has been possible in 
many cases, from a consideration of the composite phenotype of 
leukaemic cells in comparison with normal populations, to 
designate the predominant lineage and cell type involved, and 
at least to speculate as to the possible target cell for 
clonal expansion (Greaves et al, 1981; Stein et al, 1984;
Foon and Todd, 1986). Thus proliferating leukaemic cells are 
maturation-arrested at a stage similar, but not identical, to 
one occuring during normal hematopoiesis. It is this loss
by the cells of the ability to differentiate terminally 
together with a ' capacity for .continued cell division that 
leads to overt leukaemia. Several conceptual models h^ve
been formulated to explain this phenomenon. Sachs (1982) and
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Greaves (1982) have both suggested that chromosomal changes 
occuring concomitantly with progression in leukaemia affect 
genes whose expression is intimately associated with the 
coupling of proliferation with differentiation (for example, 
the growth factor or growth factor receptor genes previously 
discussed). The more stringent the uncoupling of these two 
processes in a leukaemic clone due to these chromosomal 
changes, these two authors suggest, the less mature the 
phenotype of cells in the transformed clone. Similarly
Nowell (1977) has argued that a small shift uncoupling 
proliferation with differentiation in the stem cell 
compartment due to tumorigenesis may result in a gradual 
clonal expansion allowing cells to differentiate almost to 
termination. Alternatively, a large shift in the balance 
between proliferation and differentiation would result in a 
very rapid clonal proliferation and a reduction in the 
capacity of these cells for differentiation. Would such a 
model explain different leukaemia types? For the myeloid
leukaemias the former situation could possibly explain the 
predominance of more mature relatively normal myeloid cell 
types in the peripheral blood of a typical case of CGL, while 
the latter situation would be reflected in the high proportion 
of rapidly dividing early blast ceils of the myeloid lineage 
seen in acute non-lymphocytip, leukaemia (ANLL).
Leukaemias are highly heterogeneous, but can be divided 
into two main categories, lymphoid and nyelorc. Each
category contains both acute (teptd ^ t , *-•»** c». o.i~-
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(relatively slow development) types of disease. The four
main classifications of human leukaemia are therefore: acute
lymphocytic leukaemia (ALL), acute non-lymphocytic leukaemia 
(ANLL), chronic lymphocytic leukaemia (CLL) and chronic 
myeloid (granulocytic) leukaemia (CML, CGL). A more subtle 
classification of leukaemias based on reactivity with panels 
of monoclonal antibodies to cell surface markers as well as 
enzyme markers will be discussed in Section 1.4.3.
1.4.2 Growth factors and leukaemia
With our present knowledge of the role of growth factors 
in the control of normal hematopoiesis, the possibility 
presents itself that one mechanism whereby a pluripotent stem 
cell could uncouple proliferation from differentiation would 
be simply by proliferating independently of an exogenous 
supply of growth factor. Such growth factor autonomy could 
subsequently lead to maturation arrest or might possibly be 
concomitant with it. In this respect it is logical to ask
two main questions; are the genes for the CSFs or CSF
receptors oncogenes and does autocrine production of CSFs lead 
to leukaemia?
In answer .to the first question no sequence homology 
between the CSFs and known oncogenes has been found.
However, it should be borne in. mind that the lj.st of oncogenes 
(dominantly-acting genes implicates i p  * .vld- >. a^..e^y o j .
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neoplasias) is probably incomplete - particularly in respect 
to hematopoietic neoplasias, because of the use of a 
fibroblast (NIH 3T3) detection system.
The possible role of CSFs as autocrine stimulators of 
proliferation in myeloid leukaemia cells is a complex question 
for which evidence is quite conflicting. Certainly, for 
primary myeloid leukaemia in the murine system and in man, the 
leukaemic cells remain absolutely dependent on exogenous CSF 
for survival and continued proliferation in vitro. This 
situation persists throughout the clinical course of the
disease. Thus, it seems unlikely that myeloid leukaemias 
exhibit autocrine growth, assuming that the in vitro data 
reliably reflects the situation in vivo. Furthermore, there 
are multiple normal tissue sources of CSF, probably producing 
CSF levels greatly in excess of those conceivably able to be 
produced by the first emerging leukaemic cell. Nonetheless, 
it is conceivable that independence from normal growth inducer 
could explain the survival and growth of metastasizing cells 
in places in the body where growth inducer required for the
viability of normal cells is absent. Might leukaemic cells 
simply produce more CSFs or abnormal forms Oj. ubese molecules 
to which they themselves are abnormally or selectively 
responsive? Most evidence suggests thar this is not the
case: where leukaemia cel'l-derived CSP*. have been
biochemically characterized, they ate :s bei«g
similar to the normal equivalent molecule 3rd afg
produced in amounts similar to those prodded by normal
hematopoietic cells.
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Despite this evidence against an involvement of growth 
factors in leukaemia, certain other observations have linked 
acquisition of constitutive CSF production with leukaemic
immortalized hematopoietic cells dependent on extrinsic IL3 
for survival and proliferation show the interesting property 
of generating extrinsic IL3— independent subclones in vitro. 
These subclones are capable of autonomous proliferation and 
IL3 production and, most importantly, thereby acquire the 
capacity to produce transplanted leukaemias in syngeneic 
recipients (Hapel et al, 1981; Schrader and Crapper, 1983). 
One could argue, however, that perhaps some other changes 
occuring during cell culture in this system were responsible 
for autonomous proliferation and leukaemic capacity and that 
autocrine CSF production was an advantageous byproduct of 
these changes. However, a more causal relatioiship has been 
established by Lang et al (1985) who showed that infection of 
cells of one such IL3-or GM-CSF— dependent line, FDC—PI, with a 
retroviral construct containing the GM-CSF cDNA leads to the 
emergence of autonomous GM-CSF-producing sublines that are 
uniformly leukaemogenic on transplantation to syngeneic 
recipients. Several other experimental systems utilizing
retroviruses as transduction vehicles have also demonstrated 
that expression of some known oncogenes oi growth, factor genes
t ransformation For example, some murine nonleukaemic but
can induce factor production and thus lead to growth autonomy
in certain hematopoietic cells. However, n
prior immortalization of the target cells (whate
appears that
means
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m  molecular terms) is a prerequisite tor malignant 
transformation. When the same retroviruses are introduced 
into normal, freshly isolated hematopoietic progenitor cells, 
these cells also acquire the ability to grow in the absence of 
added growth factor, but in this case the growth is 
accompanied by terminal maturation; the cells do not become 
malignant (Metcalf, 1986). Thus it seems that, as in other 
systems, at least two events are required for acquisition of a 
malignant phenotype. Moreover, some studies using similar 
systems have demonstrated, in contrast to the above findings, 
that a loss of factor dependency and acquisition of the 
leukaemic phenotype can occur without detectable factor 
production after introduction of oncogenes. For example, 
Cook et al, ( 1985) and Pierce et al (1985) have shown that
Abelson virus infection of immortalized CSF-dependent murine 
hematopoietic cell lines can transform the cells to leukaemic 
cells under conditions where autocrine production of either 
IL3 or GM-CSF could be excluded and in which membrane 
receptors for CSF appeared to be unaltered in the transformed 
cells.
Thus, although CSF production by preleukaemic cells may 
be able to lead to the transformation of such cells to fully 
leukemic cells, leukaemic transformation can also occur by 
other mechanisms. Recently, Stocking et al (1988) using a 
factor-dependent myeloid precursor cell line D35 derived from 
in vitro. infection of Dexter’s long-term murine marrow 
cultures, have shown that growth factor-independent sublmes
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do indeed show a mechanistic heterogeneity in transformation 
to growth autonomy. Essentially, all mutant sublines in 
their study were tumorigenic in nude mice and, furthermore, 
could be grouped into two classes depending on whether they 
secreted a diffusible stimulating factor. Of the mutants 
releasing a factor (10/11), approximately two-thirds secreted 
GM—CSF, one-third secreting IL3 with one mutant releasing a 
possible new hematopoietic growth factor. Activation in
most cases was due to rearrangement of the activated allele 
associated with juxtaposition of enhancer and o the r 
transcriptional regulatory signals contained in a virus or 
virus-like LTR either 5* or 3 f of the factor coding region. 
In some other cases of mutants releasing a factor, no gross 
genotypic alterations were observed and small rearrangements 
not detectable by conventional Southern analysis of genomic 
DNA within the immediate 5'— regulator region or within distant 
upstream promoter sequences were postulated by the authors to 
account for aberrant expression of the growth factor. Most 
interesting in this study, was the finding that one of the 
eleven growth-autonomous mutants tested did not produce a 
diffusible factor as assayed by stimulation of the parental 
D35 line or other factor-dependent hematopoietic cell lines. 
It seems a distinct possibility that this type of tare mutant, 
able to grow autonomously by a mechanism not involving 
autocrine stimulation by growtn factors, may represent an 
initial stage in leukaemogenesis hitherto uncharacterised. 
The authors themselves suggest that, by r.ne constitutive 
expression of a receptor or. - n °11 '*c“ A
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configuration, these types of mutants are able to 
short-circuit and thus activate the normal signal transduction 
pathway as proposed for several oncogenes (Weinberg, 1985).
Although much work has concentrated on growth factors and 
the role of growth factor autonomy in leukaemogenesis, there 
is some evidence that inhibitory factors may have some role. 
In normal hematopoiesis, Lord et al, (1976), for example, have 
identified a factor that specifically and reversibly inhibits 
the entry of multipotent stem cells into S-phase of the cell 
cycle and is found in medium conditioned by bone marrow 
stromal cells. Moreover, they have shown also that it can 
prevent entry into the S-phase of CFU-S stimulated by cell
cycle activators (Lord et al, 1977) and that its inhibitory
effects are apparently restricted to multipotent stem cells 
with no cell-cycle inhibitory effects on lineage-restricted 
progenitor cells. Clearly, since the basic mechanism
underlying leukaemogenesis is perturbation of the growth 
control system that operates in normal hematopoiesis, it is 
possible to envisage that one such possible perturbation may 
well be unresponsiveness to the normal growth inhibition
system. In fact, there is some evidence that multipotent
stem cells from CGL patients do not respond to the CFU-S
inhibitory factor produced i_n vitro in long-term marrow
cultures. It is a possibility that this may be the reason 
for the selective advantage seen for CML stem ceils over
normal stem cells in CGL patients (LaVts
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The phenomenon of maturation arrest, involving as it does 
a defect in differentiation, has been approached from another 
angle by asking the question of exactly how colony-stimulating 
factors might induce differentiation of committed 
precursors. It appears unlikely that a growth factor that 
induces cell multiplication would also induce differentiation 
which stops cell division in mature cells. In fact, proteins 
that induce myeloid cell differentiation but not growth have 
been identified (Sachs and Lotem, 1984; Sachs, 1980; Olsson 
et al> 1984) termed macrophage and granulocyte inducers-type 2 
(MGI-2). Sachs (1987) has suggested that induction of these 
differentiation factors by growth factors might serve as an 
effective mechanism to couple growth and differentiation in 
vivo. Differences in the time of switch-on of the
differentiation inducer, he suggests, might be responsible for 
the observed differences in the amount of cell division before 
differentiation. Furthermore, different growth inducers
could switch on different differentiation inducers which might 
in turn determine the differentiated cell type. Since it has 
been found that a differentiation inducer can in turn switch 
on growth factor production in myeloid cells, this could also 
presumably ensure cell viability and ennance the function of 
mature cells. It should be stressed, however, that evidence 
for the importance of these differentiation Lactors has mainly 
come from studies on their rois in j.nciuci ug primary myexoio. 
leukaemia to differentiate in.. vitro. Can maturation arrest 
be overcome by these fa-ctors and. as •- t i I . i. ^
maturation arrest perhaps caused by .-j defeat -n ~ne .v i---
r _ fVioco fp*'tors'? There are r<. dnof, or response to, these ra^t>
h i «,
second question, but Sachs has provided evidence that at least 
some myeloid leukaemias can be induced to differentiate in 
response to these factors (Sachs and Lotem, 1984; Ichikawa et 
al^ , 1976). Mature cells from these differentiation-positive 
(D ) clones, moreover, stop multiplying and are no longer 
malignant in vivo (Lotem and Sachs 1981 and 1984). 
Furthermore, studies in animals and man have shown that normal 
differentiation of D"*’ myeloid leukaemia cells, to mature 
non— dividing cells can be induced not only in culture but also 
in vivo (Lotem and Sachs (1978), (1979); Fearton et al,
1986). Sachs has suggested (1987) from this work that these 
D+ leukaemias may grow progressively only when there are too 
many leukaemic cells for the normal amount of differentiation 
inducer in the body. In support of this idea, he has found
that development of leukaemia can be inhibited in mice with
these D+ leukaemia cells by increasing the amount of 
differentiation inducer protein, either by injecting it or by 
injecting a compound that increases its production by cells in 
the body (Lotem and Sachs, 1981 and 1984). Interestingly,
Sachs has also described differentiation-defective (D“ ) 
clones. Some D“ clones are induced by differentiation
inducing factors to an intermediate stage of differentiation
that then slows down the growth of the cells; others, though,
cannot be induced to differentiate even to this intermediate 
stage. The immediate significance of this work is not clear, 
but Sachs has proposed (Sachs, 1987) that 0+ clones may be the 
early stages of leukaemia and that possibly the formation of 
different types of D" clones may be later stages in the
progression to malignancy.
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1.4.3 Using molecular markers to classify leukaemias
We have seen that the concept of maturation arrest has 
arisen from a consideration of the composite phenotype of 
leukaemic cells in comparison with normal populations^allowing 
in most cases a designation to be made of the predominant 
lineage and cell type involved in a given leukaemia. Such 
considerations increasingly do not rely simply on 
morphological/ultrastructural considerations, but on the 
expression of cell-surface antigens on the leukaemic cells and 
their detection by monoclonal antibodies (Foon and Todd, 
1986). Furthermore, the use of molecular probes that
identify immunoglobulin and T-cell receptor genes (the protein 
products of which in normal hematopoiesis are expressed in B- 
and T- cells respectively) and the use of enzymatic markers 
such as myeloperoxidase (expressed in immature cells of the 
myeloid lineage), have strengthened the idea that leukaemic 
cells resemble their normal counterparts in hematopoiesis in 
many details (Greaves, 1986). However, it must be kept in 
mind that leukaemic phenotypes are not perfect replicas of 
normal ones. In addition to specific chromosomal changes and 
alteration in the structure and/or control of particular 
genes, leukaemic cells may show some asynchrony phenotypic 
expression in comparison to their equivalent maturation 
compartment in normal tissue. An exampxe of this occurs in T- 
cell leukaeraip. , In one «?tudy of the composite 
immunophenotype in 82 cases of T-C-rl- l.eukaemi^ . s 26 shov,ed
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some asynchrony or abnormal combination of T-cell markers with 
respect to intralineage maturation status (Greaves et al, 
1981). Additionally, all cases of thymic or T—acute 
lymphoblastic leukaemia (T—ALL) tested in this study expressed 
high density HLA (A;B) combined with nuclear terminal 
deoxynucleotidyl transferase (TdT) in individual cells 
(Greaves et al, 1981; Bradstock et al, 1980a) whereas in the 
normal thymus TdT—positive cells have very low density HLA 
(A;B), the density of this glycoprotein increasing with 
further T— cell maturation and loss of TdT activity (Bradstock 
et al, (1980b). Similarly in leukaemia of B-cell precursors, 
a substantial proportion of cases are cytoplasmic p chain/TdT- 
positive (Vogler et al, 1978; Greaves et al, 1979), whereas
in normal populations this is an extremely rare (though 
detectable) cellular phenotype (Janossy et al, 1979), pre~B
cells presumably losing TdT prior to detectable p chain 
synthesis. Although a case can be made for this extremely
small sub-population being the target for clonal expansion, 
the finding that these distortions in phenotype are much more 
pronounced in cell lines established from ALL patients 
compared with uncultured cells studied at diagnosis, suggests 
that outwith normal homeostatic control asynchrony ot 
phenotypic expression manifests itselr, Although the
significance of these findings. • is unclear, Greaves has
suggested that they may still be cons I w i i r  the concept
of maturation arrest if' the arru:"'. Is Oh Lai to
maturation, but rattier a regal aonj uncoupl ing v.E variable
stringency (Greaves et al,
The concept of maturation arrest/clonal expansion arises 
principally from the rather faithfully conserved lineage 
specificity observed in leukaemia and lymphoma. An example 
of this is the expression of the gplOO/common acute 
lymphoblastic antigen (GALLA, CD10) structure. This
structure itself is non-lineage specific (Metzgar et al, 1981) 
but is selectively expressed on certain cell types in concert 
with maturation status. Thus, although granulocytes express 
CALLA weakly, myeloid progenitors are unreactive (Clavell et 
al, 1981; Braun et al, 1983), in contrast to lymphoid
precursors in the bone marrow and thymus which are
CALLA-positive (Greaves et al, 1981; Greaves et al, 1983a).
Significantly then, in a survey of over 2000 cases of
leukaemia with the anti-CALLA monoclonal antibody J5, almost 
75% of ALLs were reactive compared with only 2.4% cases of 
ANLL. Furthermore, of these ’positive1 ANLL cases, on
further examination, all turned out to be either dual
lymphoid—myeloi d, had no unequivocal evidence for myeloid 
cytochemistry, or subsequently relapsed as ALL. Thus,
mirroring the situation in normal hematopoiesis, it is clearly 
exceedingly rare for myeloblasts to express illegitimately the 
CALLA marker. Similarly, glycophorin, an eryth rcid cell
specific membrane glycoprotein expressed on. roost but not 
erythroleukaemias (Greaves et al, 198ob.) snows a
1 ineage-rest rictedness. When a mono cion a.-. * r t a *»y
LICR.LON.RIO (Edwards, 1980) was used to screen 329 CQSes or
ALL (Greaves et al_, 1983b), only two pos/t'Ve blasts.
Subsequent review of these two cases, moreover, revealed ttat
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although both had lymphoblast morphology, they did not express 
an ALL immunophenotype and were almost certainly cryptic 
erythroleukaemias.
1.4.4 Lineage infidelity in leukaemia
From the assembled data then, the idea that leukaemic 
cells are phenotypically similar in many details to normal 
hematopoietic progenitors or subsets seems compelling. 
Further insight on how the choice of lineage is established in 
normal hematopoiesis has also come from the study of molecular 
markers on leukaemic cells. Several models for self—renewal 
and differentiation of pluripotent stem cells have been 
proposed (Ogawa et al, 1983). Two major competing models
which make quite different predictions exists. The model 
first suggested by Till et al (1964) and later developed by 
others (Johnston, 1981; Eaves et al, 1982; Kurnit et al,
1985), predicts that adoption of lineage commitment at a 
genetic level is indifferent to external directive influences, 
but rather follows an intrinsic program that is either 
stochastic (probabilistic) or deterministic (ordered) in 
nature. fin alternative model, first proposed by Trentin 
(1979), suggests that, in contrast to lineage commitment 
existing as a mechanistically ’hard-wired1 system indifzerent 
to external influences, choice of commitment to a pai.’_i.cu_ai 
lineage may be determined or perhaps imposed by external 
microenvironmental influence, e.g. growtn lactoru Zfimfc ^
al, 1978; Metcalf and Burgess, 1982) and/or stromal cHMfcttts
77
(Dexter, 1982) or other positional information (Wolpert, 
1969). In considering these models, it is worthwhile to ask
whether strict lineage fidelity of markers is always observed 
in leukaemia, as the concept of maturation arrest would
suggest, and, if not, what this may imply about normal
hematopoietic development. In fact, a number of instances 
of so-called ’lineage infidelity’ (McCulloch, 1983) have been 
reported in leukaemia. As argued by Greaves, however
(Greaves et al, 1986) some such claims can be discounted for 
purely technical reasons (for example monoconal antibody
cross—reactivity) as well as for reasons of interpretation 
(for example where a given marker is mistakenly thought to be 
lineage-specific in normal hematopoiesis but is, in fact, 
expressed at different developmental stages in more than one 
lineage). However, some bona fide examples of lineage
infidelity exist and should be considered. One example is 
the finding of immunoglobulin gene rearrangements and/or 
expression in T-cell leukaemia (Korsmeyer et al, 1981; Ford
et al, 1983; Ha et al, 1984a) and some myeloid leukaemia
(Rovigatti et al < 1984; Ha et al, 1984b; Palumbo et al,
1984) and T-cell receptor gene rearrangements and/or 
expression in some non—T—cell leukaemias. Since the
immunoglobulins and T-cell receptor proteins are highly 
cell—type specific In normal development, are the. above 
findings indicative of a type of aberrant picgrammj.ng oi gens 
expression in these leukaemias (i.e. lineage infxdelxty) or do 
they indicate a type of loose plasticity of genetic events 
occuring in early progenitor cells.' j-hu q«*esti<. . ..s,
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whether the molecular rearrangements underlying the assembly 
of these genes occurs in a lineage—restricted way. In fact, 
in the murine system it has been demonstrated that, contrary 
to expectations, normal mouse thymocytes (T—cell precursors) 
as well as some cytotoxic T-cell clones, leukaemic T-cells and 
myeloid cells all can have immunoglobulin heavy chain gene 
rearrangements (Kemp et al, 1980; Cory et al, 1980; Forster 
et al , 1980; Kurosawa et al, 1981). Immunoglobulin
transcripts of various sizes have also been reported and, in 
one case, shown to result from joining of the D (diversity) to 
J (joining) segments in the absence of V (variable) region 
(Kurosawa et al, 1981). Furthermore, studies on Abelson
virus-transformed B-cell precursors in fetal liver (Alt et al, 
1984; Reth and Alt, 1984) have revealed that DJ joining with 
transcription of a truncated mRNA probably actually precedes 
recombination involving V —  region genes in normal B-cell 
ontogeny. Moreover, transcripton of unrearranged V— gene
segments is predominant in cells underoing Vjj to DJ 
rearrangement and is B-cell specific (Yancopoulos and Alt, 
1985). Significantly, later events than these in B-cell
Ontogeny, -rearrangement of K or X light chain genes, have not 
been reported in non—B cell leukaemias.
The situation with respect to the T-cell receptor p-chain 
gene is similar (Moller, 1984). This gene has an
immunoglobul in —  1 ike VDJC suprast ructure and aj.so undergoes 
rearrangement. In both the murine system and in man both 
normal and leukaemic immature thymocytes transcribe a 1Kb mRNA
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product of the DJC p-gene lacking a V-region. Very immature 
T-ALL also have these p-gene rearrangements and express this 
transcript* Some, significantly also have a rearrangement of 
the immunoglobulin p. chain gene. Finally, p-gene
rearrangement and/or expression of the p-gene mRNA has also 
been detected in a few immature myeloid and pre—B leukaemias*
It would seem then that the early events in programming 
gene expression in normal hematopoiesis of the immunoglobulin 
and T-cell receptor genes are not lineage-restricted. Thus 
this ’lineage infidelity’ seen in leukaemia would seem to 
present a molecular ’snap-shot’ of early lineage markers being 
coexpressed on cells of different lineages. Greaves (Greaves 
et al, 1986) has termed this phenomenon ’1ineage-promiscuity' 
and his conception of this phenomenon is that some markers that 
are exclusively expressed in a lineage-restricted fashion on 
precursor cells committed to a single lineage are also 
transiently coexpressed on some or all multipotential cells, 
and perhaps briefly on the progeny of these cells following 
the initiation of commitment, but prior to full or 
irreversible determination. Thus, if some limited degree of 
lineage promiscuity of gene expression preceded lineage 
fidelity in the normal course of events, then if a leukaemia 
arose in such a precommitment phase cf ncmatopoiesis and was 
subject- to a ^relatively stringent maturation arrest, 
appropriate marker analysis might reveal Q asijfec lineage 
phenotype on individual cells and be pcetfcd as lineage
infidelity. Since several lineage-and lari"gf.aociateo
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markers (e.g. CALLA, glycophorin, T3) are not found on 
multipotent progenitors, a more realistic version of this 
model would be that limited or selective promiscuity may occur 
with respect to genes that are among the first to be expressed 
in a lineage and whose activity is perhaps functionally 
involved in lineage commitment. The case of immunoglobulin 
heavy chain rearrangement may be an example of just such a 
phenomena. Speculating, perhaps successful joining of VDJ is 
some signal for cessation of p-gene T-cell receptor 
rearrangement and thus commits a progenitor cell to B—cell 
ontogeny. Unsuccessful joining might in turn lead to the
choices of successful joining of the ]5-gene segments (and 
thus T-cell ontogeny) or even unsuccessful joining here and 
the choice of other lineages.
The lineage promiscuity model implies that if 
lineage—associated genes are indeed required as part of the 
initiation process of commitment (and are thus coexpressed in 
some multipotent cells) we would expect to see 'lineage 
infidelity' more often with markers expressed early in a 
lineage than for markers that arise during maturation. One 
marker which shows this pattern is TdT,
T dT is a gene expressed Ik jLeukaeraic and normal cells of 
the pre-B and pre-T phenotype.' is absent from mature 
lymphocytes (Bollum, 1979; fcirtazionl arc Bollum, 1982) and 
Is postulated to play a roic in irtCr«aSL«K the diversity of
immunoglobulin and T-cell receptor genes by the random 
addition of nucleotides in the N region (Desiderio et al, 
1984; Siu et al, 1984). Since it is expressed in pre-B
lymphocytes, it is a useful marker for ALL and lymphoid blast 
crisis of CGL. However, its expression is not restricted to 
ALL; it is also expressed in some ANLLs. In two extensive 
surveys of ANLLs, 5-10% of cases were found to be TdT positive 
(Paietta et al, 1985; Jani et al, 1983). Furthermore, in 
several instances it has been unambiguously demonstrated that 
TdT and a myeloid marker such as myeloperoxidase coexist in 
the same cells. Although this may well be a case of lineage 
infidelity/abnormal expression, lineage promiscuity cannot be 
ruled out. As Greaves suggests (Greaves et al, 1986), it is 
quite conceivable that TdT could be induced very early in 
heraatopoiesis in preparation for the modification of 
immunoglobulin and T-cell receptor rearrangements but be 
carried over and transiently expressed in some cells that 
adopt myeloid commitment. The latter might, especially if 
arrested in their maturation, continue to express TdT as a 
relic of their prior promiscuity. If maturation were to 
continue,' then, expression of such inappropriate genes would 
be expected to be switched off. This indeed seems to be the 
case for TdT, since, in contrast to IdT-positLve ANLL. no TdT- 
positive CGL has been recorded in chronic ohco-e (relatively 
mature granuloycyte lineage cells) ccspite ‘-his
leukaemia in pluripotent stem celts. Slash Crist5 o- CGL 
(early myeloid cells) that 3 « 5 « !  in H e  progenitor 
compartment with associated maturation arrest CQfi, however, he 
TdT positive (McCafferty et al, 1^7?/ ttoffbrand et_al, 1-977).
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With these observations of possible lineage promiscuity
in mind, Greaves et al, (1986) have suggested a model
incorporating features of the previously alluded to models of 
Till et al, (1964) and Trentin (1970) in sequence. The model 
proposed that if certain early lineage-associated markers are 
promiscuously coexpressed on bi- or multipotent cells (and 
their corresponding leukaemias) then they may function to 
advertise the accessibility of particular lineage options. 
Activation of particular early genes could then arise 
intrinsically in a programmed or randomly generated fashion as 
suggested by Till and thereby indicate spontaneous initiation 
of the commitment process in one or more lineages. The
actual lineage option endorsed in individual cells might 
subsequently be determined both by the particular pattern of 
markers expressed (and hence lineages actually available) and 
by the balance of external influences according to the model
of Trentin. What kind of genes would one expect then to be
prime candidates for promiscuous expression? The previously 
described colony-stimulating factor receptors and as yet 
undiscovered receptors for regulators of early lymphoid 
development are obvious candidates. This suggestion, that 
uncommitted progenitors might be expected to express 
concomitantly or sequentially receptors for growth factois 
that regulate growth and maturation in a lineage-restri'; o 
fashion, has previously been made by Till et al U97C\' anc Varv 
Zant and Goldwasser (1978).
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5 CHRONIC GRANULOCYTIC LEUKAEMIA
5.1 Cellular aspects of CGL
Chronic granulocytic leukaemia (CGL) is a hematologic 
malignancy characterized by the proliferation and subsequent 
accumulation of myeloid cells and their precursors (Koeffler 
and Golde, 1981). It is probably the best characterized 
naturally-occuring human leukaemia with the primary 
leukaemogenic event identified at the molecular level (Groffen 
et al, 1984; Shtivelman et al, 1985). The disease can be
clinically divided into two phases. The initial chronic 
phase lasts for a median 3-4 years and is characterized by a 
marked increase in the stem-cell compartment committed to 
myelopoiesis. The acute phase (blastic crisis) of 3-6 months 
duration almost invariably follows the chronic phase of the 
disease and is characterized by a nonregulated outgrowth of 
immature myeloid or lymphoid blast-like cells and a loss of 
differentiation.
CGL was the first human neoplasia to be associated with a 
consistent chromosome abnormality, the Philadelphia chromosome 
(Rowley, 1973), which is present in 90-95% of cases (Galton, 
1981; Clarkson, 1985). The target for leukaemic
transformation in CGL appears to be at the level of Lee 
pluripotent stem cell, since the Philadelphia chromosome ic 
present in all hematopoietic elements of pat .'.cuts with .••.-.■L, 
including B- and T- cells . (Tough fit_al, 19*3: Wvins fll,
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1963; Golde et al, 1977; Martin et al, 1980; Fauser et al,
1985). The clonal origin of CGL was indicated further by the 
analysis of patterns of expression of glucose—6—phosphate 
dehydrogenase and adenylate kinase (Fialkow et al, 1977 and
1978).
Although multiple cell lineages are involved in CGL, the 
clinical features of the disease are usually limited to 
excessive granulocytosis alone or with thrombosis (Spiers, 
1977). The increased myelopoiesis observed, however, is not 
due to an accelerated proliferative rate as measured by 
labeling index or doubling time of myeloid cells (Chervenick 
and Boggs, 1968). Rather, the disease is characterized by 
massive expansion of pools of committed progenitors (Galbraith 
and Abu-Zahra, 1972; Moore et al, 1973; Goldman et al,
1980). The peripheral blood of a person presenting with CGL 
in chronic phase contains a large number of circulating 
leukocytes, many of which resemble normal mature neutrophil 
polymorphonuclear cells, although progenitor cells such as 
promyelocytes, myelocytes and metamyelocytes are also present 
(Koeffler'and Golde, 1981). The presence of these immature 
cells (especially myelocytes) was relevant to the isolation of 
the recombinant cDNA pCG14 (the starting point for the work 
described in Section 3) and will be discussed in Section 4.1.
Like most primary leukaemia cells, CGL cel ls require 
colony-stimulating activity for growth in_vitro i.e. their 
growth is not autonomous (Chervenick et al, 197.* ; Metcalj. ei
<a, 1974). Similarly, erythropoeisis in CGL is generally
erythropoietin-dependent (Goldman et al, 1980; Greenberg et 
al, 1980). Interestingly, CGL stem cells seem to be
compromised in their ability to interact with (adhere to) 
stromal cells in Dexter’s long term bone marrow culture system 
(Coulombel et al, 1983; Gordon et al, 1987). However,
whether this has any relevance to their growth in vivo remains 
to be established. What is known is that during the chronic 
phase of CGL the proportion of Philadelphia
chromosome-positive cells progressively increases over time to 
typically involve 99% of dividing bone marrow cells. This
growth advantage may be due to suppression of growth of
persisting Philadelphia chromosome-negative cells by the 
malignant clone (Gupta et al, 1984; Dube et al, 1984),
although convincing evidence for an inhibitory activity is 
lacking.
In general, during the chronic phase of CGL, although 
there are subtle abnormalities of granulocyte (Broxmeyer et 
al^ , 1977; Olofsson et al, 1976) and platelet (Shafer, 1984) 
function,' myeloid cells mature normally. CGL cells are
minimally invasive in chronic phase with malignant cells 
generally remaining restricted to hematopoietic tissues such 
as the marrow, spleen and cords of the liver.
As mentioned previously the chronic phase of CGL is 
unstable and is followed by an acute phase (blast crisis) 
characterized by loss of cell mauration anc. i.eque^uly oca h
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within 6-12 months. Since acute phase CGL is often
refractory to common anti-leukaeraic regimens, the duration of 
chronic phase is the major determinant of survival. Although 
most patients with CGL enter acute phase within 7 years, 
approximately 20/6 have a longer chronic phase. There appears 
to be a link between the length of chronic phase of the 
disease and the position of the breakpoint in bcr, the site 
involved in the reciprocal translocation giving rise to the 
Philadelphia chromosome (Birnie et al, 1989) although why this 
might be so in molecular terms in unclear.
1.5.2 Molecular nature of the Philadelphia translocation
CGL is one of the few leukaemias for which the primary 
leukaemogenic event has been identified. The Philadelphia 
chromosome, first described by Nowell and Hungerford (1960) is 
the cytogenetic hallmark of CGL. Using a combination of 
staining procedures, Rowley (1973) showed that this small 
chromosome 22 resulted from a specific reciprocal translOGjfioft 
t (9;22) q34.1; q11.21. In a small percentage of CGL cases 
the Philadelphia chromosome arises from anomalous complex 
translocations, but nonetheless studies using in situ 
hybridization have demonstrated that chromosomes 9 and /.2 are 
usually involved.
The localization of the cellular oncogenes c-abl_ and 
c-sis close to or at the breakpoints of chrcmosoitas 9 and '/ir­
respectively and the finding that then.’, oacogeoeu ore IRC
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in the exchanged segments of these chromosomes (de Kline et 
3l_> 1982), first suggested that one or both were involved in 
the development of CGL. It appears, however, that the c-sis 
oncogene is not transcribed in CGL leukocytes at a detectable 
level indicating that this oncogene does not play a direct 
role in the disease (Gale and Cananni, 1984). In contast, 
the c-abl gene is indeed one partner in the translocation.
The t(9;22) translocation in CGL leads to the fusion of 
c-abl sequences from chromosome 9 to sequences from a gene 
termed either phi or BCR in a small region of this gene termed 
bcr (break-point cluster _region) (Groffen et al, 1984). The 
c-abl gene is transcribed in a variety of human cell lines 
(Gale et al, 1984; Wang and Baltimore, 1983) giving rise to 
two normal RNA. species of 6kb and 7kb. However, in CGL
leukocytes, both in chronic and acute phases a novel 8kb c-abl 
transcript is detected. Direct cloning of this novel c-abl 
transcript from K562 cells, a CGL-derived cell line, and 
isolation of the genomic sequences of bcr, c—abl and bcr-abl 
fusions (Shtivelman et al, 1985; Grosveld fit al > 1986;
Groffen et al, 1984) led to the following molecular picture.
The breakpoints on chromosome 22 qll occur in a small region 
of 5.8kb (bcr). The bcr is itself part of a large gene (BCR) 
and comprises 5 exons of the gene. In contrast, breakpoint*
on chromosome 9 are scattered over a distance of at least 
200kb and are all located 5 ’ of the tyrosine kinase domain of 
the c-abl proto-oncogene (Heisterkamp 1983; Sht.ivej.inan
et al, 1985).
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As a result of the Philadelphia translocation, the c-abl 
gene is transferred from its normal position on chromosome 9 
q34 to the Philadelphia chromosome. This event creates a 
novel head-to-tail bcr-abl fusion on the Philadelphia 
chromosome, with the BCR gene closer to the centromere
(Heisterkamp et al, 1983). The fusion gene is thus
transcribed using the BCR promoter into a chimeric bcr-abl
mRNA consisting at its 5'-end of approximately 3.2kb of bcr 
sequences linked to 5.3kb of c-abl sequences, lacking the 
first exon of c-abl, lost during splicing. The result of the 
transcription of the chimeric bcr-abl mRNA then is the
production of an in-frame fusion protein of 210kD which 
exhibits an in vitro tyrosine kinase activity distinguishable 
from the enzymatic activity of the wild-type 145kD c-abl 
protein (Konopka and Witte, 1985; Konopka et al, 1984;
Ben-Neriah et al, 1986).
The very high correlation of the clinical pattern of CGL 
with the presence of the Philadelphia chromosome and 
expression of the chimeric protein argues strongly for a 
central role of the bcr-abl gene in the pathogenesis of the 
disease. One can envisage at least two possible mechanisms 
whereby fusion of bcr to c—abl could lead to neoplasia.
Firstly, since the t-(9;22) translocation subjects c-abl to the 
control of the BCR promoter element 2, jtt is possible that 
bcr-abl is expressed in a cell type* does not normally
express c ab^. This possibility seems unlikely, however,
since c—abl is expressed in diverse tissues including the 
hemolymphoid system and CGL cells (Gale et al, 1984; Westin 
et al, 1982). It is possible though that the neoplastic
effect of bcr-abl expression may be largely confined to a stem 
cell compartment within a CGL cell population which would not 
normally express c-abl protein; whether that minor 
sub—population of cells expresses c-abl is not known. An 
extension of this idea is the possibility that increased 
transcription of the bcr-abl and/or increased stability of the 
hybrid bcr-abl mRNA or fusion protein in such a stem cell 
compartment may contribute to neoplasia simply by unregulated 
expression of the c-abl tyrosine kinase activity. Relevant 
to this idea is the finding that although the normal BCR and 
c-abl genes are expressed at a low level (around 10-20 
copies/cell) in a relatively tissue non-specific fashion, the 
chimeric bcr-abl gene can be expressed at a 10-20-fold higher 
level (Collins and Groudine, 1983; Heisterkarap et al, 1985; 
Shtivelman et al, 1985).
A second possibility as to how bcr-abl protein might 
transform comes from in vitro studies on. the tyrosine kinase 
activity of it in relation to the proteins encoded by c-abl 
and ,v-abl. Protein tyrosine kinases themselves have been
implicated in both neoplastic t ranstevmation and in the 
control of normal cell- growth v. f&VlfiW&d trf. Foufces and 
Rich-Rosner, 1985; Hunter and Cooper. L98S). Xn 
assays the bcr-abl p210 polypeptide, hdS
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kinase activity to that of v-abl, the pi 60 transforming 
protein of Abelson marine leukaemia virus in which the 
N—terminal portion of the viral gag gene has replaced that of 
c-abl (Konopka and Witte, 1985). Moreover, in contrast to 
the normal c-abl gene product (pl45), both p210 (bcr-abl) and 
pl60 (v—abl) proteins are phosphorylated on tyrosine in vivo 
(Konopka and Witte, 1985). The possibility arises then that 
the fusion of bcr to c-abl sequences may either increase the 
tyrosine kinase activity or alter the substrate specificity of 
the c—abl protein either or both of which could potentiate 
transformation. However, despite the in vitro similarity of 
p210 (bcr abl) and pl60 (v-abl) their properties in vivo show 
major differences. The Abelson virus can transform bone 
marrow cells to yield tumorigenic cell lines (Whitlock and 
Witte, 1985) and can render factor-dependent cell lines 
independent of exogenous factor (Pierce et al, 1985; Cook et 
al, 1985). In contrast, the development of CGL appears to be 
a slow multi-stage process and CGL cells synthesizing the 
bcr-abl protein still require exogenous factor for growth
(Metcalf, 1985), and only rarely form permanent cell lines.
Furthermore, for most of the tyrosine kinases so far isolated, 
association with the plasma membrane appears to be crucial to 
their transforming ability (Hunter- and Cooper, 1985). in
both v—abl and v—src, myristylation of the N—terminal giVCx-ie 
residue leads to association with r.ne inner surface Oi. i_oe
cell membrane (Kamps et al , 1905* > Mattu~.y--P>.e'*of and
Baltimore, 1985); disruption of ryrintylation r^ovcs tfofs 
association and prevents . cellular . Tlv
S ' ' ’
sequence of bcr however, (Adams and Hariharan, 1987) provides 
no indication that bcr-abl would associate with the 
membrane. Direct proof that bcr-abl is not membrane bound, 
however, is lacking.
An intriguing finding which might relate to any mechanism 
whereby bcr-abl expression might lead to neoplasia is that the 
BCR gene itself is expressed in a variety of cell types, 
including fibroblasts, diverse lymphoid and myeloid cell lines 
and HeLa cells (Ben-Neriah et al, 1986). It follows then 
that the bcr-abl gene would most probably be transcribed in 
many cell types should a t(9;22) translocation occur. 
However, t(9;22) translocation and bcr-abl fusion is 
absolutely restricted to CGL and some cases of ALL. If, as 
seems likely, the translocation in CGL is a random event that 
could occur in any cell type, the marked specificity of 
t(9;22) for CGL and ALL requires an explanation. Evidence 
from Epstein-Barr virus immortalized B-lymphoid cell lines 
derived from patients with CGL (Konopka et al, 1986) and from 
interspecies human CGL cell—mouse fibroblast hybrids (Kczbor 
et al , 1986) demonstrates, respectively, that p210 is
expressed from the Philadelphia chromosome even. in. 
hematopoietic cells which do not have a f rarucly malignant 
phenotype and, in a non—hematopoietic eelx background (mouse 
fibroblasts). This pattern suggests that the simple
expression of p210 is not in itself, at lenst xi.- 
types, sufficient to elicit a full malignar-L p.i.e./n.ty pe. - -x.- 
specificity of t(9;22) for CGL then coc.'d; be cL-S. f 0 ■£h&
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restriction of crucial substrates of the p210 kinase 
(substrates which could in turn mediate transformation) to the 
pluripotent stem cell from which CGL originates.
Additionally, the long life-span of such pluripotent CGL 
stem cells with the Philadelphia chromosome could increase the 
likelihood of further carcinogenic events occuring 
stochastically. For example, it is known that blast crisis 
phase CGL cells are characterized by additional non-random 
chromosome abnormalities (Rowley, 1980; Champlin and Golde, 
1985) such as trisomy 8 or 19 or isochromosome 17q. The 
precise role of these further genetic changes in the progress 
of CGL from its chronic to its acute phase has yet to be 
established.
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.6 GENE EXPRESSION IN NORMAL AND LEUKAEMIC LEUKOCYTES
_ .P£j-Q.rA  it would seem that classification of leukaemias 
by surface marker expression alone is not ideal. For
example, any differences observed in marker expression may 
represent phenotypic changes not directly relevant to actual 
gene expression in leukaemic cells. Lack of correct display 
on the membrane, post— translational modification/processing, 
in addition to any translational controls^ might all serve to 
complicate a classificiation based simply on surface antigen 
expression. A more direct objective way of classifying
leukaemias (or indeed normal tissue sources) should be by 
directly detecting the abundance of individual mRNAs, since 
the most important single factor in determining the protein 
composition of a cell is the concentrations of these 
individual mRNAs. It has been known from some years that 
while many mRNAs are common to a variety of types of cell the 
abundance of some mRNAs can vary through several orders of 
magnitude in cells of different lineages (Ilastie and Bishop, 
1976; Young et al, 1976), as well as for cells at different 
stages of differentiation (Harrison, 1976; Minty et al, 
1978). Consequently, a comparison of the mRNAs of two
populations of cells might be expected to show whether these 
populations are composed of cells of the same or different 
types. How might one investigate leukaemic gene expression 
using differences in mRNA abundance oetweeu cii- o t 
leukaemias and between leukaemic and ncimni i.issue.' On- WGjj
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chosen by many workers is simply to isolate cells from 
leukaemic individuals peripheral blood or bone marrow and 
measure the abundances of mRNAs for which cloned probes are 
available, for example the mRNAs for the proto-oncogenes 
implicated in a wide range of neoplasias. Many studies of 
this type exist and have been instructive. For example, in 
CGL this approach demonstrated that there is an abnormal 
transcript of c-abl expressed in the bone marrow and 
peripheral blood cells of leukaemic individuals. This mRNA 
was subsequently shown to be a chimeric mRNA containing both 
sequences from c-abl and sequences from a gene termed BCR 
(breakpoint cluster region) (See Section 1.5.2). In most
cases, however, no abnormal transcripts of oncogenes are seen 
in leukaemia. In general, though, oncogene expression is 
higher in leukaemias which represent maturation arrest of more 
immature hematopoietic cells. For example, the c-myc mRNA is 
elevated in the peripheral blood and marrow cells of ANLL 
patients, as compared to CGL (Birnie et al, 1984) or normal 
hematopoietic cells (Westin et al, 1981; McLain, 1984;
Rothberg et al, 1984). This type of finding for c-myc is in 
accord with its role in cell differentiation and proliferation 
and the findings from other systems such as HL60 
differentiation that c-myc tends to be switched off before or 
concomitant with differentiation (Eick and Bornk.amm, 1980, 
Bentley and Groudine, 1986; Siebenlist et al, 1988j *
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.6.1 Differential cDNA libary screening
An alternative approach (and perhaps a more instructive 
one) in characterising leukaemias by gene expression is to 
isolate genes either expressed in one leukaemia and not in 
others, or expressed at higher abundance in one type than in 
others. This method was first used for human leukaemias by
Wiedemann et al (1983). By the process of differential
screening of cDNA libraries derived from the mRNA populations 
of leukaemic patients peripheral blood leucocytes, it was 
possible in this instance to isolate clones for mRNAs found at 
higher abundance in CGL than CLL leukocytes. Furthermore, 
using a panel of such recombinants it was possible to 
distinguish other patients by the patterns of hybridization 
since the patterns were significantly different between all 
CGLs and other populations of normal and leukaemic 
leukocytes. One clone isolated in this study, pCG14, will be 
discussed in detail shortly. A similar approach was later 
used by Mars et al (1985) with a similar outcome (Mars et al, 
1988).
This approach was also taken by Warnock et al (1985) by 
making a cDNA libary from an ANLL leukaemia (acute 
myelomonocytic) and 'screening with CGL, CLL and ALLcONfj. one 
clone in this study (designated pAM6) appeared to be 
characteristic of cells of early monoc3rte stage in 
differentiation, although its expression in individual ANLL 
cases was variable. Thus pAM6 expression was h..-h ->..n L. a>.t
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crisis of CGL where early myelomonocytic blast cells 
predominate. Moreoever, pAM6 was also found to be expressed 
in normal bone marrow (i.e. was not leukaemia-specific) and 
localized to NSE-positive (monocyte) cells by density gradient 
separation and Northern blotting of RNA prepared from normal 
bone marrow cells.
For all of the clones so far isolated in these two 
studies, where it has been checked, none have a  found to be 
leukaemia-specific, i.e. they were also expressed at some 
stage in normal hematopoiesis. This is to be expected,
however, since most of the programme of gene expression in a 
maturation-arrested leukaemic clone might be expected to be 
very similar if slightly asynchronous compared to the normal 
cell equivalent (see Section 1.4.3).
.6.2 Isolation of cDNAs for mRNAs found at high abundance in CGL
The lead-in to the work described in Section 3 was the 
isolation of cDNA clones representing mRNAs found at high 
abundance- in CGL leukocytes. Using differential screening of 
cDNA libraries (a forerunner of subtractive hybridization) 
Wiedemann et al (1983) isolate^ several cDNA clones 
representing mRNAs found at: high abundance in the peripheral 
blood leukocytes of chronic phase CGI patients. One of the 
recombinants, termed pCG14, was icsr.rc - to expressed at high
abundance in the leukocytes invas:iqa-koA- 33a i.icu out Oi. 2t<
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recombinants chosen at random, 4 of them were shown to be 
homologous to pCG14 (Wiedemann et al. 1983). One of these, 
pCG32, was also chosen for investigation.
.6.3 Expression of the pCG14 gene
Several studies on the expression of the gene encoding 
pCG14 were carried out prior to the work described in Section 
3. The first finding was that the gene encoding pCG14 seemed
only to be expressed in chronic phase CGL cells, and not in
the leukocytes of other leukaemias or normal peripheral blood 
leukocytes (Wiedemann et al, 1983; Warnock et al, 1985;
Birnie et al, 1983 and 1984). Birnie et al (1983) first
showed that pCG14 hybridized to an approximately 750-base mRNA
species. Interestingly, this mRNA was undetectable in
leukocytes from CLL, ANLL and ALL patients. In contrast 7
out of 7 chronic phase CGL patients’ leukocytes had moderate
to high levels of this mRNA.
The immediate possibility from these results was that 
expression of ,this gene might be diagnostic of CGL
leukaemia. However, expression of the gene was also found at
moderate to high levels in normal bone marrow (Milic et__ai ,
1987). This was the first indication chat expression In CGL 
leukocytes might be a result of an increased amount of
immature myeloid ceils spilling f;U.C into bur pfi '
blood. • Expression of the gene in ltnen?-.& S-e-efaftd
most likely because of the well-kr\6ww lf\er&a$& in fhvjtl £>Po I&S I-S
found in chronic phase CGL (see Section 1.5.1) and this was 
shown directly by Wiedemann et al (1989). Using a
combination of density gradient fractionation of normal bone 
marrow cells (and then Northern blotting and in vitro 
clonogenic growth of fractions) and in situ hybridization, 
expression of the pCG14 gene was shown to be restricted to a 
particular differentiation stage of myelopoiesis, that of the 
neutrophilic myelocyte. This cell is committed to
neutrophilic differentiation and forms pure neutrophil 
colonies in vitro (Wiedemann et al, 1989). In situ
hybridization studies on CGL peripheral blood leukocytes, 
moreover, localized expression to a cell type morphologically 
indistinguishable from that seen in normal bone marrow (Birnie 
et al ? 1984; Wiedemann et al, 1989), conf irming the hypothesis 
for expression of the gene in CGL leukocytes.
The above results were of 
the gene encoding pCG14 
leukaemia-specific way, its 
differentiation stage-specific, 
the protein encoded by the 
expression was controlled 
unknown. The work in Section 
also shed some light on the 
describes the characterization 
homologous clone pCG32 shown 
whilst Section 3.2 describes ho
obvious interest since although 
was not expressed in a 
normal expression was highly 
However, both the nature of 
gene and precisely how its 
during differentiation was 
3 clarified the first point and 
second. Thus Section 3.1.
of the pCGl4 cDNA (and the 
to anc ode the same protein) 
w jerve expressed dunr-
myelopoiesis In vitro, using the HL60 cell line 
differentiation system. Lastly, Section 3.3 describes the 
characterization of the genes encoding both pCG14 and mrs, a 
closely homologous gene.
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2. MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Reagents and glassware
All chemicals used were generally Analar Grade, British 
Drug Houses. Some of the more specialised chemicals,
including sodium lauryl sarcosine, MOPS, antibiotics, ethidiura 
bromide, 2—mercaptoethanol and all the reagents required for 
hybridization solutions, except where stated, were purchased 
from Sigma. Yeast extract, bacto-tryptone and agar for 
bacterial culture, were purchased from Difco Laboratories. 
Ultra-pure CsCl, sucrose, urea and agarose were obtained from 
Bethesda Research Laboratories, Gibco Limited. All tissue 
culture media were obtained from Gibco Limited or Flow
Laboratories. All radioisotopes were supplied by Amersham 
International.
All glassware, for handling RNA or DNA, was sterilised by 
treatment with Baysilon-Olemulsion-H and baked at 80° 
overnight. All plasticware, tubing and glassware was further 
sterilised by soaking overnight in 0.05% diethyl pryocarbonate
in water then drying in an oven at 80°C. Exogenous nucleases
were removed from all buffers used during the preparation of 
nucleic acids, by addition of diethyl pyrocarbonate at
0.05% and then destruction of the chemical by 
autoclaving at 15 lbs/in2 for approximately 15 min.
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Disposable plastic pipette tips and tubing were sterilised by 
autoclaving. Other solutions were either sterilised by
autoclaving or by passing through a Millex 0.45 pm filter 
(Millipore (UK) Limited).
Normal leukocytes used in Western blotting were kindly 
supplied by the West of Scotland Blood Transfusion Service, 
Law Hospital.
Both normal and leukaemic leukocytes used to provide 
material for Southern blotting, PCR amplification and Northern 
analysis were obtained by informed consent from patients 
attending hospitals mainly in the Glasgow area.
A rabbit anti-peptide antiserum against human defensins 
was raised by Pat Barber and Neville Husskins at the AFRC in 
Cambridge using an oligopeptide representing sequences from 
mature defensin (see Fig. 12).
2.1.2 E.coli strains and cloning vectors
Several E.coli strains were utilized, the particular 
strain used depending on the experiment.
For plasmid and M13 cloning, both JM83 and JM101 (Viera 
and Messing, 1983) were used. For plating of genomic DNA 
libraries in lambda vectors both LE392 (lambda L47.1 vector) 
and NM538 (EMBL3 vector) were used.
106
Vectors used were pUC8 (Viera and Messing, 1982), pAT153 
(Twigg and Sherratt, 1980) and pUC 18/19 (Yanish-Perron et al, 
1985), all for plasmid cloning. For M13 cloning, both M13 
mp 10 and 11 (Messing and Viera, 1982) and M13 mp 18 and 19 
(Yanish-Perron et al, 1985) were used.
For genomic library construction in lambda vectors, both 
L47.1 (Loenen and Brammar, 1980) and EMBL3 (Frischauf et al, 
1983) were used.
2.1.3 Cloned probes used
P2-microglobulin, containing DNA representing 77% coding 
region plus 3'— flanking sequence of the human ^-microglobulin 
gene in the Pstl site of pBR322; supplied by Dr. S. Suggs 
(Suggs et al, 1981).
C-myc exon 1, contains exon 1 sequences (Aval-Aval, 340bp 
fragment) of human c-myc gene cloned into the Aval site of 
pBR322.
C-myc exon 2, contains exon 2 sequences (Pstl - Pstl 415bp 
fragment) of the human c-myc gene cloned into the Pstlsite of 
pBR322.
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2.1.4 DNA, RNA and protein size markers
DNA size markers used were lambda CI857 digested with Hind 
3 or Hind 3 and EcoRl, and (j) X174 (replicative form) digested 
with Hae3 (Bethesda Research Laboratories, Gibco Limited). 
RNA size markers were derived from bacteriophage T7, yeast 2 
p, and bacteriophage cr DNA and were purchased as an RNA Ladder 
from Bethesda Research Laboratories.
Protein molecular weight size markers were obtained from 
BRL and contained pre-stained proteins at a concentration of 
lmg/ral varying in size fftlm 3kD (insulin A and B chains) to 
44kD (ovalbumin).
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2.2 METHODS
2.2.1 Cell culture
HL60 cells were cultured in RPMI-1640 (Gibco) plus 0.2% 
sodium bicarbonate, 2 mM sodium pyruvate, 10% foetal calf
serum and 4 mM glutamine. Cells were passaged every 3 days 
at 5 x 105 cells/ml in Nunclon tissue culture grade flasks and 
kept at 37°C in 5% CO2, 95% O2. The average doubl ing^t irae 
for HL60P25 cells was 36 hours.
2.2.2 Mycoplasma testing
Cells were tested periodically for the absence of 
mycoplasma. The cells to be tested were pelleted by
centrifugation at 1500 rev/min for 5 min in an MSE bench 
centrifuge. The cell free supernatant was then placed in a 
sterile tissue culture grade petri dish (Nunclon), 2 ml of 
fresh medium was added, and 2 x 10^ NRK49 fibroblasts were 
seeded into the dish. These cells are known to be mycoplasma 
free. The dish was incubated at 37°C in a humidified
incubator at 5% CO2 , 95% 02 for 3 days. At the end of the 
incubation period the cells were fixed by addition of an equal 
volume of fixative (1 volume of glacial acetic acid : 3 
volumes of methanol) for 5 min. The fixative was then
removed and the cells air dried. Hoechst 33258 stain was 
prepared from a 1 mg/ml stock by diluting 1:20,000 in
phosphate buffered saline. This solution was poured onto the
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fixed cells and incubated at room temperature for 10 min. 
The stain was removed and the cells were washed two times in 
water. The cells were viewed by fluorescence microscopy
using a water immersion lens. Hoechst 33258 is a fluorescent 
stain for DNA. If the cells were mycoplasma-free, only the 
cell nucleus fluoresced’ however if the original cells had 
been mycoplasma infected fluorescence was also detected in the 
cytoplasm of the NRK49 cells.
2.2.3 Induction of differentiation
(i) Dimethyl Sulphoxide
HL60 cells were induced at a concentration of 2 x 10^ 
cells/ml with Merck dimethyl sulphoxide giving a final inducer 
concentration of 1.5% (v/v) DMSO. Induction was over a 5 day 
period with only one addition of the inducing agent.
(ii) Retinoic Acid
Retinoic acid (Sigma) was kept in solution, in ethanol, 
at a concentration of 10~^ M. Stock solution was kept for up 
to 2 weeks only and stored in a light-tight container at 
-20°C. HL60 cells were induced at 5 x 105 cells/ml giving a 
final RA concentration of 10-6 M. RA was added every 24 
hours throughout the 5 day induction period. The induced 
cultures were incubated at 37°C as normal but in the dark to 
limit degradation of the inducing agent throughout the period
of treatment.
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All cells used in the inductions were taken from 
exponentially growing cultures. The cells were passaged 24 
hours before addition of inducing agent to reduce any 
potential serum stimulation from the fresh medium.
2.2.4 Staining procedures
(i) May-Grunwald and Gierasa Staining
Cells were spun onto clean glass slides using a Shannon 
cytocentrifuge at 50 rev/min for 5 rain and air dried. The 
cells were then fixed in 70% (v/v) methanol. May-Grunwald 
stain was prepared by diluting 2 volumes of stain in 3 volumes 
Sorensen’s Buffer pH 6.85 (0.066M disodium hydrogen
orthophosphate, 0.066M potassium dihydrogen orthophosphate) 
and filtering through Whatman Filter paper. Giemsa stain was 
also diluted in Sorensen's buffet (1 volume stain: 9 volumes
buffer) and filtered. The slides were stained for 5 mins in 
May-Grunwald stain, followed by 10 mins in Giemsa stain. 
They were then washed twice in double—distilled water, air 
dried and mounted in DPX mountant (BDH), and examined by light 
microscopy.
m
(ii) Nitroblue Tetrazoliura - a Myeloid Cell Specific Stain
1 x 106 cells were harvested by centrifugation in an MSE 
bench centrifuge at 1500 rev/rain for 5 rain at room 
temperature. The supernatant was discarded and the cell 
pellet was resuspended in 10 mM tetradecanoyl phorbol acetate 
(Sigma) containing 0.2% (w/v) nitroblue tetrazoliura (NBT) 
(Sigma) in PBS. The cell suspension was incubated at 37°C
for 25 min. Following incubation, 0.5 ml of the cell
suspension was removed and the cells centrifuged on to a clean 
glass slide using a Shannon cytocentrifuge. The slide was 
then air dried before staining for 5 min in May-Grunwald stain 
followed by 10 min in Giemsa stain. The stains were prepared 
as described in Section 2.2.4.
After removing excess stain by washing in double 
distilled water, the slide was air dried and mounted in DPX
(BDH)
mountant before viewing by light microscopy.
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2.3 ANALYSIS OF RNA
2.3.1 Cell harvesting
1 X 10? - 1 X 109 cells were harvested from exponentially 
growing cultures by centrifugation in an MSE bench centrifuge 
at 1500 rev/min for 5 rains, if the volume was less than 
100ml. For larger volumes, cells were spun in a GS-3 rotor 
at 2000 rev/min for 10 mins in a Sorvall RC-5B centrifuge at 
0°C.
2.3.2 Preparation of whole cell RNA
The method used was adapted from that of Chirgwin et al 
(1979). Following cell harvesting, cells were lysed by
addition of 5 M guanidinium isothiocyanate (Bethesda Research 
Laboratories), 0.05 M tris pH 8.0, 0.5 M EDTA, 0.7 M
2-raercaptoethanol at pH 7.0 to give a final cell concentration 
of 1-2 x 108 cells/ml. The preparation could be stored
frozen at this stage before the isolation of total whole cell
RNA. The solution was then sonicated, in a Bronson sonicator 
at 20 Hz, by 3 x 30 second pulses, to shear the DNA. The 
preparation was kept on ice at all times. Lauryl-sarcosine 
was then added to a final concentration of 1/> and the solution 
heated for 2 min at 68°C to dissolve the sarcosine. This was 
then loaded on to a 2.5 ml CsCl cushion (5.7M CsCl, 50 mM EDTA 
pH 7.0, at a refractive index of 1.3995) in a B60 14 ml
polypropylene tube and spun for 36 h at 15°C, 35,000 rev/min
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in a B60 Damon IEC ultracentrifuge. Following
centrifugation, the guanidinium isolthiocyanate was unloaded 
leaving the RNA clearly visible as a gelatinous, clear
pellet. The tubes were inverted and allowed to drain well. 
The RNA pellet was then resuspended in DEPC-treated double
distilled water and precipitated from solution at -20°C, by 
the addition of 3 M sodium acetate to 0.3 M and 2.5 volumes of 
ethanol. RNA was retrieved by centrifugation at 10,000
rev/min for 10 min at -15°C in a Sorval HB-4 swing out
rotor. The pellet was resuspended in DEPC-treated double
distilled water to which was added an equal volume of 4 M LiCl 
and 8 M urea. The RNA was precipitated from this solution by 
incubation overnight at 4°C. This precipitation step removed 
any residual DNA from the RNA, as DNA does not precipitate 
under these conditions. The RNA was again collected as
before by centrifugation at 10,000 rev/rain in a Sorval HB-4 
swing out rotor. Finally, the RNA was precipitated once more 
by addition of sodium acetate to 0.3 M and 2.5 volumes of 954 
ethanol, colleted by centrifugation and washed in 70% (v/v)
ethanol and then 95% ethanol. The pellet was then dried 
briefly and resuspended at 1 pg/ul in DEPC-treated double 
distilled water.
2.3.3 Preparation of poly(A)+ RNA
Poly A+ mRNA was separated from whole cell RNA using 
Hybond-mAP (Amersham), a diazonium-activated paper substituted 
with polyuridylic acid according to a method described in the
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manufacturer’s manual. Briefly, approximately 1 mg of whole 
cell RNA as a 1 mg/ml solution in DEPC-treated water was 
denatured by incubation at 65°C for 5 minutes, chilled on ice 
and 4M NaCl added to give a final concentration of 0.5M. To
this solution was added Hybond m—AP (7cm^), prewetted by
washing in 0.5M NaCl for 5 rains at room temperature. The
mixture was then incubated for 2 hours at room temperature 
with agitation. The mAP paper was then removed from the RNA 
solution and washed three times in 30ml 0.5M NaCl, 5 mins per 
wash, to remove unbound RNA. Salt was removed by washing the 
paper in 70% ethanol for 2 rains with continuous shaking. 
Poly A+ RNA was eluted from the mAP paper by the addition of 
500 jil DEPC-treated water and incubation for 5 mins at 70°C. 
The paper was then removed from the poly A+ RNA solution and 
the yield of poly A+ RNA obtained determined by 
spectophotoraetric means.
2.3.4 RNA fractionation on denaturing agarose gels
This method was taken from Boedtker (1971). 10-30 pg of
total whole cell RNA, or 1-5 jug poly (A+) RNA was freeze-dried 
then resuspended in 9 pi formfl^mide denaturation buffer (504
forraomide, 2.2 M formaldehyde, lx MOPS buffer (40 mM sodium 
MOPS, 10 mM sodium acetate, 1 mM EDTA pH 7.0)). The samples 
were then denatured by heating for 15 min at 68°C and chilled 
immediately. Prior to loading on the gel, 1 p'l of loading 
buffer (50% glycerol, 0.1% bromophenol blue, 10 mM sodium 
p hosphate pH 7.0) was added. The RNA was
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electrophoresed through 50 ml horizontal, denaturing, 1% 
agarose gels containing 2.2 H formaldehyde. Gels were
buffered in MOPS buffer (40 mM sodium MOPS, 10 mM sodium
acetate, 1 mM EDTA pH 7.0) and subjected to electrophoresis at 
90 volts for 1 h with buffer recirculation. Prior to
transfer, gels were stained in a solution of ethidium bromide 
(5 ug/ml) in DEPC-treated water (20 rains, room temperature), 
visualized under UV to check integrity and amount of RNA, and 
photographed.
2.3.5 Northern blot analysis of RNA
The elecrophoresed RNA was transferred directly onto 
Hybond-N (Amersham) by blotting in 20 x SSC (3M NaCl, 0.3M 
sodium citrate pH 7.0) as described by Thomas (1980). The 
blotting apparatus was set up as described by Southern
(1975). The membrane was first soaked in DEPC-treated double 
distilled water then in 20x SSC for 30 min prior to blotting 
overnight. At the completion of transfer the membrane was air 
dried and then irradiated on a UV transilluminator for 5 mins 
to immobilize the RNA.
2.3.6 Slot blotting of RNA
2 }ig aliquots of total cellular RNA in DEPC-treated water 
(10 ul) were heated at 65°C for 15 mins and chilled on ice.
Samples were then slot-blotted onto Hybond-N (Amersham) using
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a Hybri Slot Manifold slot-blotter (BRL) following 
manufacturers instructions. The Hybond—N membrane was
prepared by soaking in DEPC-treated water, then in 20x SCC (3M 
NaCl, 0.3M sodium citrate pH 7.0) for 30 rains and air dried. 
After slot-blotting, the membrane was allowed to air dry and 
then irradiated on a UV t ransillurainator for 5 rains to 
immobilize the RNA.
2.3.7 Primer extension analysis of RNA
Primer extension reactions were performed by a 
modification of the method of Jones et al (1985). 
Lyophilized RNA (typically 10 pg poly A+ or 50 pg total RNA) 
was dissolved in 8 pi of 10 mM Tris-HCl, pH 7.9, containing 25 
ng of 32p-5»-end-labelled synthetic oligodeoxynucleotide and 
heated at 85°C for 5 rains. After addition of 2 pi of a 
solution containing 10 mM Tris-HCl, pH 7.9, 1 mM EDTA, 1.25 M 
KC1, the mixture was annealed at 65°C for 60 min, then diluted 
with 25 pi of 20 mM Tris-HCl, pH 8.7, containing 10 mM MgCl2 , 
5 mM dithiothreitol, 50 pM deoxynucleoside triphosphates
(dNTPs), 10 pg/ral actinomycin D, and 20 units of avian
myeloblastosis virus (AMV) reverse transcriptase (Boeringer 
Corporation Ltd, London). The mixture was incubated at
48°C for 60 mins, chilled and mixed with 300 pi of 95% 
ethanol. The precipitate was collected by centrifugation,
washed with 70% ethanol, and dried. The precipitate was
resuspended in 5 pi of water, mixed with 5 pi of forrflamide 
dye m i x t u r e  ( U n i t e d  States B i o c h e m i c a l s
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Sequenase Kit), heated at 90°C for 5 rains, and fractionated on 
an 8% polyacrylamide sequencing gel. Dried gels were exposed 
to Kodak X-OMAT AR film with intensifying screens at -70°C for 
varying times.
2.3.8 Primer extension sequencing
The 5'—end of pCG14-homologous mRNA was sequenced 
directly by the primer extension/dideoxynucleotide method of 
Geliebter et al (1986). Briefly, lyophilized RNA (10 pg poly 
A+ from CGL leukocytes containing highly abundant 
pCG14—homologous RNA (see Fig. 22A, lane 9) was dissolved in 8 
pi of 10 mM Tris-HCl, pH 7.9, containing 25 ng of 
32p-5’-end-labelled sythetic oligodeoxynucleotide A (see Fig. 
3) and heated at 85°C for 5 mins. After addition of 2 pi of
a solution containing 10 mM Tris-HCl pH 7.9, 1 mM EDTA, 1.25 M
KC1 the mixture was annealed at 65°C for 60 mins and split 
into 5 2 pi aliquots. Four sequencing mixes (A, C, G and T) 
containing 10 mM MgCl2 , 5 mM dithiothreitol, 50 pM
deoxynucleoside triphosphates (dNTPs), 10 pg/ml actinomycin D 
and 2 Units AMV reverse transcriptase, in addition to 0.5 mM 
dideoxy-ATP (A), 0.25 mM dideoxy-CTP (C), 0.5 mM dideoxy-GTP 
(G) or 1 mM dideoxy-TTP (T) in 3.3 pi aliquots was then added 
to each of the four 2 pi aliquots of oligo A—annealed RNA. A 
parallel reaction lacking dideoxynucleoside triphosphates was 
also set up to rule out premature terminations obtained during 
primer extension. The mixtures were then extended at 48®C
for 60 rains, chilled on ice, and 5 pi formqmide dye mixture
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(United States Biochemicals Sequenase Kit) added. The
mixtures were then heated at 90OC for 5 mins and fractionated 
on an 8% polyacrylamide sequencing gel. Dried gels were 
exposed to Kodak X—OMAT AR film with intensifying screens at 
-70°C for 7 days.
2.3.9 SI nuclease protection analysis 
(i) Probe Preparation
To map the junction in pCG14 cDNA of pCG14 mRNA-derived 
and foreign sequences, a single-stranded uniformly-labelled 
probe containing sequences spanning the hypothesized junction 
was prepared by subcloning a Bgl 2-Pstl probe (see Fig. 2) of 
pCG14 into M13 raplS. Cloning into M13, identification of 
recombinants and preparation of single-stranded M13 DNA are as 
described in Section 2.7. A uniformly-labelled probe was 
prepared essentially using the method of Bentley (1984). 
Approximately 1 pg of M13 recombinant (containing the coding 
strand of pCG14) was annealed with 200 ng M13 universal primer 
(BRL) in a volume of 7 pi buffer containing 15 mM Tris-HCl, pH 
8.0, 7 mM MgCl2 by placing the mixture (in a 1.5 ml eppendorf) 
in a large beaker of water at 70°C and allowing it to cool to 
30°C. An antisense uniformly-labelled probe was synthesized 
by the addition of 7 pi of a buffer containing 0./ mM dAlP, 
0.7 mM dGTP, 0.7 mM dTTP, 0.35 mM dCTP, 30 pCi ( 32P)dCTP (400 
Ci/mM, Amersham), 2 units Klenow Ej f coli DNA polymerase 
(Boeringer Corporation Ltd, London) and incubating
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for 15 mins at room temperature. DNA synthesis was
terminated by incubation at 60°C for 10 mins. A secondary 
restriction enzyme cut was performed on the DNA using EcoRl by 
the addition 5 pi of 5x EcoRI buffer (0.5M NaCl, 0.1M 
Tris-HCl, pH 7.5, 0.05M MgCl2) and 2 pi EcoRI (lOU/pl,
Boeringer Corporation Ltd, London) incubating for 4 hours at 
37°C.
The mixture was then extracted twice with 
phenol/chloroform, the DNA ethanol precipitated, washed in 70% 
ethanol, dried and resuspended in 5 pi TE (10 mM Tris-HCl pH
7.6, 1 mM EDTA) prior to the addition of 5 pi formQmide dye
mixture (United States Biochemicals Sequenase Kit). The DNA 
was denatured by heating at 90°C for 5 minutes and the 
255-base probe purified by elecrophoresis on a 6% 
polyacrylamide sequencing gel. The probe was localized by 
autoradiography and extracted from the gel slice by incubation
at 37°C for 12 hours in 200 pi of a buffer containing 0.5 M
ammonium acetate, 1 mM EDTA. Acrylamide fragments were
removed by passing the solution through glass wool and the DNA 
ethanol precipitated, washed in 70% ethanol, dried and 
resuspended in 50 pi of TE buffer. The probe was frozen at
-20°C until use within 7 days.
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(ii) SI protection
60,000 cpm of probe and either 10 pig poly A+ RNA or 50 pig 
total RNA or tRNA were lyophilized together and resuspended in 
8 pi form inide prior to the addition of 2 pi of a buffer 
containing 2M NaCl, 0.2M PIPES, pH 6.4, 0.005M EDTA. The
mixtures, in 500 pi eppendorfs, were overlaid with 20 pi 
mineral oil to prevent evaporation, denatured by incubation at 
90°C for 10 rains, and allowed to hybridize at 50°C for 18 
hours. To each mixture 235 pi of a buffer containing 0.25M 
NaCl, 0.03M sodium acetate, pH 4.6, 0.001M ZnS0 4, 200 pg/ml 
salmon sperm DNA and 500 Units/ml SI nuclease (Boeringer 
Corporation Ltd, London) was added and SI digestion allowed to 
proceed for 1 hour at 37°C. The mixtures were then extracted 
twice with phenol/chloroform, nucleic acids ethanol- 
precipitated, washed with 70% ethanol, dried and resuspended 
in 5 pi TE. After addition of 5 pi form mide dye mixture 
(United States Biochemicals Sequenase Kit), the samples were 
heated at 90°C for 5 mins and fractionated on an 8% 
polyacrylamide sequencing gel. Dried gels were exposed to 
Kodak X-OMAT AR film with intensifying screens at -70°C for 7 
days.
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2.3.10 PCR amplification of RNA
(i) cDNA Reaction
10 pg total or 0.2 pg poly A+ RNA was freeze-dried and
lyophilized under vacuum prior to the addition of 18 pi
annealing buffer (250 mM KC1, 10 mM Tris-HCl, pH 8.3, ImM
EDTA) and 1 pi of a 500 ng/pl solution of oligo D (see Fig. 3) 
in H2O. The samples were then denatured for 3 rains at 80°C 
before being transfered to a large beaker of water at 70°C for 
25 mins to allow annealing. Samples were then allowed to 
cool to room temperature and 30 pi cDNA buffer (24 mM
Tris-HCl, pH 8.3, 16 mM MgCl2 , 8mM DTT, 0.4 mM (each) dATP,
dCTP, dGTP, dTTP, 10 pg/ml actinomycin D and 20U AMV reverse 
transcriptase (Boeringer Corporation Ltd, London) added before 
incubating at 45°C for 60 rains.
(ii) PCR Protocol
To amplify by the polymerase chain reaction (Saiki et al 
1985), 25 pi of the cDNA reaction was added to 10 pi Taq
polymerase buffer (100 mM Tris-HCl pH 8.3, 500 mM KC1, 15 mM
MgCl2 , 0.1% (w/v) gelatin). 20 pi 2.5 mM dNTPs, 1 pi oligo 
B 1 (500 ng/pl) (see Fig. 3) and 3 pi Taq polymerase (lU/pl, 
Cetus) were then added and the reactions made up with water to 
100 pi. The mixtures were then heated to 90°C for 5 rains, 
overlaid with 100 pi mineral oil to reduce evapor ation and 
subjected to 30 cycles of the polymerase chain reaction on a
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Perkin Elmer Cetus DNA. thermal cycler. Each cycle consisted 
of 1 rain denaturation, 3 mins annealing and 2 mins
extension. Following PCR, the mixtures were extracted with 
phenol/chloroform, DNA. ethanol-precipitated, washed with 70% 
ethanol, dried and resuspended in 20 jul water. Following gel 
electrophoresis on a 1.8% TBE-agarose gel, the 270bp amplified 
products were purified and V 3 of the amount digested with Hae 
3 (20U) or Hind 3 (20U, to ensure complete digestion with
another restriction enzyme) for 12 hours at 37°C in buffers 
recommended by the manufacturer (Boeringer Corporation Ltd, 
London), including 5 mM spermidine. Both undigested amplified 
DNAs Hae 3-digested and Hind 3-digested DNAs were then 
electrophoresed on a 1.8% TBE agarose gel and the gel Southern 
blotted onto a Hybond-N membrane as described in Sections
2.4.5 and 6. The membrane was then hybridized with 5 '-end 
labelled oligo C as described in Section 2.6.3.
2.3.11 Nuclear run-on analysis
(i) Preparation of nuclei
Cells at a density of 5 x 105/ml were harvested from
exponentially growing cultures of HL60P25 (see Section 2.3.1)
and washed with PBS three times. Nuclei were prepared by
resuspension of the cell pellet (containing approximately 10^ 
cells) in 5 ml of NP40 lysis buffer (10 mM Tris-HCl,
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pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5% (v/v) NP40) and
incubating on ice for 5 mins. Nuclei were pelleted by
centrifugation at 500g (2,400 rev/min on an MSE centrifuge) 
for 5 rains prior to resuspension in 1 ml of nuclei storage 
buffer (50 mM Tris-HCl, pH 8.3, 40% (v/v) glycerol, 5 mM
MgCl2, 0• 1 EDTA). Nuclei were stored at -70°C for a
period of up to six months before nuclear run-on assay.
(ii) Nuclear run-on assay
Nuclei (200 p 1, approximately 2 x 10^ nuclei) were added 
to 200 pi nuclear run-on reaction buffer (2 mM dithiothreitol,
10 mM Tris-Hcl, pH 8.0, 5 mM MgCl2 , 300 mM KC1, 0.5 mM each of
ATP, CTP, GTP and 200 pCi (^^P)-UTP) and incubated for 30 rains 
at 30°C. Reactions were stopped by the addition of 30 pi 
RNase-free DNasel (Bethesda Research Laboratories) incubating 
for 5 rains at 30°C. The reaction mix was made 1 X SET (5 X
SET is 5% SDS, 25 mM EDTA, 50 mM Tris-HCl, pH 7.4) prior to
the addition of proteinase K (BRL) to a final concentration of
200 pg/ml. Reaction mixes were incubated at 37°C for 45 mins 
then extracted with an equal volume of phenol/chloroform. 
The interphase was also extracted with 1 X SET, both aqueous
phases pooled prior to the addition of ammonium acetate to a 
final concentration of 2.3M, and an equal volume of isopropyl 
alcohol. Labelled RNA was precipitated by incubation on dry
ice for 15 rains, and the precipitate collected by 
c e n t r i f u g a t i o n  at 1 0 , 0 0 0  r e v / m i n  for
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10 rains. The precipitate was then washed with 70% (v/v)
ethanol, washed with 95% ethanol, dried and resuspended in 100 
pi TE.
(iii) Hybridization
Nitrocellulose filters containing 500 ng/slot denatured 
double-stranded cDNA probes were prepared on a Hybri-Slot 
Manifold slot-blotter (BRL) under conditions suggested by the 
manufacturer. Filters were prehybridized in hybridization 
solution (10 raM TES, pH 7.4, 0.2% SDS, 10 mM EDTA, 0.3 M NaCl,
IX Denhardts and 250 fig/ml E . col i RNA) for 12 hours at 65°C.
Following prehybridization, the filters were hybridized to the 
run-on RNAs in hybridization solution for 36 hours at 65°C.
A typical reaction contained 2 ml of hybridization solution at 
IX 107 cpra/ml. Following hybridization, the filters were 
washed twice for 15 rains in 0.1X SDS, 2X SSC at room 
temperature and then washed at 60°C (0.1% SDS, 0.1X SSC) for 
30 rains. Filters were then exposed to Kodak XAR film in 
cassettes containing intensifying screens at -70°C for various 
times prior to autoradiography.
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2.4 ANALYSIS OF DNA
2.4.1 Preparation of genomic DNA
Genomic DNA was prepared using a modificaiton of the method of 
Gross-Bellard et al (1973). 1 x 10^ cells were harvested as
described in Section 2.3.1. The cells were then lysed by 
resuspension in 10 mM EDTA, 10 mM tris-HCl pH 8 , 10 mM NaCl 
contaiing 5% sarcosine (w/v) and proteinase K (20 units/mg)
(Boehringer Corporation Ltd) at a final concentration of 100 
jug/ml. This mix was incubated overnight
at 37°C. An equal volume of phenol and chloroform with 0.5 M
tris-HCl pH 8.0, 10 mM NaCl, 10 mM EDTA, 0.5% SDS, was added 
and mixed gently for 10-30 min. This was followed by
centrifugation in an MSE 4L centrifuge at room temperature and 
at 1000 rev/min for 10 min. The aqueous phase was then 
removed and sodium acetate added to a final concentration of 
0.3 M. Following the addition of 2.5 volumes of ethanol, the 
DNA was spooled out from the solution using a sterile glass 
rod. This was washed twice in 70% (v/v) ethanol, twice in 95% 
ethanol and then once in chloroform. The DNA was washed,
while still wound onto the glass rod, by immersion in each 
wash for 1 min, followed by expulsion of as much fluid from 
the DNA as possible before moving on to the next wash.
Finally the DNA was air dried and the rod placed in 10 ml of 
0.1X SSC overnight to allow the DNA to resuspend. Following 
resuspension, the solution was RNase treated for 3 h by
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addition of boiled RNase A (50 jig/ml) and KNase T (1 pg/ml). 
0.4 M EDTA was added then to a final concentration of 10 mM, 
sarcosine to 4% and proteinase K (20 units/mg) to a final 
concentration of 50 pg/ml. This solution was incubated for 3 
h at 37°C. At the end of incubation the DNA solution was 
again phenol/chloroform extracted as before and the DNA from 
the aqueous phase spooled out of solution containing 0.3 M 
sodium acetate and 2.5 volumes ethanol. The DNA was washed 
and dried as described above and then dissolved in TE buffer 
(10 mM tris pH 8.0, ImM EDTA) to give a final concentration of 
500 jig/ml.
2.4.2 Preparation of plasmid DNA
(i) Large Scale Preparation
This method was a modification of that described by Birnboim 
and Doly (1979). From 10 ml overnight cultures of the 
bacteria containing the plasmid to be prepared? 1 ml was 
inoculated into 500 ml of L-broth (1% (w/v) bacto-tryptone, 1% 
(w/v) NaCl, 0.5% (w/v) yeast extract). 50 pg/ml ampicillin 
was added if the plasmid contained the appropriate antibiotic 
resistance gene. The culture was incubated overnight at 37°C 
in a shaking incubator. Following incubation, the cells were 
pelleted by centrifugation at 7000 rev/min for 5 min at 4°C in 
a GS-3 rotor of a Sorvall RC-5B centrifuge. The supernatant 
was decanted and the pellet drained. The cells were then 
lysed by resuspension of the pellet in 18 ml
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of cold lysis buffer (50 mM glucose, 25 mM tris-HCl pH 6 .8 , 10 
mM EDTA, 2 mg/ml lysozyme). The resuspended pellet was left 
on ice for 30 min. To this was added 40 ml of a solution 
containing 0.2 M NaOH, 1% SDS and the mixture further 
incubated on ice for 5 rain. The solution denatures the
bacterial chromosomal DNA. Finally, 20 ml of ice-cold 5 M
potassium acetate pH 4.8 was added to neutralize the lysate.
Addition of this causes the bacterial chromosomal DNA to 
aggregate and become insoluble. After 1 h incubation on ice 
this insoluble material was pelleted by centrifugation at 8000 
rev/min, at 4°C in a GS-3 rotor of a RC-5B Sorvall
centrifuge. The supernatant was then removed and filtered 
through gauze to prevent any contamination by aggregated 
bacterial DNA. The plasmid DNA was precipitated by addition 
of 0.6 volumes of ice cold isopropanol and incubated at room 
temperature for 15 min. DNA was pelleted by centrifugation 
at 8000 rev/min for 10 min at 4°C as before. The supernatant 
was removed and the pellet drained then resuspended in 5 ml 50 
mM tris-HCl pH 8.0, 10 mM EDTA, 0.5 ml ethidium bromide (10
rag/ml) plus CsCl (Bethesda Research Laboratories) to give a 
final refractive index of 1.3890. The solution was then 
transferred to 10 ml polycarbonate tubes for an MSE 10 x 10 ml 
titanium fixed angled rotor. The tubes were filled to three 
quarters with the plasmid DNA solution, the remainder of the 
volume was filled with paraffin oil. The tubes were then 
centrifuged at 40,000 rev/min for 40— 60 h at room 
temperature. Following centrifugation, two bands were
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usually observed on UV exposure. The upper band was
comprised of residual bacterial chromosomal DNA, the lower 
band contained the plasmid DNA. This band was removed by 
pipetting using a pasteur pipette. To remove the ethidium 
bromide from solution the mixture containing the plasmid DNA 
was extracted 5 times with an equal volume of isopropanol 
saturated with CsCl. The plasmid solution was then dialysed 
for 1 day against several changes of TE buffer (10 mM tris-HCl 
pH 8.0, 1 mM EDTA) to remove the CsCl. Following dialysis, 
the plasmid DNA was precipitated from solution by incubation 
at -20°C overnight following the addition of 3 M sodium 
acetate to a final concentration of 0.3 M and 2.5 volumes of 
ethanol. The plasmid DNA was then pelleted by centrifigation 
at -15°C, at 10,000 rev/min in an HB-4 rotor on a Sorvall 
RC-5B centrifuge. The DNA was washed once in 70% (v/v)
ethanol and once in 95% ethanol then repelleted by 
cent rifugation.
(ii) Further Purification of Plasmid DNA
To further purify the plasmid DNA from contaminating 
bacterial chromosomal DNA, the DNA was resuspended in 1 M 
NaCl, 10 mM tris-HCl pH 7.5, 1 mM EDTA at a concentration of 2 
mg/ral and sedimented rate zonally by centrifugation through a 
sucrose gradient. 100 pi samples of DNA were layered on top 
of 14 ml 5% - 20% neutral sucrose gradients in the same
buffer. These samples were then centrifuged in a 6 x 14 ml 
rotor of a B60 Damon IEC ultracentrifuge for 4 h at 40,000
129
rev/min at 20°C. Following centrifugation, the gradients 
were unloaded by upward displacement by fluorochemical FC43 
(3M Chemical Company Limited) and 1 ml fractions collected.
The OD260nm was read for these fractions and those containing
plasmid DNA were pooled. The plasmid DNA was precipitated by 
additon of 3 M sodium acetate to a final concentration of 0.3 
M and 2.5 volumes of ethanol followed by overnight incubation
at -20°C. The plasmid DNA was then pelleted by
centrifugation at -15°C, at 10,000 rev/min in an HB-4 rotor on 
a Sorvall RC-5B centrifuge. The DNA was washed once in 70% 
(v/v) ethanol and once in 95% ethanol then collected by 
centrifugation as before. The DNA pellet was dried and
resuspended in IX TE buffer at 0.5 jig/jil.
(iii) Small Scale Preparation
For quick analysis of plasmid DNA, small scale 
preparations were used. To 2 ml of L-broth, containing the 
appropriate antibiotic if required, a single bacterial colony 
was inoculated and incubated overnight at 37°C with shaking. 
Cells were then pelleted from 1.5 ml of culture medium in 
screw-capped Sarstedt tubes by centrifugation at 10,000 
rev/rain, at room temperature, in an Eppendorf microfuge. The 
supernatant was discarded and the cell pellet resuspended in 
100 jul of lysis buffer which contained 0.9% (w/v) glucose, 25 
mM tris-HCl pH 8.0, 10 mM EDTA pH 7.5, and 25 pi of a fresh 
solution of lysozyme (10 mg/ml) in the same solution. This
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mixture was incubated on ice for 15 rain. To this was added 
200 ul of 0.2 M NaOH, 1% SDS and the mixture incubated on ice
for 5 rain. 150 pi of ice cold 5 M potassium acetate pH 4.8
was then added and the mixture again incubated on ice for 5 
min. This precipitates the bacterial DNA and protein. To 
remove this, the tubes were centrifuged for 5 rain in an 
Eppendorf microfuge and the supernatant containing the plasmid 
DNA then transferred to a fresh tube. Boiled RNase A (50
pg/ml) was then added to a final concentration of 10 pg/ral and
incubated at 37°C for 30 min to remove contaminating RNA. 
The plasmid DNA was then precipitated by addition of 3 M 
sodium acetate to 0.3 M and 2 volumes of ethanol and incubated 
at -20°C for 15 minutes. The DNA was collected by
centrifugation in an Eppendorf microfuge for 5 min, the pellet 
dried and then resuspended in 50 pi TE buffer which gave 
approximately 1 pg/ul DNA.
2.4.3 Purification of lambda DNA
Defensin-positive plaques were carefully picked with a 
sterile Pasteur pipette and transferred to 10 ml L-broth 
medium supplemented with 10 mM MgSO^ and 0.4% (w/v) maltose. 
A 50 pi aliquot of an overnight culture of E. coli LE392 cells 
(for lambda L47.1 recombinants) or NM538 (for EMBL3 
recombinants) was added to each tube, which were then 
incubated at 37°C on an orbital shaker for 12 hours. 100 pi 
of chloroform was then added and the tubes shaken for 2 mins 
at 37°C. Baterial debris was then removed by
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centrifugation at 2000 rev/min (560g) for 10 mins in a IEC 
Centra-8R centrifuge. The aqueous phase containing
bacteriophage virions was then transferred to a fresh 50 ml 
sterile Falcon tube and 100 pi of 1 M MgS04 added. To 10 ml 
of lysate, 10 ml of TM buffer (50 mM Tris-HCl, pH 7.4, 10 mM
MgSO^) and 320 pi of DNase 1 (100 pg/ml, BRL) were then added,
gently mixed, and incubated for 15 mins at room
temperature. Bacteriophage virions were precipitated by the 
addition of 2 ml 5 M NaCl and 2.2 g of PEG-6000, incubating
for 15 rains on ice and centrifuged at 12,000 rev/rain at 4°C on 
a Sorval HB-4 swing-out rotor. All traces of PEG were
carefully removed and the phage pellet resuspended in 300 pi 
of TM buffer. The mixture was then extracted twice with an
equal volume of chloroform. Following the addition of 15 pi 
of 0.5 M EDTA, pH 8.0 and 30 pi of 5M NaCl, the mixtures were 
extracted with an equal volume of phenol. After two more 
chloroform extractions, phage DNA was precipitated by the 
addition of two volumes of ethanol and incubation on ice for 
15 mins. Precipitates were collected by centrifugation
(10,000 rev/min, 10 mins, 4°C), washed with 70% ethanol and 
dried under vacuum. DNAs were resuspended in 100 pi TE and 
stored at 4°C. This procedure typically yielded 50-100 pg of 
phage DNA. For restriction endonuclease digestion of phage 
DNA, approximately 1 pg was digested with the relevant enzyme 
according to madifacturers instructions. At the completion of 
digestion (typically in 10 pi volumes), 1 pi of 40 rag/ml 
boiled RNase A (BRL) was added to digest bacterial RNA.
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2.4.4 Restriction endonuclease digestion
Digestions were carried out as recommended by the 
manufacturers. For plasmid, DNA restriction enzyme
digestions were routinely carried out with the appropriate 
restriction enzyme added to a final concentration of 5 
units /jag of DNA. The mix was then incubated for 1 h at 37°C 
in the appropriate buffer. Restriction digestion of genomic 
DNA was carried out using the appropriate restriction enzyme 
added to a final concentration of 10 units/jig of DNA. 
Incubation of the mix was 12 h at 37°C; genomic DNA was at a 
concentration of 50 pg/ml. At the completion of the
incubation period the reaction was stopped by addition of EDTA 
pH 8.0 to 20 mM. To determine the concentration of genomic 
DNA present accurately, after digestion, the digested samples 
were dialysed against 0.1X TE buffer (10 mM tris-HCl pH 8.0, 1 
mM EDTA) and then the OD260nm each sample read on a Cecil 
spectrophotometer.
2.4.5 DNA fractionation by gel electrophoresis
Digested genomic DNA samples were fractionated by 
horizontal electrophoresis on a 0.8% agarose gel. The gel 
was made up by boiling the appropriate weight of agarose with 
200 ml of IX TBE electrophoresis buffer (0.089M Tris base, 
0.089M boric acid, 0.002 M EDTA pH 8.3). This was cast in a 
14 cm by 20 cm mould. Separation of plasmid DNA fragments of 
greater than 1 Kb was also accomplished by the method
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described above. However, DNA fragments of less than 1 Kb 
were fractionated on 1% agarose TBE buffered gels. 10-20 pg 
of genomic DNA in 30 pi TE buffer, or 0.5-2.0 pg plasmid DNA 
were routinely electrophoresed. Prior to loading of the DNA 
samples a sixth volume of sample loading buffer was added to
each tube (30% sucrose, 10 mM tris-HCl pH 8.0, 1 mM EDTA, 5%
SDS, 0.1% bromophenol blue). Electrophoresis was carried out 
overnight at 30 volts. Markers were run simultaneously,
these were normally lambda phage digested with EcoRl/Hind3 for 
sizing of large DNA fragments, or (j) X174 DNA (replicative
form) digested with Hae3 for sizing of small fragments. 
Following electrophoresis, the gel was stained for 15 min in 
ethidium bromide at a final concentration of 0.5 pg/ml, in 
water. The DNA was visualised by UV fluorescence on a
Chromato-Vue transilluminator, then photographed through a red 
No. 9 Kodak Wratten gelatin filter.
2.4.6 Southern blot analysis of DNA
Following fractionation of endonuclease restriction 
digested DNA as described in Section 2.4.5, DNA was
transferred to nylon membranes as described by Southern 
(1975). Prior to blotting, the marker lanes were removed
and the gel subjected to a number of washes. The gel was 
washed twice for 20 min in 1.5 M NaCl, 0.5 M NaOH to shear and 
denature the DNA. The gel was then neutralised by washing 3 
times for 30 min in 3 M NaCl, 0.5 M tris pH 7.4. Each wasn
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was carried out with gentle shaking. The DNA was then
transferred from the gel to Hybond-N membrane by blotting in 
20X SSC (3 M NaCl, 0.3 M
sodium citrate). The nylon membrane was first wetted in
DEPC-treated double distilled water then soaked in 20X SSC for 
30 min before assembly of the blotting apparatus. Blotting 
transfer was carried out overnight. The nylon membrane was 
then air dried and irradiated on a UV transillurainator for 5 
mins to immobilize the DNA.
2.4.7 Synthetic oligodeoxynucleotides
All oligonucleotides (17-20 mers) were synthesized on an 
Applied Biosystems Model 381 DNA sythesiser. 
Oligonucleotides were synthesized trityl-on and purified on 
OPC purification cartridges (Applied Biosysteras) following 
manufacturers instructions. All oligonucleotides used for 
primer extension and PCR amplification were additionally 
purified by gel electrophoresis prior to use.
2.4.8 Restriction mapping of defensin genomic clones
For each of the five defensin genomic clones isolated from human genomic 
libraries (Section 3.3) the 8kb BamHl fragment containing the entire coding 
region of the genes (see Figs. 26 and 32C) was isolated by digestion of the 
relevant plasmid or lambda clone and purification of the 8kb BamHl fragment 
from a 0.8% LMP-agarose (BRL) gel after visualization by U.V-staining. The 
5-3' order of restriction fragments generated by digestion of these 8kb BamHl 
fragments with EcoRl or Hinc 2 was established by oligonucleotide 
hybridization to Southern blots (Sections 2.4.6, 2.6.3). To establish a 
complete restriction map of all 5 clones with respect to the enzymes EcoRl,
Hinc 2 and Hind 3 the 8kb BamHl fragment for all 5 clones was digested with 
each of the three enzymes and fragments purified from ethidium bromide 
stained LMP-agarose gels. Each of the fragments were then digested with 
either of the other restriction enzymes either singly or as double digests. For 
mapping of the 3' Hae 3 sites of the 5 clones, the order of sites was established 
using a singly end-labelled 2.6kb Hinc2-BamHl fragment (see Figs. 27 and 
32) and employed partial digestion with Hae 3 (Smith and Bemstiel, 1976).
2.5 RADIOLABELLED PROBES
2.5.1 Preparation of cDNA hybridization probes by random priming
DNA labelling was carried out using the Boehringer 
Mannheim random priming kit and following the protocol 
described by the supplier. This in turn is based on the 
random priming technique of Feinberg and Vogelstein (1984). 
25 ng of denatured DNA was added to a reaction mix containing 
0.5 mM dATP, 0.5 MM dTTP, 0.5 MM dGTP, 50 pCi (32P)- dCTP (3000 
Ci/mmole), and 2 pi of the kit reaction mix which contains 1 M 
tris pH 7.4, C.T. hexanucleotide (150 OD/ml) 2 M Hepes, 1 M 
MgCl2 and 0.004% (v/v) 2-mercaptoethanol. 1 unit of Klenow
enzyme (1 unit/pi) (Boehringer Manneira) was added and the 
total volume of the reaction mix made up to 20 pi with double 
distilled water. The mixture was incubated for 30 min at 
37°C, following this the reaction was stopped by addition of 
EDTA to 20 mM. The labelled cDNA was separated from
unincorporated nucleotides by gel filtration through Biogel 
A-1.5M agarose (BioRAD) columns. Columns were prepared by 
plugging a siliconized pasteur pipette with a small plug of 
sterile glass wool. The column was then filled with A-1.5M 
Biogel (100-200 mesh) and allowed to settle. Presaturation 
of the column was carried out by elution with 10 pi of a 
solution containing 500 pg/ml sonicated salmon sperm DNA. 
This was eluted with 0.1X SSC solution before the reaction mix 
was loaded on to the column. The eluted DNA peak fraction 
was collected from the column and used as a
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hybridization probe. Prior to use, DNA probes were boiled 
for 10 rains to denature any secondary structure, then cooled 
rapidly on ice.
2.5.2 5'-end-Labelling of DNA oligonucleotides
100-500 ng of oligonucleotides were 5’-end-labelled in a final 
volume of 20 pi in a buffer containing 50 mM Tris-HCl, pH 8.0, 
10 mM MgCl2, 0*5 ®M spermidine, 0.01 mM EDTA, 0.1 mM ZnS0 4 , 30 
pCi (Jf-32p) dATP and 10 U T4-polynucleotide kinase (BCL) by 
incubation at 37°C for 30 mins. The end-labelling reaction 
was terminated by the addition of 1 pi 0.25M EDTA (pH 8.0) and 
DNA precipitated by addition of 10 pi 7.5M ammonium acetate 
and 90 pi ethanol followed by storage at -70°C for 15 rains. 
The precipitate was then collected by centrifugation at 12,000 
rev/min for 10 mins, at 4°C, washed twice with 70% ethanol to 
remove unincorporated nucleotides, dried under vacuum and 
resuspended in 100 pi H 2O.
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2.6 HYBRIDIZATION PROCEDURES
2.6.1 Hybridization procedure for Southern blots (cDNA probes)
The method used to prehybridise and hybridize nylon 
membranes produced from the previously described procedures 
was taken from Jeffreys and Flavell (1977). 
Prehybridization was carried out at 42°C in sealed polythene 
bags. Prehybridization buffer contained 50% formqmide
(Fluka), 5X Denhardts solution (IX Denhardts solution is 0.02% 
(w/v) ficoll, 0 .02% (w/v) polyvinylpryrrolidone, 0 .02% (w/v)
bovine serum albumin), 50 mM sodium phosphate pH 6.8 , 0.1%
SDS, 100 pg/ml sonicated salmon sperm DNA, 10 pg/ml poly (A) 
and 10 jig/ml poly (C). Approximately 1.5 ml of
prehybridization buffer was added per 5 cm^ of filter. 
Incubation was carried out overnight in a shaking water 
bath. Following prehybridization the buffer was removed from 
the bag and replaced with hybridization buffer (approximately 
1 ml per 5 cm^ filter). The hybridization buffer contained 
radioactively labelled probe at a concentration of 1-2 x 10  ^
cpm/ml. The buffer contained 50% formamide (Fluka), 5X SSC, 
IX Denhardts solution, 20 mM sodium phosphate pH 6.8 , 0.1%
SDS, 10% dextran sulphate, 100 }ig/ml sonicated salmon sperm 
DNA, 10 pg/ml poly (A) and 10 pg/ml poly (C). The polythene
bags were then resealed, ensuring all air bubbles were
expelled and incubated overnight at 42°C in a shaking water 
bath. Washing of hybridized filters was carried out with 
buffers preheated to 65°C. Prior to washing the
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hybridization solution was removed from the polythene bags, 
the filters were then put into approximately 250 ml of 3X SSC, 
0.1% SDS and washed at room temperature. Five washes in this 
solution for 5 rain each, ensured that all unbound radioactive 
probe was removed. Filters were then washed two times, for 
30 min each wash, in 0.5X SSC, 0.1% SDS at 65°C in a shaking 
water bath. Finally filters were washed twice in a solution 
of 0.1X SSC, 0.1% SDS, 1 h for each wash, in a shaking water 
bath at 65°C. At the completion of washing filters were 
placed in polythene bags and autoradiographed with Kodak "XAR" 
or "XRP" X-ray film using Cronex "lightning plus" intensifying 
screens in Harmer X-ray cassettes. After exposure at -70°C 
the films were developed in a Kodak M7A automatic X-ray 
processor.
2.6.2 Hybridization procedure for Northern blots (cDNA probes)
Prehybridization and hybridization of Northern blots of 
Hybond-N (Amersham) membranes were essentially as recommended 
by the manufacturers. Prehybridization was carried out at 
42°C in sealed polythene bags in a buffer containing 5X SSPE 
(20X is 3.6M NaCl, 0.2 M sodium citrate, pH 7.7, 0.002M EDTA), 
50% (v/v) forraimide, 5X Denhardt’s solution (IX is 0.02% (w/v) 
ficoll, 0 .02% (w/v) polyvinylpyrrolidone, 0 .02% (w/v) bovine
serum albumin), 0.5% (w/v) SDS and 100 fig/ml sonicated salmon 
sperm DNA. Approximately 1.5 ml of prehybridization buffer 
was added per 5 cm^ of filter. Incubation was carried out 
overnight in a shaking water bath. Following
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prehybridization the buffer was removed from the bag and 
replaced with hybridization buffer. The hybridization buffer 
contained radioactively labelled probe at a concentration of 
1-2 X 10^ cpm/ml and was otherwise the same as 
prehybridization buffer. The polythene bags were then 
resealed, ensuring all air bubbles were expelled and incubated 
overnight at 42°C in a shaking water bath. Washing of 
hybridized filters was carried out as detailed in Section
2.6.1. At the completion of washing filters were placed in 
polythene bags and autoradiographed with Kodak XAR film in 
cassettes with intensifying screens. After exposure at -70°C 
the films were developed in a Kodak M7A automatic X-ray 
processor.
2.6.3 Oligonucleotide hybridization
20-mer digonucleotides 5 ’-end labelled as described in 
Section 2.5.2 were hybridized to nylon filters in a buffer 
containing 6X SSC (0.9 M NaCl, 0.09M sodium citrate), 10X 
Denhardts (0.2% (w/v) ficoll 0.2% (w/v) polyvinylpyrrolidone, 
0 .2% (w/v) bovine serum albumin) and 100 jig/ml denatured
salmon sperm DNA. Filters were first prehybridized at 65°C 
for 4 hours in this solution, prehybridization buffer removed 
and hybridization fluid containing IX 10^ cpm/ml of labelled 
oligonucleotide added. Oligonucleotide hybridization
temperature was calculated from an empirical formulae T^ = 4X 
(G or C) + 2X (A or T) - 5°C and hybridization was
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allowed to proceed for 12-18 hours. Filters were then washed 
at T-t for 60 mins in a buffer containing 6X SSC, 0.1% SDS and 
for 5 mins in the same buffer at + 5°C. At the completion 
of washing, filters were placed in polythene bags and 
autoradiographed with Kodak XAR film in cassettes with 
intensifying screens.
2.6.4 Removal of hybridised probe from nylon membranes
Membranes were placed in 250-300 ml of strip buffer (10 
mM sodium phosphate pH 6.5, 50% formftmide) and incubated for 1 
h at 65°C with shaking. Following this, to ensure total 
removal of probe, the filters were washed in wash buffer (2X 
SSC, 0.1% SDS) for 15 min at room temperature, with vigorous 
shaking. The membranes were then ready for further 
prehybridization and hybridization.
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2.7 MOLECULAR CLONING
2.7.1 Preparation of recombinant DNA molecules
Vector DNA (plasmid or M13) was prepared in the following 
manner. The vector was linearized with the appropriate
restriction endonuclease (in certain cases the vector was 
digested with two restriction endonucleases), run on an 
agarose gel and then purified. The linearized vector DNA
was then phosphatased by treatment with 1 unit of calf 
intestinal phosphatase (C1P, Boeringer Corporation Ltd) in 
phophatase buffer (0.05M Tris-HCl, pH 9.0, 1 mM MgCl2 , 0.1 mM 
ZnCl2 and 1 mM spermidine) for 30 mins at 37°C. Following 
this, another 1 unit of CIP was added to the reaction mix 
which was incubated at 37°C for a further 30 mins. After 
phosphatase treatment, the reaction mix was incubated at 65°C 
for 15 mins to destroy the CIP. The reaction mix was then
run on a 1% agarose gel and the vector DNA isolated. Insert 
DNA was prepared by digesting the appropriate recombinant 
plasmid or phage with restriction endonuclease(s). The 
digestion mixture was then run on an agarose gel and the
relevant DNA fragment purified. In both cases all
restriction endonuclease digestions were carried out according 
to the manufacturer’s instructions.
Following the preparation of the vector and insert DNA, 
recombinant DNA molecules were made by ligation reactions. 
In these reactions approximately 50 ng of the linearized
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vector DNA was incubated with approximately 200 ng (I pg in 
the case of blunt-ended fragments) of insert DNA with 1 unit 
of T4 DNA ligase (BCL) in ligation buffer (0.07M Tris-HCl, pH
7.6, 5 mM MgCl2 , 5 mM DTT and 1 mM ATP). This provided a high 
ratio of insert DNA ends to linearized vector DNA which 
favours the insertion of the insert DNA fragment into the 
linearized vector DNA. The ligation reaction was incubated 
for 12-18 hours at 13°C.
2.7.2 Preparation of competent JM83 cells
A glycerol stock of E.coli JM83 cells (see Section 2.1.2) 
was used to inoculate 10 ml of L-broth (1% (w/v)
bactotryptone, 0.5% (w/v) yeast extract, 1% NaCl). This was 
incubated at 37°C overnight in an orbital shaking incubator. 
The following morning 1 ml was taken from this overnight 
culture and added to 100 ml of L-broth which was incubated at 
37°C in an orbital shaking incubator. When the OD500 of the 
culture was approximately 0.6 it was split between two 50 ml 
Falcon tubes. The bacterial cells were pelleted by
centrifugation of the culture at 2000 rev/min (560 g) for 5 
mins at 4°C in an IEC Centra-8R centrifuge. The cells were 
then resuspended in 10 mM MgSO^ (10 ml in each 50 ml Falcon 
tube) and incubated on ice for 30 minutes. Following this 
incubation, the bacterial cells were pelleted once more by 
centrifugation at 2000 rev/min for 5 mins at 4°C in a IEC 
Cent ra-8R centrifuge. The pelleted cells were then
resuspended in 50 mM CaCl2 (10 ml total for both 50 ml
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Falcon tubes) and incubated on ice for at least one hour. 
Following this procedure, the cells were competent i.e. they 
were capable of being transformed by circular recombinant 
molecules.
2.7.3 Transformation of competent JM83 by recombinant plasmids
One half of the ligation reaction (10 pi) was placed in a 
fresh, sterile 1.5 ml eppendorf and 100 pi of competent JM83 
cells added. This mixture was incubated on ice for 20-60 
mins, heat-shocked at 42°C for two minutes and then allowed to 
stand at room temperature for 10 minutes. The mixture was 
then mixed with 800 pi of L-broth and incubated at 37°C for 90 
minutes. Following this incubation, an appropriate aliquot 
(100-250 pi) of each culture was spread onto L-broth agar 
plates containing arapicillin (L-broth, 1.5% bactoagar 50 pg/ml 
ampicillin). The culture was allowed to dry onto the agar 
plate which was then incubated overnight at 37°C. In the 
case of pUC plasmids, plates also contained 0.5 mM IPTG and 
0.05% (w/v) X-gal.
2.7.4 Screening of bacterial colonies containing plasmids
Any bacterial colonies that form after the overnight 
incubation at 37°C contained circular plasmid DNA molecules 
that conferred ampicillin resistance to the bacterial cells. 
To determine which of the colonies contained recombinant
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plasmids, small scale plasmid preparations were carried out to 
isolate plasmid DNA for restriction endonuclease analysis.
This procedure was also carried out with pUC transformations 
with the additional selection that white (recombinant) 
colonies were chosen. Bacterial colonies were picked from
the agar plates and used to inoculate 2 ml of L-broth 
containing 50 pg/ml ampicillin and processed as described in
Section 2.4.2 (iii). Plasmid DNA was finally resuspended in
30 ul of TE. For each restriction endonuclease reaction 5 pi 
of the plasmid preparation was used.
2.7.5 Transformation of competent JM83 by M13 fgcombinants
To transfer JM83 cells with M13 phage DNA, 0.3 ml of 
competent cells were added to 10 /ul of ligation mix and the 
mixture incubated on ice for 2 hours. The cells were then 
heat-shocked by incubation for 2 rains at 42°C then returned to 
ice. To each tube of heat shocked cells IPTG and X-gal were 
added to 0.5 mM and 0.05% (w/v) respectively and 3 ml of
molten H top agar (at 48°C) (H top agar is 1% (w/v)
bactotryptone, 0.8% (w/v) NaCl, 0.8% (w/v) bactoagar) added.
This mixture was then poured out on to freshly prepared, 
prewarmed (37°C) H-plates (1% (w/v) bacto-tryptone, 0.8% (w/v) 
NaCl, 1.2% (w/v) bactoagar). The top agar was allowed to set 
then the plates inverted and incubated overnight at 37°C.
Recombinants (white plaques) were then picked and the desired 
clone identified by sequencing.
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2.7.$ Preparation of single-stranded template
This method was taken from Amersham (1984). 100 ml of
2X TY medium (0.016% (w/v) bactotryptone, 0.01% (w/v) yeast
extract, 0.005% (w/v) NaCl) was inoculated with 1 ml of an
overnight E.coli (JM83) culture. 1.5 ml samples of this were 
aliquoted into sterile bijou tubes (Sterilin). From the
H-plates set up previously (Section 2.7.3) single, white 
plaques were removed using sterile, wooden cocktail sticks and 
inoculated into the bijou tubes. The tubes were then 
incubated, with shaking, for 5 h at 37°C. At the completion 
of the incubation period, the medium was transferred into 
Sarstedt microcentrifuge tubes and centrifuged for 5 min at
10,000 rev/min in an Eppendorf microfuge to collect the 
cells. The supernatant, containing the viral particles, was 
transferred to fresh tubes and 0.12 volumes of PEG/NaCl (20% 
polyethelene glycol 6000, 2.5 M NaCl) added. The tubes were 
vortexed briefly then left to stand for 15 min at room 
temperature. To collect the viral particles, the tubes were 
centrifuged at 10,000 rev/min for 5 min in an Eppendorf 
microfuge and the supernatant discarded. To remove 
contaminating protein, the viral pellet was resuspended in TE 
buffer and 0.5 volume of phenol saturated with TE buffer was 
added. The tubes were vortexed for 30 sec then centrifuged 
for 3 min. The aqueous phase, containing the DNA was removed 
and transferred to fresh tubes. To precipitate the single 
stranded viral DNA, 3 M sodium acetate was added to 0.3 M and
2.5 volume of ethanol. The tubes were incubated overnight at
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20°C. The viral DNA was collected by centrifugation in an 
Eppendorf microfuge and then washed once in 1 ml of cold 
(-20°C) ethanol. The pellet was drained and dried before 
resuspension in 30 pi of TE buffer.
2.7.7 M13 dideoxy chain-termination sequencing
(i) Using Klenow enzyme
Initial sequencing (for example of the clone pCG14) was 
performed with a commercial Klenow sequencing kit (Amersham). 
The method used is exactly as described by Amersham (1984). 
Briefly, annealing of the M13 primer to the single — stranded 
viral template was carried out in a reaction mix containing 
0.5 volume of single-stranded template, 0.1 volume M13 primer, 
0.15 volume IX Klenow reaction buffer (10X Klenow reaction 
buffer is 0.5M Tris-Hcl pH 7.2, 0.1 M MgS0 4 , 1 mM
dithiothreitol, 500 pg/ml bovine serum albumin). These
components were well mixed then incubated for 2 h at 60°C. 
To the annealed template/primer hybrid 15 pCi of (35s)- dATP 
(600 Ci/mmole) and 1 unit of Klenow fragment (1 unit/pi) were 
added. 2.5 pi of this mix were added to tubes marked A, C, 
G, T (4 tubes/clone). To each of the 4 tubes was added the 
appropriate dideoxy mix (the mixes contained 0.5 mM of each 
appropriate deoxynucleotide plus the appropriate molarity of 
dideoxynucleotide). The reaction was incubated for 15 min at 
room temperature following which 0.5 volume of chase mix was 
added. The chase mix is 0.5 mM dATP, 0.5 mM dCTP, 0.5 mM
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dTTP and 0.5 mM dGTP. The tubes were again incubated for a 
further 15 min at room temperature. At the completion of 
incubation an equal volume of formqmide dye mix (20% 
formamide, 0.002% (w/v) xylene cyanol FF, 0.0002% (w/v)
bromophenol blue, 500 mM sodium EDTA) was added to each tube 
to stop the reaction. The tubes were then incubated for 3 
min at 90°C, to denature the DNA, before loading on to a 
polyacrylamide gel.
(ii) Using Sequenase
All later sequencing of both Ml3 and plasmid DNA was 
performed using a modified T7 DNA polymerase Sequenase (United 
States Biochemical Corporation) using protocols described by 
the manufacturers. Annealing of primer (5-10 ng) to single 
stranded M13 templates (1-2 pg) was performed in a IX 
Sequenase buffer (40 mM Tris-HCl, pH 7.5, 20 mM MgCl2 , 50 mM 
NaCl) by warming to 65°C and allowing to cool to 30°C in an 
eppendorf placed in a breaker of water. Following annealing, 
the reaction mix was labelled by the sequential addition of 1 
pi 0.1 M DTT, 2 pi diluted labelling mix (1.5 pM each of dGTP, 
dCTP and dTTP) 10 pCi (35S)- dATP and 0.5 units Sequenase (2 
pi )  and incubation for 3 mins at room temperature. 
Chain-terminating mixes were set up (4 tubes, 2.5 p i / tube, of 
mixes containing 80 pM dGTP, 80 pM dATP, 80 pM dCTP, 80 pM 
dTTP, 50 mM NaCl and 8 pM of the relevant dideoxynucleoside 
triphosphate ddATP (A), ddCTP (C), ddGTP (G) or ddTTP (T) and 
to each 3.5 pi of the reaction mix added and
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incubated at 37°C for 5 minutes. At the completion of
incubation, 4 pi of formflmide dye mix (95% formamide, 20 mM 
EDTA, 0.05% (w/v) broraophenol blue, 0.05% xylene cyanol FF was 
added to terminate the reactions and the tubes incubated for 3 
mins at 90°C to denature before loading onto a polyacrylamide 
sequencing gel.
2.1,% Sequencing of plasmid DNA
All plasmid DNA sequenced was prepared using the CsCl 
method described in Section 2.4.2(i). The DNA (3-5 pg) was 
denatured by treating with 0.2M NaOH for 5 minutes (a total 
volume of 20 pi). After this incubation, 8 pi of 5M ammonium 
acetate was added along with 100 pi of 100% ethanol. This 
mixture was incubated at -70°C for 10 minutes and then 
centrifuged for 15 minutes at 4°C in an Eppendorf centrifuge 
5415. The pellet of denatured DNA was resuspended in 9 pi of 
IX Sequenase buffer (USB Sequenase Kit) and 1 pi (5-10 ng) of 
sequencing primer added. This mixture was heated to 65°C and 
then allowed to cool very slowly to below 30°C (1-2 hours). 
This solution was then ready for sequencing as described in 
Section 2.7.5(ii).
2.7 Gel electf ophoresis
Sequencing gels consisted of 6-8% (w/v) acrylamide, 7M 
urea, IX TBE (filter sterilized, 0.45 um (Millipore)). 60 ml
of this solution was required. To this was added 0.001%
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(w/v) TEMED, (NNN'N'-tetramethylethylenediamine) and freshly 
prepared 0.001% (w/v) ammonium persulphate solution. This
solution was carefully poured between two glass plates (40 x 
20 x 0.04 cm) which had previously been siliconised using 2% 
dimet hyl-dichlorosilane in 1,1,1 — trichloroethane 
(BDH-Replicote). The plates were taped together with spacers 
in place prior to pouring of the gel. The gel was poured by 
slowly letting the solution flow between the glass plates 
ensuring that no air bubbles were trapped. The gel was left 
to set for 1 h at room temperature. Samples were loaded on 
to the gel and then electrophoresis was carried out at 45 mA,
1.5 kV for 2 h. The gel was buffered in IX TBE buffer. 
Following electrophoresis the gel apparatus was dismantled and 
the glass plates separated. The gel, still resting on one
glass plate, was immersed in Fix buffer (10% (v/v) methanol, 
10% (v/v) glacial acetic acid) for 15 min then drained. It
was then transferred on to Whatman filter paper, covered in 
saran wrap, and dried on a Shandon Gel drier for 1 h. The 
saran wrap was removed and the dried gel autoradiographed 
using Kodak "XAR" X-ray film in Harmer X-ray cassettes with
Cronex "lightning plus" intensifying screens. After exposure 
the films were developed in a Kodak M7A automatic X—ray
processor.
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2.8 ISOLATION OF GENOMIC DEFENSIN CLONES
A total of three libraries of human genomic sequences 
were screened. Two were construcrted from BamHl-digested 
size-selected DNA cloned into lambda L47.1 (Loenen and 
Brammar, 1980), the other was constructed from human DNA
partially digested with Sau3A cloned into lambda EMBL3 
(Frischauf et al, 1983) and was purchased from Clontech 
Laboratories (Palo Alto, USA).
2.8.1 Construction of human genomic libraries in lambda L47.1
High molecular weight DNA from both white blood cell DNA 
(WBC) and normal granulocyte DNA (G) was prepared and 300 jig 
of each DNA cut to completion with BamHl and size-fractionated 
on 30 ml neutral 10-40% sucrose gradients. Fractions 
containing pCG14-hydridizable sequences (8-12 Kb in size) were 
pooled for both WBC and G DNAs. Lambda vector L47.1 was 
digested to completion (50 fig) with BamHl and size 
fractionated twice on neutral 10-40% sucrose gradients to 
remove the stuffer fragment. Vector DNA and both WBC and G 
human DNAs were ligated and packaged using extracts made for 
E.coli BHB2688 and BHB2690 and the titre of plaques obtained 
assessed by titering on E. coli DB102. For the WBC and G 
libraries the titres obtained were 2.4 X10^ pfu/pg and 1.4 
X10^ pfu/pg respectively. (7.5 X10^ plaques and 4.3 X10^ 
plaques from 3.1 fig genomic DNA ligated).
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8.2 Screening of L 4 7 .1 and EMBL3 libraries
Screening of both L47.1 libraries and the EMBL3 library 
Was performed using similar methodologies. In the case of the
WBC and G libraries approximately 5 XIO^ plaques were screened 
in both cases as follows. 1 XI0-* pfu of each library was
added to 1 ml of an overnight culture of LE392 (in 10 mM
MgS04) and phage allowed to absorb by incubation at 37°C for 
15 mins. To this was added 50 ml of top agarose (at 45°C)
which was then plated onto a large plate (23 x 23 cm, Nunc)
containing LB agar preheated to 37°C. After the top agar had
set, the plates were incubated at 37°C for 12 hours until
plaques were visible. 5 plates, each containing
approximately 1 X10^ plaques were prepared for both WBC and G 
libraries. For the EMBL3 library 10 plates each containing 
approximately 1 X10^ plaques were similarly prepared. The
plating cells used for EMBL3 were E.coli NM538 (see Section 
2.1.2). Plaque lifts of all plates were performed with
Biodyne nylon membrane (Gallenkamp) using conditions 
recommended by the manufacturer. The method used was 
essentially that of Benton and Davis (1977). Filters were 
cut (23 x 23 cm) and placed onto the surface of the plate 
allowing surface moisture to absorb the filter throughout its 
surface. After 5 minutes the filter was carefully lifted
and placed, plaque side up, on filter paper (Whatman) 
saturated in 1.5 M NaCl 0.5 M NaOH, left for 5 minutes and 
then placed, again plaque side up, on filter paper (Whatman)
saturated in 1.5 M NaCl, 0.5 M Tris-HCl, pH 8.0. Filters 
were then removed, air dried and baked for 60 minutes at 80°C.
For screening of the WBC and G libraries, filters were 
prehybridized and hybridized with a radiolabelled full-length 
HNP3 cDNA probe as described in Section 2.6.1. Positive
areas (one per library) containing 10-20 plaques were picked 
and placed in 200 jil of SM buffer (140 mM NaCl, 10 mM 
Tris-HCl, pH 7.4, 10 mM MgS0 4 , 2% gelatin) vortexed, and
serial dilutions made in order to perform a secondary screen, 
each dilution was used to infect 200 ul of E. coli LE392 cells 
(in 10 mM MgSO^) at 37°C for 15 mins and 3 ml molten top agar 
(supplemented with 10 mM MgS0 4 , 0.4% (w/v) maltose) at 45°C 
added and poured onto 90 mm L-agar plates preheated to 37°C.
Plates were incubated at 37°C until plaques became visible 
(12-18 hours). One plate from each library was then chosen 
containing 50-100 plaques and rescreened with a radiolabelled 
full-length HNP3 cDNA probe. From each plate
defensin-positive plaques were identified and grown up as 
described in Section 2.4.3. One clone (HNPIA) as derived 
from the G library, the other (HNPIB) from the WBC library.
A similar methodology was used to isolate
defensin-related clones from the library cloned into EMBL3.
In this* case, however, a radiolabelled E2-E3 HNP3 cDNA probe 
was used to screen a total of 1 X10^ recombinant plaques.
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Three were isolated in a primary screen and individual plaques 
picked following a secondary screen. For EMBL3, E.coli NM538 
cells were substituted for LE392.
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2 .q WESTERN BLOTTING
Cytoplasmic extracts from normal white cells or IIL60 
cells were prepared by NP40 lysis. Approximately 1 X108
cells were resuspended in 2 ml of NP40 buffer (10 mM Tris-HCl 
pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5% (v/v) NP40 plus protease 
inhibitors 0.5 mM PMSF, 0.5 mM benzamidine, 1 ug/ml pepstatin 
A-, 1 ug/ml aprotinin, 1 ug/ml leupeptin). Nuclei were
sedimented by centrifugation on an MSE bench centrifuge at 500 
g (2400 rev/min) and cytoplasmic extracts stored at -70°C 
until use. The protein concentration of extracts was
determined using a Biorad Protein Assay Kit. Approximately 
10-20 pg of protein in a volume of 15 pi was added to an equal 
volume of sample buffer (0.125 M Tris-HCl, pH 6.8, 4% (w/v) 
SDS, 10% (v/v) glycerol, 0.02% bromophenol blue), heated to
90°C for two minutes to denature proteins and electrophoresed 
on an 17.5% SDS PAGE gel. This gel contained 17.5% 
acrylamide, 0.073% bisacrylamide, 0.375 M Tris-HCl pH 8.7,
0.4% SDS, 0.033% TEMED in a discontinuous buffer system as 
described by Laemmli (1970). The gel solution, before
addition of TEMEDf was degassed by placing under a vacuum for 
15 mins to remove oxygen. TEMED was added to catalyze
polymerization of the gel and the gel was cast in a vertical 
gel mould (150 mm X 165 mm X 0.75 mm) to within 20 mm of the 
top. The surface was overlayered with a solution containing 
0.375 M Tris-HCl, pH 8.7 and allowed to polymerize. After 
polymerization was complete, the buffer on the gel surface was 
removed and a stacking gel containing 5% acrylamide, 0.i3%
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bisacrylamide, 0.125 M Tris-HCl, pH 6.8, 0.2% SDS, 0.05%
TEMED, 0.05% ammonium persulphate was formed in the remainder 
of the gel mould with slots. Heated samples were then
loaded. Electrophoresis was carried out at 75 volts using a 
0.192 M glycine, 0.025 M Tris-HCl, pH 8.7, 0.1% SDS buffer at 
4°C for 12-18 hours. If gels were to be stained, they were 
first fixed in a solution of 10% acetic acid, 50% methanol, 
40% water for 2 hours then in the same solution containing 
0.2% Coomassie brilliant blue R (Sigma) for 4 hours. Gels 
were destained by washing for 6-8 hours in the same solution 
lacking Coomassie stain. For Western blotting, gels were
placed on a sandwich-type apparatus. Filter paper (Whatman) 
was cut to the size of the gel, 6 pieces soaked in dry blot 
buffer (50 mM Tris-HCl, pH 9.2, 0.3% (w/v) glycine, 0.04% SDS, 
20% methanol) and the gel placed on top. Nitrocellulose 
(Schleicher and Schull BA.85) was placed carefully onto the gel 
surface and the sandwich completed by six more pieces of 
filter paper placed on top. Bubbles and excess buffer were 
carefully removed and the gel blotted for 45 mins in a 
Sartoblot Electroblotter (Sartorius) at 250 mA. Transfer was 
monitored by visualization of pre-stained low size range 
molecular weight standards (BRL). Nitrocellulose was then 
carefully removed from the gel surface and placed in TBST 
solution (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20 
(Proraega)). To detect defensin peptides, an alkaline
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phosphatase-conjugated secondary antibody system was used 
(Protoblot Western Blot AP system, Promega) using a protocol 
suggested by the manufacturer. Filters were first blocked in 
blocking solution (1% (w/v) BSA, 2% Marvel in TBST) for 1 hour 
at room temperature. This solution was then removed and the 
blot incubated with the primary rabbit anti-defensin 
antiserum. The third bleed (3 months after the first
injection of peptide) rabbit antiserum was used and found to 
be effective at a 1:500 dilution in TBST. Incubation was for 
2 hours at room temperature. Filters were then removed and 
washed in fresh TBST ( 3 X 5  min/wash). The secondary
antibody incubation utilized goat anti-rabbit lgG alkaline 
phosphatase conjugated antibody (at a dilution of 1:7500 of 
that supplied in the kit) incubating for 2 hours at room 
temperature. Filters were washed in TBST as before and then 
placed in 10 ml of alkaline phosphatase buffer (100 mM 
Tris-HCl, pH 9.5, 100 mM NaCl, 5 mM MgCl2). To this was
added 66 pi nitroblue tetrazolium solution (50 mg/ml in 70% 
diraethyIformamide) and 33 pi 5-brorao-4-chloro-3-indolyl 
phosphate (50 mg/ml in dimethylformamide) and colour 
development allowed to proceed for 10-15 rains. Filters were 
then washed in double—distilled water and stored in the dark 
prior to photography. In peptide blocking experiments, 1 pi 
of 1 mg/ml peptide (used to elicit antibody response) was 
incubated with 10 pi antiserum at room temperature for 15 
mins. This was found to abolish the defensin signal
detectable on Western blots.
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2.10 IMMUNOPRECIPITATION
Exponentially growing HL60 cells were pulse-labelled by 
addition of 500 pCi (35g)_ cysteine to cultures of 2 X107 
cells. Labelling of protein was carried out for 8 hours at 
37 ° C , cells harvested, washed three times in PBS and
cytoplasmic extracts made. Cells were lysed by the addition 
of 1 ml lysis buffer (Na2HP04 pH 8.0, 140 mM NaCl, 3 mM MgCl2, 
1 mM DTT, 0.5% (v/v) NP40 containing protease inhibitors 0.5 
mM PMSF, 0.5 mM benzamidine, 1 pg/ml pepstain A, 1 pg/ml
aprotinin and 1 pg/ml leupeptin) and nuclei sedimented by 
centrifugation at 500 g (2400 rev/min on an MSE bench 
centrifuge). To 200 pi of extract was added 40 pi of 
correction mix (5% (w/v) sodium deoxycholate, 2.5% (v/v) NP40, 
0.5% (w/v) SDS) and 0.5 pi anti-defensin antiserum (1:500
final dilution) or 0.5 pi preimmune serum.
Immunoprecipitations were carried out at 4°C for 12 hours on a 
Spiramix agitator. Immunoprecipitates were complexed by the 
addition of 40 pi Protein-A-Sepharose (Pharmacia) and another 
4°C incubation for 2 hours. Immunoprecipitates were
collected by centrifugation and washed six times in wash
buffer (10 mM Tris-HCl, pH 7.5, 140 mM NaCl 1% (v/v) NP40, 1% 
(w/v) sodium deoxycholate) and once in 10 mM Tris-HCl, pH 
7.5. In later experiments sodium deoxycholate was left out 
and NP40 reduced to 0.05% (v/v') to reduce washing stringency. 
After the final wash, immunoprecipitates were resuspended in 
30 pi sample buffer (125 mM Tris-HCl, pH 6.8, 20 mM DTT, 3.3% 
(w/v) SDS, 0.2% bromophenol blue) the samples heated for 5
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mins and centrifuged for 5 rains to remove
Protein-A-Sepharose. Supernatants were then run for 12 hours 
at 4°C on an 17.5% SDS PAGE gel (see Section 2.10). 
Following electrophoresis, gels were fixed for 30 rains in 
fixative solution (50% isopropanol, 10% acetic acid), this 
solution removed and fluorographic agent added (Amplify, 
Amersham). The gels were washed for 20 mins in this solution 
and then dried. Fluorography was carried out at -70°C in 
cassettes with intensifying screens with Kodak XAR film for 
7-10 days.
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3.1 IDENTIFICATION AND CHARACTERISATION OF A CGL cDNA CLONE
Two cDNA clones were isolated by differential screening 
of a CGL library on the basis of increased expression of their 
complementary mRNA in leukocytes from a CGL patient, as 
compared to leukocytes from a patient with CLL (Wiedemann et 
al, 1983).
Initial experiments indicated that both these cDNA clones 
hybridized to a mRNA of approximately 750 nucleotides in size 
abundant in leukocytes of most patients in chronic phase of 
CGL, but absent from the leukocytes of normal individuals and 
non-CGL leukaemias (Birnie et al, 1983; Birnie et al 1984).
Moreover, this mRNA was also expressed in normal bone marrow 
cells, although not to an appreciable extent in normal 
peripheral blood leukocytes (Wiedemann et al, 1989).
In situ hybridization to normal bone marrow cells of one 
of these cDNAs termed pCG14, further indicated that expression 
of this mRNA had an almost unique differentiation—stage- 
specific specificity of expression in an immature cell of the 
myeloid lineage, the neutrophilic myelocyte (Birnie et al, 
1984; Wiedemann et al, 1989).
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3.1.1 Characterisation of cDNA clones pCG14 and pCG32
Initial restriction mapping of the two clones pCG14 and 
pCG32 showed that both clones were homologous where they 
overlapped at their 3'—  ends, but contained non-homologous 
sequences at their 5’— ends (Fig. 2). Most work subsequently 
concentrated on clone pCG14; this cDNA was completely 
sequenced on both strands in bacteriophage vectors M13 mplO 
and mpll (see Section 2.1.2). The sequencing strategy is 
shown in Fig. 2 and the complete sequence shown in Fig. 3.
To determine the coding strand of pCG14 cDNA, two 20-mer 
oligonucleotides, oligos B and B ’ (see Fig. 3) representing 
antisense and sense mRNA sequences, were synthesized and each 
used to probe Northern blots of RNA from CGL leukocytes 
previously shown to contain a high abundance of the 
750-nucleotide pCG14 mRNA. Oligo B ’ failed to detect any RNA 
species (data not shown) whilst oligo B detected a single 
750-nucleotide species (Fig. 7C). This established the
coding strand of the pCG14 cDNA as that shown in Fig. 3, 
presented translated in all three reading frames.
At the time this work was done, no sequences similar to 
pCG14 had been entered into EMBL nucleic acid and protein 
databases. Thus all three potential reading frames shown in 
Fig. 3 seemed equally likely to encode che ?CG14 polypeptide. 
Reading frame one (RFl) contained the longest OFF, with j. Ls 
coding potential apparently sc retching from outwith tne clone
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S Ha
S Hi S P P H Hfi i________ i_____t____ !_____!___________ !_______
B g l 100 2 0 0  3 0 0  4 0 0  5 0 0
pCG14
Hf S
J _________________________ ' p C G 3 2
Fig.2 Restriction map of clones pCG14 and pCG32.
Both cDNA clones isolated from the CGL library had been 
cloned into the BamHl site of pAT153 (Twigg and , 19&>)
Arrows above clone pCG14 represent restriction fragments 
cloned into bacteriophage M13 vectors mplO and 11 (Messing, 
1982) with the direction of the arrow indicating the 
direction of sequencing. Sequencing was performed with a 
commercial Klenow dideoxy sequencing kit. Arrows below 
clone pCG32 represent the extent of plasmid^sequenc-_ 
ing of this clone: top arrow, primed with oligo A (Fig- 3); 
bottom arrow, primed with pAT153 oligo 
( 5' GCCGGCCACGATGCGTC 3')-
Sau3A sites (S) at ends of cDNA clones are^tnose constructe 
during cloning into the BamHl site of pAT15j .
Abbreviations: S, Sau3A; H, Hind3; Ha, Hhal; Hi, Hmc2;
Hf, HinFl; P, Pstl; Bgl, Bgl2.
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F i g . 3 Sequence of coding s trand of pCG14.
The sequence is shown translated in all 3 reading frames 
RF1, RF2, and RF3. Open reading frames are shown in bold 
typeface. The position of oligonucleotides X, A, B, C and 
D used in primer extension, oligonucleotide hybridization 
and sequencing experiments is indicated in the figure. 
Overlining of the sequence indicates that the oligonucleo­
tide is complementary to that sequence; underlining in­
dicates that the oligonucleotide is that sequence. Thus 
oligos X, A, B, C and D are all complementary to the 
sequences underlined, whilst oligos A' , B' , C' and D' 
are the sequences underlined. The mapped end-points of primer 
extension at nucleotides 77 and 78 (p-ex) are indicated with 
points above them. The junction with non-pCG14 sequence 
revealed by SI nuclease protection is indicated with a 
line above the sequence (SI, nucleotides 75-7 8) . The meth­
ionine residue most likely to initiate protein synthesis 
is shown underlined (nucleotides 166-168). At either 
end of the sequence the Sau3A site constructed during 
cloning is shown underlined. Also shown is the position 
of Hae3 restriction enzyme sites (see Section 3.3) and 
the positions of the Pstl and Rsal sites used to bind 
the E2-E3 HNP3 cDNA probe used in Section 3.3.
io 30 oligo X  so
GATCCCAGGCATTTAGCCCTCACATTAGATCTAGTTACTGTGGTATGGCTAATACCTGTC 
RF1 AspProArgHisLeuAlaLeuThrLeuAspLeuValThrValValTrpLeuIleProVal 
R F 2 IleProGlyIleEndProSerHisEndlleEndLeuLeuTrpTyrGlyEndTyrLeuSe 
R F 3 SerGlnAlaPheSerProHislleArgSerSerTyrCysGlyMetzAlaAsnThrCysG
70 si— —  p-ex 90 n o  o ligos A/A'
AACATTTGGAGGCAATCCTACCTTGCTATAGAAGACCTGGGACAGAGGACTGCTGTCTGC 
AsnlleTrpAxgGlnSerTyrLeuAlalleGluAspLeuGlyGlnArgThrAlaValCys 
rTh rPheGlyGlyAsnProThrLeuLeuEndLysThrTrpAspArgGlyLeuLeuSerAl 
InH is LeuGluAlaIleLeuP roCysTyrArgArgP roGlyThrGluAspCysCysLeuP
______ 130 150 170
CCTCTCTGGTCACCCTGCCTAGCTAGAGGATCTGTGACCCCAGCCATGAGGACCCTCGCC 
ProLeuTrpSerProCysLeuAlaAjrgGlySerValThrProAlaMetArgThrLeuAla 
aLeuSe rGlyHisP roAlaEndLeuGluAspLeuEndP roGlnP roEndGlyP roSerP r 
roSerLeuValThrLeuProSerEndArglleCysAspProSerHisGluAspProArgli
190 210 Hae3 230 oligos B/B
ATCCTTGCTGCCATTCTCCTGGTGGCCCTGCAGGCCCAGGCTGAGCCACTCCAGGCAAGA
IleL.euAlaAlaIleLeuLeuValAlaL.euGlnAlaGlnAlaGluProLeuGlnAlaAjcg
oSerLeuLeuProPheSerTrpTrpProCysArgProArgLeuSerliisSerArgGlnGl
isProCysCysHisSerProGlyGlyProAlaGlyProGlyEncLAlaThrProGlyLysS
250 Pst1 Hae3 270 290
GCTGATGAGGTTGCTGCAGCCCCGGAGCAGATTGCAGCGGACATCCCAGAAGTGGTTGTT
AlaAspGluValAlaAJLaAlaProGluGlnlleAlaAJLaAspIleProGluValValVal
uLeuMetAxgLeuLeuGlnProAjrgSerArgI.euGlnAjcgTlirSerGlnL.ysTrpL.euPb.
erEndEndGlyCysCysSerProGlyAlaAspCysSerGlyHisProArgSerGlyCysP
310 330 350
TCCCTTGCATGGGACGAAAGCTTGGCTCCAAAGCATCCAGGCTCAAGGAAAAACATGGAC 
SerLeuA-laTrpAspGluSerLeuAlaProLysHisProGlySerArgLysAsnMetAsp 
eProLeuHisGlyThrLysAlaTrpLeuGlnSerlleGlnAlaGlnGlyLysThrTrpTh. 
heProCysMetGlyArgLysLeuGlySerLysAlaSerArgLeuLysGluLysHisGlyL
/
370 oligosC/C 390 410
TGCTATTGCAGAATACCAGCGTGCATTGCAGGAGAACGTCGCTATGGAACCTGCATCTAC
CysTyrCysArglleProAlaCysIleAJLaGlyGluArgArgTyrGlyThrCysIleTyr
rAlalleAlaGluTyrGlnArgAlaLeuGlnGluAsnValAlaMetGluProAlaSerTh
euLeuLeuGlnAsnThrSerValHisCysArgArgThrSerLeuTrpAsnLeuHisLeuP
430 450 430
CAGGGAAGACTCTGGGCATTCTGCTGCTGAGCTTGCAGAAAAAGAAAAATGAGCTCAAAA 
GlnGlyArgLeuTrpAlaPheCysCysEndAlaCysArgLysArgLysMetSerSerLys 
rArgGluAspSerGlyHisSerAlaAlaGluLeuAlaGluLysGluLysEndAlaGlnAs 
roGlyLysThrLeuGlyIleLeuLeuLeuSerLeuGlnLysLysLysAsnGluLeuLysI
490 oligos D/D 510 Rsa1 530
TTTGCTTTGAGAGCTACAGGGAATTGCTATTACTCCTGTACCTTCTGCTCAATTTCCTTT 
PheAlaLeuArgAlaThrGlyAsnCysTyrTyrSerCysThrPheCysSerIleSerPhe 
nLeuLeuEndGluLeuGlnGlyIleAlalleThrProValProSerAlaGlnPheProPh 
leCysPheGluSerTyrArgGluLeuLeuLeuLeuLeuTyrLeuLeuLcuAsnPheLeuS
CGATC
Aug
eAsp
erlle
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to nucleotide 447 , giving rise to a nascent polypeptide in 
excess of 147 amino acids. RF2 had a somewhat smaller coding 
potential stretching from an AUG at nucleotide 245 to 
nucleotide 469 and would have given rise to a 100 amino acid 
polypeptide. Lastly, RF3 stretched from nucleotide 309 to 
outwith the clone at its 3’—end and would have coded for a 
polypeptide in excess of 97 amino acids.
Since for most eukaryotic mRNAs the 5'-most AUG is used 
to initiate protein synthesis (Kozak, 1983), of the three 
possible ORFs, the ORF in RF1 seemed the most likely to encode 
the pCG14 polypeptide (see Fig. 3). However, since the
coding potential of this ORF apparently stretched from outwith 
the cloned sequence, it seemed likely that the 5'-end of pCG14 
mRNA had not been cloned during construction of the CGL cDNA 
1ibrary.
3.1.2 Primer extension analysis of pCG14 mRNA
To determine therefore how much 5 ’-sequence was absent 
from the pCG14 cDNA clone, a 20-mer oligonucleotide, oligo X, 
was synthesized in order to carry out primer extension with 
CGL RNA, shown previously to contain abundant pCG14-homologous 
mRNA. However, after several attempts using this
oligonucleotide, no specific primer extension could be 
demonstrated (Fig. 4A) i.e. no unambiguous primer extension 
product was present with CGL RNA that was not also present in 
HL60B RNA (see Section 3.2.7) or yeast tRNA, RNA samples knov/n
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Fig.4 Primer extension with oligos X and B.
Note:
: Primer extension with oligo X (see Fig. 3) . Lane 1, oligo 
X alone (no RNA.); lane 2, 50pg yeast tRNA; lane 3, 50pg 
HL60B total cellular RNA; lane 4, 50pg HL60P25 total 
cellular RNA; lane 5, lOpg CGL polyA+ RNA. Note lack of 
CGL-specific primer extension (lane 5) .
: Primer extension with oligo B. Lane 1, oligo B alone 
(no RNA); lane 2, 50pg yeast tRNA; lane 3, 50pg HL60B 
total cellular RNA; lane 4, 50pg HL60P25 total cell­
ular RNA; lane 5, lOpg CGL polyA+ RNA. Note CGL-specific 
primer extension (lane 5) . This extension is approx­
imately 150 nucleotides relative to a sequencing gel 
run in parallel as size markers (data not shown) .
the lack of defensin-specific prim er extension  
seen in Fig.4B lane 4 reflects the relatively  
small amount of polyA+ mRNA present in this 
total RNA sample (approxim ately 1 -5%  of total 
RNA is mRNA). Thus the detection of defensin- 
specific primer extension in Fig.4B lane 5 but 
not in lane 4 reflects, in part, an approximately 
20-fold difference in the amount of m RNA  
present in these two samples.
A
1 2 3 4 5
-15*0
- loo
*
-So
t
t
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1 2  3 4
FIg75 Primer extension
A: Primer extension with oligo A (Fig.3). Lane 1, 
oligo A alone (no RNA); lane 2, 56jig yeast tRNA; 
lane3, 50pg HL60P25 total cellular RNA; lane 4, lOpg 
CGL polyA+ RNA. Note two main primer extension 
products, one nucleotide apart (lane 4).
R: DNA sequence ladders generated from Ml3 mplS which 
were used for size estimation of the primer extended 
material.
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to contain no pCG14-homologous mRNA. In contrast, with two 
other 20-mer oligonucleotides 3 ’ to oligo X, oligos A and B 
(see Fig. 3), CGL - specific primer extension could be 
demonstrated (Figs. 4B, 5).
With oligo A this analysis established that the mRNA(s) 
to which this oligonucleotide hybridized contained a further 
29 and 30 nucleotides of 5'—sequence, with two main extension 
products, one base apart. The same conclusion could also be 
drawn from the same experiment performed using oligo B (Fig. 
4B): CGL-specific primer extension in this case extending
150± 2 nucleotides.
3.1.3 Oligonucleotide hybridization
The most obvious possibility from these results was that 
most, if not all, sequence in pCG14 5' to oligo A was not 
derived from pCG14 mRNA and had been fused to pCG14-homologous 
sequences during construction of the CGL cDNA library from 
which the clone was isolated (Wiedemann et al, 1983). This
idea was tested in two ways. Firstly, oligos X and B were 
used to probe a Southern blot of pCG14 and pCG32 plasmid DNAs 
in addition to a 8Kb genomic clone for HNP1A (see Section 3.3.) 
digested with a number of restriction enzymes. Probing with 
oligo X indicated that oligo X sequences were only present in 
the pCG14 clone and absent from both pCG32 and the HMD. A 
genomic clone (Fig. 6A). In contrast, the same blot stripped 
and probed with oligo B showed that both pCo;4 a no p.<ob2
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Fig.6 Oligonucleotide hybridization to plasmid 
Southern blots.
Restriction enzyme digests of approximately lpg each 
of plasmids pCG14, pCG32 (inserts cloned into the filled-in 
BamHl site of pAT153) and pHNPlA (an 8kb defensin genomic 
clone recloned from lambda L47.1 into pUC8, see Section 
3.3) were performed and digestion products electrophoresed 
on a 1% agarose gel. The gel was Southern blotted onto a 
Hybond N membrane. Approximately 150ng of each oligonucleo­
tide was 5'-end labelled and each hybridized to the filter 
in turn. A: blot hybridized to oligo X ; B: stripped blot 
hybridized to oligo B. The absence of signal with oligo B 
in the Pstl lanes of pCG14, pCG32 and pHNPlA is due to the 
position of this oligo. lying on a Pstl fragment of 50bp 
which runs off the gel. Faint bands seen in the Pstl lane 
of pHNPlA (B) are partial digestion products.Abbreviations: 
H, Hind3; He, Hinc2; P, Pstl.
O L IG O -X
A
peg 14 peg 3 2
H N P 3  (I) H N P 3 (2) HNP I.A 
CDNA cDNA genomic
1  ^ He P H He P H He P
B O LIG O - B
peg 14 peg 3 2
H NP 3  (I) HNP 3  (2) H N P1A
cDNA cDNA genomic 
~H He P H He P H he P 
0
well as the HNP1A clone contained oligo B—homologous sequences 
(Fig. 6B). Thus pCG14 and pCG32 were shown to have distinct 
5 ’-sequences, a result later confirmed by sequencing of pCG32 
at its 5 f-end (Fig. 10).
Since the possibility existed that clone pCG14 was
derived from an alternatively spliced mRNA differing from the
predominant form(s) revealed by primer extension by the
presence of sequences 5* to oligo A, oligos X, A and B were
used to probe Northern blots of CGL and HL60P25 RNAs (known to
contain the 750-nucleotide pCG14-homologous mRNA) as well as
HL60B and human mucosal RNAs (known to contain no
pCG14-homologous mRNA). This experiment revealed that oligo X
detected a single 1500-nucleotide mRNA present at very low
coloruc
abundance in human a mucosal, HL60P25 and HL60B RNAs and
undetectable in CGL RNA (Fig. 7A) but did not detect the 
750-nucleotide pCG14 mRNA. In contrast, oligos A and B only 
detected this 750-nucleotide mRNA (Figs. 7B, C).
3.1.4 SI nuclease protection of pCG14 cDNA
Both these experiments supported the idea that the pCG14 
cDNA clone was a chimaera, with sequences at its 5'-end 
derived from a 1500—nucleotide mRNA distinct from the 
750-nucleotide mRNA from which the main body of the clone was 
derived. To confirm this hypothesis, and to map the position 
of the junction between the two sequences, an SI nuclease 
experiment using a single-stranded uniformly— labelled pCG14
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HL60s 
CGL. P25.B.M
1 5 0 0
A
CGL CGL
750
B C
Fig.7 Oligonucleotide hybridization to Northern blots.
Approximately 150ng of each oligonucleotide was 5'-end 
labelled and hybridized to Northern blots of various 
RNAs. A: Oligo X; CGL, 0.2pg polyA+ RNA; P25, 6pg total 
cellular RNA from HL60P25 cells; B, 6pg total cellular RNA 
from HL60B cells; M, 6pg huirian mucosal total, cellular RNA 
(a kind gift from Dr. Paul Elvin) , B: Oligo A; CGL, 0.2pg 
polyA+ RNA; C: Oligo B; CGL, 0.2pg polyAH- RNA.
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Fig.8 SI nuclease protection experiment.
A Bgl2-Pstl fragment of pCG14 was cloned into M13mpl8.
A single-stranded uniformly-labelled probe complementary 
to pCG14 mRNA was prepared using an Ml3 universal 
primer to prime DNA synthesis using the Klenow fragment 
of E.coli DNA polymerase. A 255-nucleotide probe was 
gel-purified and hybridized to various RNAs, prior to 
SI nuclease digestion. Lane 1, SI probe digested; lane 2, 
SI probe undigested; lane 3, 50pg yeast tRNA; lane 4, 50 
pg HL60B total cellular RNA; lane 5, 50pg HL60P25 total 
cellular RNA; lane 6, lOpg CGL polyA+ RNA. An identically 
sized Sl-protected fragment is detected with both HL60P25 
(faint) and CGL (strong) RNAs f  The size of the protected 
fragment was estimated relative to a sequence ladder gen­
erated from the same M13mpl8/Bgl2-Pstl pCG14 clone run in 
parallel (data not shown) and was 130(+ 2) nucleotides.
* see Fig.4 (Note) regarding the 20-fold difference in 
starting mRNA between the samples in lanes 5 and 6 
which accounts in part for the difference in signal of 
the protected fragment in these two samples.
HL60 CGL 
1 2 3 4 5 6 M
probe ^  -255
p  ^protected (130)
cDNA probe prepared by subcloning a Bgl2 — Pstl fragment (see 
Fig* 2) into M13 mpl8 was undertaken. The SI probe spanned 
the hypothesized junction between pCG14 homologous and 
non-homologous sequences since it contained both oligo X and 
oligo A sequences. Complete protection from SI digestion of 
sequences from Bgl2 to Pstl would have yielded a protected 
fragment of approximately 180 nucleotides after digestion of 
M13 probe sequences. However CGL RNA protected a sequence 
130^2 nucleotides in length. (Fig* 8, lane 6), indicating 
that the junction hypothesized in pCG14 lay around nucleotide 
78 (see Fig. 3) in the clone. Since this position mapped to 
within a few nucleotides of the predominant 5’-ends of 
pCG14-homologous mRNA (Fig. 5), it seemed likely that almost 
the complete 5*-end sequence of pCG14 mRNA was present in the 
pCG14 clone and was juxtaposed to non-pCG14-derived sequences 
which thereby appeared to lengthen RF1.
3.1.5 Direct primer extension sequencing of pCC14 mRNA
To establish unequivocally the identity of sequences in 
the pCG14 cDNA clone 5 T to oligo A, up to the junction with 
non-pCG14-homologous sequences with those in pCGl4 mRNA, oligo 
A was used to primer extend sequence pCG14 mRNA present in CGL
RNA. The sequence obtained (Figs. 9 and 3.IB) indicated that
only the last 3 or 4 nucleotides were missing from the 5!-end 
of the pCG14 clone. Thus, although the fusion of non-pGG14 
homologous sequences had appeared to ic-ngtnen RP 1. Jie 5 --nk/st 
AUG in the clone in a good sequence context (Kozak, 3986; most
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Fig. 9 Sequence of 5'-end of pCG14 mRNA..
The sequence was determined by primer extension 
sequencing using reverse transcriptase. Each lane 
T, G, C, and A represent primer extension reactions 
(2pg CGL polyA+ RNA, 25ng 5'-end labelled oligo A) 
carried out in the presence of the corresponding di- 
deoxynucleotide triphosphate. P-ex is the same reaction 
run in the absence of dideoxynucleotide triphosphates 
and is the same result (2 main primer extension prod­
ucts representing extensions of 28 and 29 nucleotides) 
as that shown in Fig.5. The intense autoradiographic 
signal at the bottom of the gel represents unextended 
oligo A.
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likely to initiate protein synthesis occured at nucleotide 166 
(Fig* 3) such that RF1 would encode a 9 4 — amino acid 
polypeptide (Fig. 11A).
Sequencing of the 5’—end of pCG32 (Fig. 10) indicated
that this clone was homologous to pCG14 3 T to nucleotide 89 in 
pCG14 (Fig. 3)? but diverged in sequence 5’ of this position. 
A computer search in an EMBL nucleic acid sequence database 
indicated that the non-pCG14 mRNA sequence in pCG32 was
identical to part of human mitochondrial URF1 sequence.
However, the 1500-nucleotide mRNA from which the foreign 
sequence in pCG14 is derived remains unidentified.
Thus both cDNA clones pCG14 and pCG32 were shown to be 
chimaeric at their 5’-ends. Further experiments (data not 
shown) using oligonucleotides C and D (see Fig. 3) as 
hybridization probes to Northern blots of CGL RNA indicated
that the pCG14 cDNA clone at its 3'-end contained no foreign 
sequences introduced during cloning.
3.1.6 Clone pCG14 encodes defensin HNP3 peptide
Thus the clone pCG14 was shown to have the sequence and 
coding potential shown in Fig. 11A. At this time Mars et_ aj_ 
(1988) published the sequence of a cDNA clone (termed mrs) 
almost identical (differing at only one nucleotide position) 
to pCG14 cDNA. Mars et al (1988) had also isolated their 
cDNA clone from a cDNA library derived from CGL leukocytes and
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TGCTACCCTC ATCAAGATTG AGTAAACGGC TAGGCTAGGC TAGAATAAAT
CCAGG CATTTAGCCC TCACATTAGA
AGGAGGCCTA GGTTGAGGTT GACCAGGGGG TTGGGTATGG GGAGGGGGGT 
TCTAGTTACT GTGGTATGGC TAATACCTGT CAACATTTGG AGGCAATCCT
TCATAGTAGT AGAAGACCTG G-
★ 'k'k'k'k'k'k'k'kit'k *
ACCTTGCTAT AGAAGACCTG G
Fig.10 Sequences of 5'-ends of pCG14 and pCG32 
cDNAs.
The 5' sequences of clones pCG14 and pCG32 are shown 
aligned. Identity of sequences is indicated by 
stars between the sequences. The sequence of the 
5'-end of pCG14 is derived from an as yet unident­
ified 1.5kb mRNA (see Fig.7) . The sequence at the 5'- 
end of pCG32 is different and shares 100% identity 
with part of a human mitochondrial transcript URF1. 
Thus both these cDNA clones are very nearly full- 
length at their 5'-ends and contain foreign seq­
uences fused to this. The strategy for sequencing 
these clones at their 5'-ends is shown in Fig.2.
pCG32
pC G 14
pCG32
pC G 14
pCG32
pCG 14
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A HNP3/PCGI4 cDNA
C T CCT TG CTATAGAAGACCTGGGACAGAGGACTGCTGTCTGCCCTCTCTGGTCACCCT
g c c t a g c t a g a g g a t c t g t g a c c c c a g c c a t g a g g a c c c t c g c c a t c c t t g c t g e c a t t
METArgThrLeuAlalleLeuAlaAlalle
CT CCT GG TGG CCCTGCAGGCCCAGGCTGAGCCACTCCAGGCAAGAGCTGATGAGGTTGCT 
Le uLeuValA1aLeuGlnAlaGlnAlaGluProLeuGlnAlaArgAlaAspGluValA1a
GC AGC CC CGG AGC AGATTGCAGCGGACATCCCAGAAGTGGTTGTTTCCCTTGCATGGGAC 
A 1 a A l aP roG luG ln ile Ala Al aAs pI1eProGIuValValValSerleuAlaTrpAsp
I
GA AAG CT TGG CTCCAAAGCATCCAGGCTCAAGGAAAAACATGGACTGCTATTGCAGAATA 
G1uSerLeuAlaProLysHi sP roG lySerArgLysAsnHetAspCysTyrCysArglle
CCAGCGTGCATTGCAGGAGAACGTCGCTATGGAACCTGCATCTACCAGGGAAGACTCTGG
ProAlaCysIleAlaGlyGluArgArgTyrGlyThrCysIleTyrGlnGlyArgLeuTrp
GC ATT CT GCTGCTGAGCTTGCAGAAAAAGAAAAATGAGCTCAAAATTTGCTTTGAGAGCTA
A1aPheCysCysEND
CA GGG AATTGCTATTACTCCTGTACCTTCTGCTCAATTTCCTTT
3 OLIGO A
CDNA CCTACCTTGCTAT AG AAG ACC TG GGA CAG AGG AC TGC TGT CT GCC CTC T - - - -
RNA ?? CTC CT TGC TATAGAAGACCTGGGACAGAGGACTGCTGTCTGCCCTCT
Fig.11 Revised sequence of cDNA clone pCG14.
A: A revised sequence of clone pCG14 is shown together 
with its predicted primary translation product. The pre­
dicted translational initiation region is shown under­
lined and has a 7/9 match with the initiation consensus 
( CC [A/G] CCATGG ) proposed by Kozak (1986) and predicts 
a 94-amino acid polypeptide. The arrow indicates the 
nucleotide which differs from the sequence presented by 
Mars et al (1988) : A in pCG14, C in mrs.
B: Comparison of the sequence of the 5-'’ -end of pCG14 cDNA 
(top) with that of the 5'-end of pCG14 mRNA (bottom), as 
determined by primer extension sequencing using the 
oligonucleotide complementary to bases 106-125 of the 
sequence shown in Fig.3.
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selected it on the basis of its increased expression in CGL 
leukocytes compared with normal human placental tissue and the 
leukocytes of an ANLL patient (Mars et al, 1985). The
relevance of the one nucleotide difference between the pCG14 
and mrs cDNA clones (indicated by an arrow in Fig. 11A) became 
clear very shortly afterwards by the publication by Selsted et 
al_ (1985b) of the isolation from human neutrophils and amino 
acid sequencing of a group of three peptides called defensins.
Fig. 12 shows the primary amino acid sequence of the 
three defensin peptides. It was clear that HNP1 defensin is 
the C-terrainal 30 amino acids of the mrs ORF, whilst HNP3 
defensin is the C-terrainal 30 amino acids of the pCG14 ORF 
(Fig. 11). Thus the single nucleotide difference between the 
two cDNAs (C in mrs, A in pCG14) results in two almost 
identical peptides differing only at their N-terminal residue 
(alanine in HNP1, aspartic acid in HNP3). HNP2, the other 
defensin peptide isolated by Selsted et al lacks this 
N-terminal residue (Fig. 12) and may be a processing product 
of either or both of defensins HNP1 and HNP3.
3.1.7 Western blotting of defensin peptides
Since in both cases HNP1 and HNP3 represent only the 
C-terminal 30 amino acids of their predicted 94-amino acid 
primary translation products (Fig. 11A), proteolytic cleavage 
would also have seemed to be involved in uheir ra.Vc.i i^n.
As an attempt to prove this and also to co.n. iitu th._ 3kD (.. .
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HNPl
ALACysTyrCysArglleProAlaCysIleAlaGlyGluArgArgTyrGlyThrCys
IleTyrGlnGlyArgLeuTrpAlaPneCysCys
HNP2 
IleTyrGlnG
CysTyrC 
iTv
roAlaCysIleAlaGlyGluArgArgTyrGlyThrCys
eCysCys
HNP3
ASPCvsTyrCvs 
IleTyrGlnG
sIleAlaGlyGluArgArgTyrGlyThrCys
eCysCys
Fig.12 Primary amino acid sequences of defensin peptides.
The primary amino acid sequences of the three cysteine- 
rich peptides abundant in human PMN characterized by Selsted 
et al (1985b) are shown aligned. HNPl and HNP3 are identical 
in sequence apart from their N-terminal residue (alanine 
in HNPl, aspartic acid in HNP3) . HNP2 is identical in 
sequence to both HNPl and 3, except that it lacks their 
N-terminal residue. In bold is the sequence of the oligo­
peptide used to raise a rabbit antipeptide antiserum 
against all 3 defensin peptides.
186
amino acid) size of the mature defensins, it was decided to 
raise an antipeptide antiserum to a 10-amino acid region
common to all three defensins. A rabbit antipeptide
antiserum was raised against this peptide (see Section 2.1.1) 
and used to probe a Western blot of human leukocyte proteins 
(Fig. 13). The anti-defensin antiserura recognized species 
migrating as a single band with an apparent molecular weight
of 3kD, the molecular weight of the mature defensins HNPl, 2 
and 3, described by Selsted et al (1985b). To demonstrate 
specificity of the antipeptide antiserum for defensins, 
control experiments were performed in which the antiserum was 
first preincubated with the 10-mer peptide used to raise it 
and then used to probe a Western blot of human leukocyte
proteins. This resulted in the loss of the 3kD signal shown 
in Fig. 13 (data not shown). Furthermore, preimmune serum 
from the same rabbit used to raise the antipeptide immune
serum failed to detect any species in the 3kD range (data not 
shown). The demonstration of no species detectable on
Western blots other than the 3kD mature defensins indicated 
that if indeed HNPl and HNP3 are derived from larger
precursor polypeptides that these precursors absent or
present at undetectable levels in human peripheral blood 
leukocytes. Experiments described in Section 3.2.4 further 
addressed the question of the presence of defensin precursors 
in HL60 cells.
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HNPsi
M
-l4 k D
-5 6 k D
-3 k D
Fig.13 Western blot of mature defensin peptides,
Normal peripheral blood leukocytes were prepared from a 
buffy coat and a cytoplasmic extract made by NP40 lysis. 
Approximately 20pg of protein was electrophoresed by 
SDS-PAGE and the gel electroblotted onto nitrocellulose. 
Details of the detection of defensins using a secondary 
alkaline-phosphatase conjugated antibody are given in 
Section 2 .*\ . Size markers ran in parallel were pre­
stained molecular weight protein standards (3kD is in­
sulin A and B chains, 5.6kD is bovine trypsin inhibitor 
and 14kD is lysozyme).
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3.2 DEFENSIN GENE EXPRESSION DURING MYELOID DIFFERENTIATION
As described in Section 1.3.4 one of the most useful 
systems to investigate changes in gene expression during 
myeloid differentiation utilizes HL60 cells. Cultures of 
these cells can be induced to differentiate to mature 
granulocyte-like cells by treatment with a variety of chemical 
inducers, including DMSO and retinoic acid.
Since during normal hematopoiesis defensin gene 
expression is both lineage-specific (restricted to the myeloid 
lineage) and stage-specific (restricted to myelocytic cells) 
(see Section 1.6.3), it was of interest to investigate 
whether, in a model system, defensin gene expression was also 
strictly linked to differentiation.
3.2.1 Defensin gene expression in HL60 cells DMSO-induced
One particular subline of HL60 cells (HL60P25) used in 
the laboratory wQS very similar to the original cell line 
established by Collins et al (1977), having, for example, a 
rather long doubling—time (36—48 hours) in comparison to other 
laboratories’ HL60 cells. This line was used in the majority 
of experiments described in this section. Of many other
hematopoietic cell lines investigated (Fig. 21) only HL60P25 
cells expressed defensin mRNA s. Thus in the Loilowing
experiments we are looking at a system in which the de^euoin
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Fig.14 Induction of differentiation of HL60 cells.
Exponentially growing HL60 cells were induced to diff­
erentiate by treatment with either DMSO (Section 3.2.1) 
or retinoic acid (Section 3.2.3) and trie proportion of 
NBT-positive cells in culture measured. Growing cultures 
of HL60P25 cells typically had 4-10% of NBT-positive cells 
due to spontaneous differentiation , rising to 30-90% 
and 60-70% after treatment with DMSO and retinoic acid 
(RA) , respectively.
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gene(s) are already synthesizing defensin raRNAs, a situation 
which is followed during normal myeloid differentiation by 
down-regulation of expression (Wiedemann et al, 1989).
Inducing HL60P25 cells to differentiate along the myeloid
lineage by treatment with DMSO (Fig. 14), led to a
down—regulation of defensin mRNA levels. Fig. 15A shows a 
Northern blot of polyA+ mRNA from HL60 cells, harvested at 
various times following their treatment with DMSO, and probed 
with a defensin cDNA (HNP3; pCG14 minus non-defensin 
sequences). During the first hour after addition of DMSO, 
the abundance of defensin mRNAs decrease^ whereafter their 
levels are restored to near pre-induction levels 7 hours 
later. Subsequently, the abundance of defensin mRNAs is
again decreased, this time much more slowly. Both ethidium 
bromide staining of the gel (data not shown) and reprobing of 
the filter with a cDNA probe for p2-roicroglobulin (Fig. 15B), 
detecting an mRNA whose level is known not to change to any 
extend during HL60 differentiation (Mitchell, 1987), indicated 
that each lane in Fig. 15A contained approximately the same 
amount of mRNA and, therefore, that the observed changes in 
autoradiographic signal intensity reflected real changes in
the abundance of defensin mRNAs.
Changes in gene expression can occur at a variety of 
levels, both transcriptional and post-transcriptionai. The 
early transient decrease seen with defensin mRNA ceding 
treatment of HL60P25 cells with DMSO could, Cor example.,, have
191
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750 m *
Fig.15 Northern blot analysis of defensin gene ex­
pression during granulocytic differentiation 
of HL60P25 cells induced by DMSO.
Exponentially growing HL60P25 cells were induced to 
differentiate by treatment with DMSO (1.5% v/v) and 
total cellular RNA harvested at various time intervals. 
PolyA+ RNA was prepared, and lyg from each time 
fractionated on a denaturing agarose gel. The RNA was 
then blotted from the gel onto a Hybond-N nylon mem­
brane. A: blot probed with a radiolabelled HNP3 defensin 
cDNA probe. B: blot stripped and reprobed with a radio­
labelled p2-microglobulin cDNA probe (Section 2.1.3 ), 
to ensure egual amounts of RNA on each lane of the blot.
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occured at the level of mRNA stability, a level of control of
gene expression shown for certain other mRNAs including those
for GM-CSF and c-myc (Greenberg et al, 1986; Shaw and Kamen,
1986). Alternatively, the same early decrease could have
been accounted for by a transient transcriptional block as
described (though not in these cases transiently) for the 
c-myc and c~myb genes (Bentley and Groudine, 1986; Bender et_
al, 1987).
To attempt to decide which of these levels of control 
were operating, it was decided to investigate the stability of 
defensin mRNAs in HL60 cells. The rationale for this
experiment is as follows. If defensin mRNAs in uninduced 
HL60P25 cells were ordinarily very stable, then if a 
transcriptional block were operating exclusively after 
treatment of the cells with DMSO, one would expect a
comparatively high level of defensin mRNAs after one hour,
which is not what is observed (see Fig. 15A). Therefore
treatment of the cells with DMSO must also result in a rapid 
destabilization of defensin mRNAs.
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3.2.2 mRNA stability and transcription of defensin genes
One way of measuring mRNA stability is to utilize a
potent inhibitor of transcription by RNA polymerase 2, such as 
actinomycin D, thus allowing a decoupling of the process of 
transcription from post-transcriptional levels of control of 
mRNA abundance. Fig. 16A shows a Northern blot of whole cell 
RNA harvested at various times following treatment of HL60P25 
cells with actinomycin D and probed with a defensin cDNA. Two 
features are noticeable. Firstly, a transient increase in the 
level of defensin mRNAs 30 min after treatment. This 
transient increase appears to be a real one and not due to 
more RNA loaded in this lane, since ethidium bromide staining 
of the gel prior to transfer onto the nylon filter shows that
there was an equal amount of RNA on each lane (data not
shown).
The second feature of Fig. 16A is that, even after 3
hours of treatment (no defensin transcription for 3 hours), 
there is still significant defensin mRNAs present 
(approximately two—thirds of untreated cells). A slot blot 
of the same RNAs probed with a c-myc exon 2 probe (Fig. 16B) 
demonstrated that the actinomycin D treatment is indeed 
inhibiting transcription since c-myc RNA is turning over with 
a characteristic short half—life (Dani et al, 1984).
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Fig. 16 Determination of stability of defensin mRNAs.
Exponentially growing HL60P25 cells were treated with 
actinomycin D (5yg/ml) and total cellular RNA harvested 
immediately (0 time-point) and at various time intervals 
A: Northern blot analysis of lOpg of total cellular RNA 
fractionated on a denaturing agarose gel and hybridized 
with a radiolabelled HNP3 defensin cDNA probe. B: Slot- 
blot of 2pg of total cellular RNAs from the same experi­
ment hybridized with a radiolabelled human c-myc exon 2 
probe (Section 2.1.3).
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Thus defensin mRNAs are ordinarily rather stable in 
HL60P25 cells. This finding implies then that whatever 
mechanism is involved in the initial decrease in abundance of 
defensin mRNAs during 1 hour of treatment of the cells with 
DMSO, a decrease in mRNA stability must also be involved. 
Although this established that an early decrease in the 
stability of defensin mRNAs is necessary to bring about the 
observed decrease in abundance, it does not establish that it 
is in itself sufficient to bring this about, leaving open the 
possibility that some transient transcriptional pause could 
also be involved. For the reasons explained in Section 3.2.5 
it was impossible to directly measure the stability of 
defensin mRNAs after treatment with HL60P25 cells with DMSO.
To investigate the transcription of defensin gene(s) in 
HL60P25 cells, with a view to answering this question and also 
the question of whether the later, slower decrease in 
abundance of defensin mRNAs after treatment of the cells with 
DMSO (Fig. 15A) is accomplished by a transcriptional 
switch-off, nuclear run-on transcription experiments, which 
allow one to investigate how actively a given gene or gene 
segment is being transcribed (Groudine et al , 1981), were
attempted.
In the experiment, nuclei harvested from exponentially 
growing HL60 cells were used in an in vitro run-on reaction, 
radiolabelled RNA harvested and used to probe a slot-biot of 
double-stranded cDNA probes bound to a nitrocellulose filter,
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defensins
puc 8
P2-M. 
c-myc exon 1
c-myc exon 2
Fig.17 Nuclear run-on transcription assay in HL60P25.
lpg of double-stranded plasmid inserts for HNP3 defensin, 
p2-microglobulin, c-myc exon 1, c-myc exon2 and EcoRl cut 
pUC8 were alkali-denatured and slot-blotted onto nitro­
cellulose. The filter was hybridized with radiolabelled 
RNA transcripts generated from a nuclear run-on trans­
cription assay using nuclei prepared from exponentially 
growing HL60P25 cells.
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including a full-length defensin cDNA. Fig. 17 shows the
result. Defensin gene transcription in HL60 cells is very 
low, barely in excess of a negative control (pUC8) and
certainly not as high as transcription of the genes for
Jl2-microglobul in (single copy) or c-myc (amplified some 
30-fold in these cells (Graham et al, 1985). The excess of 
c—myc exon 1 transcription over exon 2 observed is due to the 
presence of a transcriptional pause site at the end of exon 1 
(Bentley and Groudine, 1986). Unfortunately, this low level 
of transcription observed for defensin genes in HL60P25 cells 
made it impossible to study the impact of any possible
decrease in transcription to the decrease in abundance of 
defensin mRNAs following treatment of the cells with DMSO, 
since any decrease would be hard to establish unequivocally.
3.2.3 Defensin gene expression in HL60 cells RA-induced
It was decided at this juncture to change tack and look 
at the regulation of defensin mRNAs following treatment of 
HL60P25 cells with another inducer of granulocytic 
differentiation, retinoic acid, since there were indications 
of marked differences in the regulation of certain other 
mRNAs, including c-myc (Mitchell, 1987) when cells were, 
incubated with this granulocytic 'inducer rather than DMSO. 
Fig. 18A shows a Northern blot of whole cell RNA harvested at 
various times following treatment of rIL60P25 ceais wi.-.. h 
retinoic acid, probed with a defensin cDNA. cun
clearly seen that treatment with this induce_, >-0. con... . . < >
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Fig. 18 Northern blot analysis of defensin gene ex­
pression during granulocytic differentiation of 
HL60P25 cells induced by retinoic acid.
Exponentially growing HL60P25 cells were induced to diff­
erentiate by treatment with retinoic acid (lpM), and 
total cellular RNA. harvested at various time intervals. 
lOpg of RNA from each time-point was fractionated by 
electrophoresis on a denaturing agarose gel. The RNA was 
then blotted from the gel onto a Hybond-N nylon membrane. 
A: blot hybridized with a radiolabeiled defensin cDNA 
probe. B: blot stripped and reprobed with a JB2-micro- 
globulin cDNA probe.
B; p2-MICROGLOBULIN
'
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treatment with DMSO, does not lead to a decrease in abundance 
of defensin mRNAs. Levels of defensin mRNAs are constant up 
to 32 hours, whereupon an increase (2-4 fold) is seen. At 
day 5 of treatment defensin mRNAs are still detected at a 
level similar to uninduced cells. Fig* 18B shows the same
composite blot reprobed for jB2_mi cro§l°buli-n mRNA, indicating 
that approximately the same amount of RNA is present in each 
lane.
Thus, although retinoic acid is effective at inducing
HL60P25 cells to differentiate (as monitored by the ability of 
the mature cells to reduce the dye NBT (see Fig. 14), the
changes observed in the steady-state levels of defensin mRNAs 
are quite different to those observed after treatment of the 
cells with DMSO (compare Figs. 15A and 18A). Possible
reasons for this will be discussed in Section 4.2.
3.2.4 Investigation of defensin proteins in HL60 cells
At the end of these experiments all our batches of frozen 
HL60P25 cells had been used. All subsequent experiments with 
this subline are therefore with cells of the original batch 
grown up and frozen in new batches and then grown from frozen 
(now termed HL60.P25( 1)). All media, serum etc are, however, 
identical to the previous set of experiments and are as 
described m  Section 2.2.1.
- •- r*t
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As previously detailed, the mature defensin peptides are 
30 amino acids (3kD) as found in mature PMN (Fig. 13). 
However, the nascent polypeptides encoded by both the pCG14 
and mrs cDNAs (encoding HNP3 and HNP1 defensins, respectively) 
have a predicted size of 94 amino acids (approximately 9kD). 
To try to show a pro duct-precursor relationship between these 
two forms of defensin, it was decided to label the protein in 
vivo by briefly pulse-labelling HL60 cells with (35S)- 
cysteine and immunoprecipitate defensins and
defensin-precursors using the anti-defensin antiserum used to 
detect mature defensins on Western blots (Figs. 12 and 13). 
Fig. 19A shows the result of this experiment. As can be 
seen, some proteins are weakly immunoprecipitated. However, 
these proteins are immunoprecipitated with both immune and 
preiraraune antisera and cannot, therefore, be defensin-specific 
(Fig. 19A, comparing PRE and IMM).
Despite three separate attempts at different conditions 
for immunoprecipitation (altering the stringency of washing 
after the first immunoprecipitation), this result remained the
fob*
same. There seemed a two possible explanations for this:
first, the anti-defensin antiserum, although able to recognize 
epitopes on denatured defensins. presented on Western blots, 
might not be able to recognize deiensins or their precursors 
in their native non—reduced forms in cytoplasmic extracts; 
second, HL60P25<1) cells, might sot., by sythesizing defensin 
protein at all,. To-, test this 1 -.tter u/pornesis, a Western 
blot of a cytoplasmic extract; fro;, 111,6 0 cells was probed
20i
with anti-defens in antiserum. As a control, the same amount 
of total protein (estimated by staining of the gel with 
Coomassie Blue) from human PMN was run and transferred to 
nitrocellulose on the same blot. The result (data not shown) 
was a failure to detect any defensin-related species in the 
HL60P25(1) extract despite ready detection of the mature 
defensin peptides in the extract from human PMN.
3.2.5 Loss of defensin gene expression in HL60P25(1)
To determine whether HL60P25(1) cells were still 
expressing defensin mRNAs, whole cell RNA was harvested, and a 
Northern blot run with both HL&0P25(1) and HL60P25 RNAs 
(harvested previously) and probed for defensin
mRNAs. The result (Fig. 19Bi) shows that the HL60P25(1) 
cells used in both the immunoprecipitation and Western 
blotting experiments were not expressing defensin genes (Fig. 
19Bi, lane 2). Reprobing of the blot for pp-niicroglobulin 
mRNA (Fig. 19Bii) showed that there was approximately the same 
amount of RNA in both samples.
Thus it seemed that although this newly grown batch of 
HL60P25 cells (HL60P25(l)) were similar to the previous batch 
of cells (with respect to, for example,- ability to 
differentiate to granulocyte-like ceils up on. l:. eat men t with 
DMSO, doubling time and morphology (all <!s.te net shown)) they 
differed with respect to expression o o.e» < > .-.ones.
20-
Fig.19 Loss of defensin gene expression in HL60P25(1).
A: Immunoprecipitation of [35S]-cysteine labelled proteins. 
Exponentially growing HL60P25(1) cells were pulse-labelled 
with [35S]-cysteine for 8 hours, a cytoplasmic extract made 
by NP40 lysis and l/5th volume immunoprecipitated using 
either preimmune (PRE) or immune (IMM) anti-defensin anti­
sera. Immunoprecipitates collected by protein-A sepharose 
were denatured, electrophoresed by SDSPAGE and fluorographed 
prior to autoradiography. Also run on the gel was 5pl of 
cytoplasmic extract (out of a total volume of 1ml) in­
cluded to check labelling (TOTAL CYTO), and prestained 
protein molecular weight size markers (M) .
B: Northern blot analysis of defensin gene expression in 
HL60P25 (1) . CiQneU (laoii)
Total cellular RNA from HL60P25Aand HL60P25 (1)A was 
harvested from exponentially growing cultures and lOpg 
each fractionated by electrophoresis on a denaturing agarose 
gel. The RNA was then blotted from the gel onto a Hybond-N 
nylon membrane. Bi: blot hybridized to a radiolabelled HNP3 
defensin cDNA probe. Bii: stripped blot reprobed with a 
radiolabelled p2-microglobulin cDNA probe,
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3.2.6 Defeasia gene expression in other cell lines
The mechanism(s) of this loss of defensin gene expression 
is unknown and was not investigated further. However, it 
would appear to be a phenomenon not restricted to the P25 
subline of HL60 cells. Fig. 20 shows a Northern blot of RNA 
harvested from four different sublines of HL60 cells and 
probed for defensin mRNAs. Of these 4 sublines (and
subsequently another one was tested, data not shown) only the 
initial P25 subline expressed defensin mRNAs. In fact out of 
a total of 16 hematopoietic cell lines tested (including 6 
different HL60 lines) only the P25 subline of HL60 cells 
expressed defensin mRNAs (Fig. 21). The loss of defensin 
expression in HL60P25(1) has resulted in there being no cell 
line available currently in our hands in which to investigate 
defensin gene expression.
3.2.7 Differentiation of defensin expression-negative HL60 cells 
does not induce expression
Inducing another HL60 subline, HL60B, to differentiate 
along the granulocyte lineage by treatment with DMSO did not 
induce the cells to synthesize defensin mRNAs. Fig. 22A shows 
a Northern blot probed for defensin mRNAs of whole cell RNA 
harvested at various times following treatment of these cells 
with DMSO. Lane 9 is a positive control of a CGL peripheral 
blood leukocyte RNA sample containing abundant defensin mRNAs. 
As a control for equal RNA' on each lane of the HL60B RNA
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Fig.20 Northern blot analysis of defensin gene ex­
pression in 4 HL60 sublines.
Exponentially growing HL60 cells from 4 different 
laboratories (P25, B, T, and ICRF) growing in RPMI 
1640/ 10%FCS were harvested and total cellular RNA 
prepared. 10yg of each RNA was fractionated by gel 
electrophoresis, stained with ethidium bromide to 
ensure equal amounts were present in each lane, and 
blotted onto a Hybond-N nylon membrane. The blot was 
then hybridized with a radiolabelled HNP3 defensin 
cDNA probe.
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P25 
P25(l)
B 
T
ICRF 
N 
K562 
ML1 
KG1 
KG1A 
Daudi 
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CEM 
MOLT-4 
Km3 
U937
EXPRESSION OF DEFENSTN mRNAs (+/-)
Fig.21 Summary of defensin gene expression in 
hematopoietic cell lines.
Defensin mRNA levels were determined in a variety of 
HL60 sublines and other hematopoietic cell lines either 
by Northern blot analysis or by quantitative dot-blot 
analysis. Only the original HL60P25 line obtained 
from the laboratory of Dr.Robert Gallo [NIH, USA] ex­
pressed detectable defensin RNAs.
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samples, the blot was stripped and reprobed for 
p2_micr°gl°t>ulin mRNA (Fig. 22B). From this experiment it 
can be deduced that whatever mechanism is responsible for the 
loss of expression of defensin mRNAs in this subline of HL60 
cells, it cannot be reversed by inducing the cells to 
differentiate. Whether this is also the case for other HL60 
sublines, including HL60P25(1) remains to be established.
. In summary then, using the HL60 differentiation system to 
study defensin gene expression during myeloid development has 
shown that DMSO-induced differentiation of these cells more 
closely resembles in its gross characteristic of 
down-regulation of expression the in vivo regulation of these Cjtf)LS 
than RA-induced differentiation.
A seemingly more fruitful avenue for investigation, in 
the absence of an in vitro system more closely resembling in 
vivo myelopoiesis, was to investigate the defensin gene(s) 
themselves, with the ultimate view of understanding the 
mechanism(s ) of control of differentiation—stage—specific gene 
transcription. It was therefore decided to isolate and
investigate the human defensin genes.
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Fig.22 Northern blot analysis of defensin gene ex­
pression during granulocytic differentiation 
of HL60B induced by DMSO.
Exponentially growing HL60B cells were induced to 
differentiate by treatment with DMSO (1.5% v/v), 
total cellular RNA harvested at various tirne-points 
and analysed by Northern blotting of 15pg of each 
sample fractionated by electrophoresis on a denatur­
ing agarose gel. A: blot hybridized with a radiolabeiled 
HNP3 defensin cDNA probe. Lane 1, uninduced; lane 2,
1 hour; lane 3, 2 hours; lane 4, 4 hours; lane 5, 8 
hours; lane 6, 24 hours; lane 7, 2 days; lane 8, 4 days; 
lane 9, RNA from peripheral blood leukocytes from a CGL 
patient, 0.2pg polyA+. B: blot stripped and probed with 
a radiolabeiled p2-microglobulin cDNA probe.
DEFENSINS
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3.3 ISOLATION AND CHARACTERIZATION OF HUMAN DEFENSIN GENES
The realization that human defensin peptides HNP1 and 
HNP3 were encoded by distinct mRNAs (this work and Daher et 
al, 1988) immediately implied that there ought to be at least 
two distinct defensin genes, one encoding HNP1, the other 
encoding HNP3. The cloning of both HNP1 and HNP3 cDNAs from 
HL60 cells (Daher et al, 1988) added support to the notion
that both genes co-exist in the same cells.
There were, however, other possibilities to there being 
two distinct defensin genes. One possibility was that both 
HNP1 and HNP3 mRNAs were encoded by a single gene, but that 
this gene encoded two mRNAs with alternatively spliced exons, 
one exon containing a GCC triplet (alanine) and thus encoding 
HNP1, the other containing a GAC triplet (aspartic acid) and 
thus encoding HNP3. Another possibility was that again there 
was only a single gene, in this instance encoding either HNP1 
or HNP3, such that both mRNAs were derived by modification of 
the single gene—encoded mRNA by a post-transcriptional mRNA 
editing mechanism (nucleotide substitution) as has been 
described in the case of apolipoprotein B mRNAs (Powell et al,
1987).
Prior to the isolation of defensin-encoding genomic 
clones, it was decided to ask the question as to whether the 
single nucleotide change between HNP1 and HNP3 mRNAs 
previously described might be usefu.j. in distinguishing v<rhe_hc.
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Fig.23 Schematic view of the coding difference between 
HNP1 and HNP3 cDNAs.
The Hae3 restriction maps of the cDNAs encoding defensins 
HNP1 and HNP3 are shown together with the single base 
coding change (C in HNP1, A in HNP3) which distinguishes 
them (Wiedemann et al, 1989; Mars et a l , 1988) . Also 
shown is the cDNA probe (PROBE) used to distinguish the 
genomic sequences of HNPl and HNP3. This probe is a 3' 
Pstl-Rsal fragment derived from pCG14 (see Fig. 3) and 
spans the polymorphic Hae3 site. It was later shown to 
include sequences from exons 2 and 3 of the HNP1A gene 
(see Fig.27B) and was therefore termed E2-E3 cDNA probe.
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subsequently isolated genomic clones encoded HNP1 or HNP3. 
Since the C nucleotide in the GCC triplet of the HNP1 cDNA 
gave rise to a GGCC tetranucleotide sequence, a cutting site 
for the restriction enzyme Hae3, whilst the A nucleotide in 
the GAC triplet of HNP3 gave rise to a GGAC tetranucleotide 
sequence not recognized by Hae3, a possible means of
distinguishing HNP1 from HNP3 on the basis of Hae3 digestion 
was clear (shown in Fig. 23). The simple model that HNP1
gene sequences around the polymorphic Hae3 site, upon Hae3 
digestion should be detected as two fragments, whilst HNP3 
gene sequences should be detected as one larger fragment was 
tested by Southern blotting of a number of Hae3-digested human 
DNAs, probing with a HNP3 cDNA probe spanning the Hae3
polymorphism (Fig. 23).
3.3.1 Human DNAs have variable relative amounts of genomic sequences 
encoding HNP1 and HNP3
An example of this Southern blot analysis is shown in 
Fig. 24. Out of 13 DNAs (and a subsequent 19 have since been 
analyzed, data not shown) four simple patterns involving three 
fragment sizes of 350, 650 and 1150 bp have been observed.
Of these four patterns the most striking is represented in 
Fig. 24, lanes 4 and 5 where only the 350 and 650 bp fragments 
were detected.
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Fig.24 Southern blot analysis of Hae3 digested 
human leukocyte DNAs.
15pg of DNA from the peripheral blood leukocytes of 
13 individuals were digested with Hae3 and Southern 
blotted onto a Hybond-N membrane. The blot was hybridized 
with a radiolabeiled Pstl-Rsal HNP3 cDNA probe (shown 
in Fig.23). The 1150bp fragment and the 350/650bp 
fragments are those fragments derived from HNP3 and 
HNPI genes, respeccively. This was shown directly by 
the isolation of genomic clones for HNPI and HNP3 
(Sections 3.3.2, 3.3.4 ). Four distinct patterns, 
shown most clearly in lanes 2, 3, 4 and 10, have been 
found in a survey of 32 DNAs (see Fig.25) .
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In the absence of any detailed information on the 
structure of defensin-encoding genes, the interpretation of 
this result was that the 1150 bp fragment detected in the 
majority of the DNAs represented HNP3 genes (lacking the 
polymorphic Hae3 site) which, in the case of HNPI gene 
sequences (containing the polymorphic Hae3 site) was digested 
into two fragments of 350 and 650 bp (the discordance between 
350 + 650 = 1000 bp and the observed 1150 bp fragment size 
remained at this stage unexplained, see Fig., 31 for
explanation).
This interpretation, which proved to be essentially 
correct (see Fig. 31), implied that individuals had variable 
copy number of HNPI- and HNP3-encoding sequences. Some
individuals (for example lanes 4 and 5, Fig. 24) seemed to 
have only HNPl-encoding gene sequences, whilst others seemed 
to have either equal amounts of HNPI and HNP3, relatively more 
HNP3- or relatively more HNPI- encoding sequences (compare 
lanes 2, 3 and 10 respectively, Fig. 24). The relative
autoradiographic intensity of the HNP3 (1150 bp fragment) and 
HNPI (350/650bp) fragment signals in Southern blots of human 
DNAs (as evaluated by densitometric scanning of 
autoradiographs, data not shown) fitted with a model in which 
individual human DNAs had a total of four defensin—encoding 
genes. According to this model, the mdlviduaxs of iig. 2 s 
lanes 4 and 5 contained four HNPl-encoding gene sequences, 
whilst the individual in lane 2 had two HNPI- and two uNPo- 
encoding gene sequences. Similarly, cht, j.n 'fj-do
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Fig.25 HNP genotype survey.
DNAs from a total of 32 individuals (mainly UK nationals) 
were digested with Hae3 and probed with a probe which 
distinguishes HNPI from HNP3 genes (see Figs.23 and 24) . 
Densitometric scanning of autoradiographs allowed all in­
dividuals tested to be placed into one of 4 patterns (see 
Fig.24 lanes 2,3,4 and 6) . A simple model, in which all 
individuals tested had a total of 4 defensin genes per 
diploid genome, was invoked to explain these 4 patterns. 
According to this model., individuals can have either 4 
HNPl-encoding genes (4:0) or ratios of HNPI:HNP3 genes 
(3:1, 2:2, 1:3, 0:4 ). The proportions of the total number 
of individuals tested having each of these 4 patterns 
is expressed here in percentage terms. Out of a total of 
32 DNAs no individuals containing only HNP3 genes (0:4 
ratio) have been observed.
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represented by Fig. 24 lane 3 contained one HNPI- and three 
HNP3- encoding sequences, whilst the individual of Fig. 24
lane 10 had the converse. The proportions of individuals out
of a total of 32 tested having each of these four patterns is 
shown in Fig. 25. This model is discussed in more detail in 
Section 4.3. and its validity addressed in the experiment 
described in Section 3.3.7.
If there were indeed four defensin-encoding genes, one 
should be able to isolate them from individuals, with the
caveat that the genomes of these individuals should actually
contain both HNPI and HNP3 genes.
3.3.2 Isolation of genomic clones for defensin HNPI
To ensure that the entire coding region of defensin genes 
were isolated on putative defensin genomic clones, a number of 
restriction enzymes were tested by digesting genomic DNAs from 
a number of individuals, probing Southern blots with a 
full-length defensin HNP3 cDNA probe. Thus, in all
individuals tested, two EcoRl fragments of 1.7 and 4.5 Kb were 
detected (data not shown). In contrast, a single 8-9 Kb 
fragment size was detected in a number of individuals DNAs 
digested with BamHi., indicating that all defensin-encoding 
sequences were present on a 8-9 Kb BamHl Li-agment (Fig. 26).
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Fig.26 Southern blot of leukocyte DNAs digested with BamHi.
15pg of DNA from the peripheral blood leukocytes of 4 
individuals was digested with BamHi and Southern blotted 
onto Hybond-N. The blot was hybridized with a radiolabeiled 
full-length defensin HNP3 cDNA probe. DMAs from both normal 
and leukaemic individuals have been similarly analyzed and 
no gross deletions or insertions of defer'.sir* coding 
sequences noted using this probe (data noi: shown) .
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With this knowledge, it was decided to construct a BamHi 
library of human leukocyte DNA and screen with a defensin cDNA 
in order to isolate defensin genomic clones. Two libraries 
were constructed (from two individuals) in lambda L47.1 and 
two independent defensin-encoding clones isolated, one from 
each library. Both genomic glones were approximately 8-9 Kb 
in size and had similar restriction maps (Fig. 27A).
It was decided to investigate one of these genomic clones 
(termed HNPI A in Fig. 27 A) in detail by a combination of 
hybridization with defensin cDNA oligonucleotides (see Fig. 3) 
to Southern blots of restriction enzyme digests of the clone 
(data not shown), and by sequence analysis (Fig. 28).
3.3.3 Characterization of HNP1A genomic clone
Since oligonucleotide hybridization using oligo A (Fig. 
3) had revealed that the 5'-coding region of this defensin 
clone was contained on a 500bp Hinc2-Hinc2 fragment whilst 
more 3’ -coding regions (as represented by oligos B, C and D) 
were present on a 2.6 Kb Hinc 2 — BamHi fragment (data not 
shown, and Figs. 27A and B), these portions of HNP1A genomic 
clone were subcloned into M13mpl8 and j.9 vectors and 
sequenced as shown in Fig. 27B.
Fig. 28 shows the result of this sequence analysis, the 
sequence shown representing the coding strano ana ft? 
translation product shown underneath.
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Fig.27 Characterization of two HNPl-encoding defensin genes. 
A: Restriction Maps.
Clones HNP1A and HNP1B were isolated as 8-9kb BamHi 
genomic fragments cloned into bacteriophage vector lambda 
L47.1 ( Loenen and Brammer, 1980 ) . The library from 
which HNP LA was derived was constructed from DNA from 
the peripheral blood granulocytes of a normal donor. Like­
wise, the library from which HNP IB was derived was con­
structed from the peripheral blood leukocytes (total wbc) 
of another normal donor. In both cases the 8-9kb genomic 
fragment was then recloned into the plasmid vector pUC8 
( Viera and Messing, 1982) and restriction mapped with 
the enzymes Hinc2 (He), EcoRl (Rl) and Hind3 (H) .
The subscript A or B refers to the position of the first 
Hind3 site upstream of exon 1 used as a convention to dis­
tinguish the clones.Bold rectangles reffcszni 
B: Coding regions of HNPl-encoding defensin genes.
The 3'-regions of the two HNPI defensin clones isolated are 
shown. The region was restriction mapped from the 3'-most 
Hae3 site in E2 to the BamHi site at the 3'-end of the clone 
with the restriction enzyme Hae3. The map predicts that an E2- 
E3 cDNA probe, which spans the second intron,should detect two 
Hae3 fragments (650/350bp) which is what is observed (Fig.31) . 
HNP 1A, the most extensively characterized HNPI gene (consists 
of 3 exons (El, E2, and E3) and two introns (II and 12) and 
was sequenced on both strands as shown in the Figure by sub­
cloning into bacteriophage Ml 3 vectors mpl8 and 19 (Yanish- 
Perron et al, 1985), the direction of the arrow indicating 
the direction of sequencing (performed at least twice per 
direction) . Sequencing was performed with a commercial T7 
dideoxy chain terminating sequencing kit.
The following defensin cDNA oligonucleotides were used, in 
addition to the ML3 universal primer, as sequencing primers:- 
First exon region: oligo A; oligo A' .
Second exon region: oligo B; oligo B'.
Third exon region: oligo D; oligo D'.
Two other oligonucleotides derived from HNP1A intron sequences 
were also used as sequencing primers:
Oligo II (Intron 1 oligo. used to sequence into E2 5'- 3 ' ) ;
5' CCACACAGCTGCTCCTGCTC 3' .
Oligo 12 (Intron 2 oligo.used to sequence into E3 5'-3');
5' TGACGATTGAGGTATGAGTT 3'.
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(i) Structure of coding regions of HNPIA
The coding regions of this gene correspond exactly in 
sequence to the cDNA for HNPI defensin (Mars et al, 1988; 
Daher et al, 1988; and to ray sequence for pCG14 (HNP3) shown
in Fig. 11 apart from one base: A (HNP3); C (HNPI), the
relevant GCC triplet is in exon 3, Fig. 29) and thus this gene
encodes HNPI. The gene is organized into three exons and two 
introns as revealed by sequence analysis. Exon 1 (El) is small 
(76 bp) and non-coding, and is separated from exon (E2) by af\ 
intron (II) of approximately 1600 bp. The sequence of 
the 5 ’-end of El corresponds exactly to that found by direct 
sequencing of defensin mRNAs in the experiment shown in Fig. 
9. E2 is larger than El (187 bp) and encodes the
first methione and 58 residues of the defensin precursor. E3 
(219bp) encodes the mature HNPI defensin peptide and is 
separated from E2 by an intron (12) of approximately 650 bp. 
As shown in Fig. 29, the splice junctions E1-E2 and E2-E3 
correspond well to the consensus sequences proposed by Mount
(1982).
(ii) HNPIA promoter
239 bp of sequence upstream of El was sequenced and 
revealed to contain two AT-rich * elements (shown underlined 
in Fig. 28), regions typically 20-30 bases upstream of most 
eukaryotic promoters required foi normal Lnic.at^cn cl. t.^ _ i_np 
site (Breathnach and Charabon, 60
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Fig.28 Sequence of HNP1A.
The sequence of the entire coding region of HNP1A is 
shown. Also shown are the sequences of the 5'-regulatory 
region (239bp determined), some intronic 
and 3' non-coding regions. Exon sequences (E1-E3) are 
shown in bold and correspond exactly with the published 
sequence of HNPI defensin (mrs) (Mars et al, 1988). The 
transcriptional initiation points on the gene revealed by 
primer extension analysis are shown arrowed and occur 20-30 
bases downstream of two AT-rich sequence elements (under­
lined) . Also shown at the 3'-end of the gene is a poly- 
adenylation signal AATAAA (underlined) . The sequence shown 
was determined using the sequencing strategy shown in Fig. 
27B.
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AACTGTGTTAGGAGCCATTGAGAATCCATAGTTGGTTGCTGCCTGGGCCTGGCCAGGGCT
11 gACCAAGGTAGATGAGAGGTTCCTCTGTGGAGTTCTACTTTAACCTCACCTTCCCACCAA
a t t t c t c a a c t g t c c t t g c c a c c a c c a t t a t t t a a t g g a c c c a a c a g a a a g t a a c c c c g g*'-5 9
AAATTAGGACACCTCATCCCAAAAGACCTTTAAATAGGGGAAGTCCACTTGTGCACGGCT~*’
GCTCCTTGCTATAGAAGACCTGGGACAGAGGACTGCTGTCTGCCCTCTCTGGTCACCCTG
CCTAGCTAGAGGATCTGTAAGTACTACAAAACTTAAACTTTACACTGAGTTTTCATCATT
GAAGCTATGCCTCCAATCTGACCTCTGACTGTGGGGCCGCCCCAGAGGGACCCAGCGGGT
GAATCCCTGCTAGGAACGTCTGTCCGGACCTCTGGTGACTGCTGGGGACGATGGCTTCCA
GCTAACTTAATAGAGAAACTCAAGCAGTTTCCTTCTAAATACACATGTCACATGTCCTGG
TTCCGGATCCTCTAGAGTCGACCTGCA------------1350 bp--------------- C
CACACAGCTGCTCCTGCTCTCCCTCCTCCAGGTGACCCCAGCCATGAGGACCCTCGCCAT
MetArgThrLeuAlal1
CCTTGCTGCCATTCTCCTGGTGGCCCTGCAGGCCCAGGCTGAGCCACTCCAGGCAAGAGC 
eLeuAlaAlalleLeuLeuValAlaLeuGlnAlaGlnAlaGluProLeuGlnAlaArgAl
TGATGAGGTTGCTGCAGCCCCGGAGCAGATTGCAGCGGACATCCCAGAAGTGGTTGTTTC 
aAspGluValAlaAlaAlaProGluGlnlleAlaAlaAspIleProGluValValValSe
CCTTGCATGGGACGAAAGCTTGGCTCCAAAGCATCCAGGTGAGAGA----- 500 bp---
rLeuAlaTrpAspGluSerLeuAlaProLysHisProG
----------GAGGTTGTTCGTGCTACCGGCTGCAATGCAGCTGCAAGCTACACCTGTCAG
CTAGCAGTGACTTCCCCGAGATTCTTTTTCTTACCCACTGCTAACTCCATACTCAATTTC
TCATGCTCTCCCTGTCCCAGGCTCAAGGAAAAACATGGCCTGCTATTGCAGAATA.CCAGC
lySerArgLysAsnMetAlaCysTyrCysArglleProAl
GTGCATTGCAGGAGAACGTCGCTATGGAACCTGCATCTACCAGGGAAGACTCTGGGCATT 
aCysIleAlaGlyGluArgArgTyrGlyThrCysIleTyrGlnGlyArgLeuTrpAlaPh
CTGCTGCTGAGCTTGCAGAAAAAGAAAAATGAGCTCAAAATTTGCTTTGAGAGCTACAGG
eCysCys
GAATTGCTATTACTCCTGTACCTTCTGCTCAATTTCCTTTCCTCATCCCAAATAAATGCC
TTGTTACAAGATTTCTGTGTTTCCACCTCTTTAATGTGTGATATGTGTCTGTGTC7iAGAC
ACTTGGGATACACGTACCAAAACGCAAAATCAAATTTTTGAACAATATAAAATTCCAAAT
T C T A G G A A T T T C A A G C A G G A G T T T G G G C T T C A G A T C C A A A T T G A A A A G A A G G C C C a T A T G
ACACCACTGATTTCCCCACCCACTGCTCTGCCTTTTCACCCTGCCTCATTTTCTCTGGA'.
CC
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Fig.29 Sequences of HNP1A splice junctions.
The sequences of HNP1A splice junctions between exon 1 
and exon 2 (E1-E2) and between exon 2 and exon 3 (E2-E3) 
are shown compared to consensus eukaryotic splice donor 
and acceptor sites proposed by Mount (1982) .
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proximal TATA like box lies 30 bp upstream from the major 
start sites of transcription. Fine mapping primer extension 
using oligo A (Fig. 30) and mRNA from CGL peripheral blood 
leukocytes and HL60P25 revealed that both TATA-like elements 
are used to initiate transcription 30 bases downstream, albeit 
at very different levels.
Initiation from the proximal promoter (PI) 
(heterogeneous, with two main sites of initiation one 
nucleotide apart, arrowed in Fig. 30) is at least 20-fold 
greater than transcription initiating from the distal promoter 
P2, as judged by densitoraetric scanning (data not shown). P2 
transcription was only detected in CGL leukocytes and not 
HL60P25 under the experimental conditions detailed in Fig. 
30. The question as to whether both PI and P2 transcripts 
originate solely from the HNP1A gene remains to be 
established, however, since the oligonucleotide (oligo A) used 
in this primer extension experiment,being common to both HNP1 
and HNP3 mRNAs, should extend on both.
(iii) 3’ Hae3 sites in HNP1A
Hae3 mapping of HNP1A and the other clone isolated during 
library screening HNP1B (shown in Fig. 27B) revealed that they 
had identical 3f Hae3 maps, with both containing a Hae3 site 
in the 3rd exon and thus encoding HNP1 defensins. This site 
results in the detection of the 350/650 bp fragment pairing 
(Figs. 27B and 31) previously seen with Hae3-digested hurn^n
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Fig.30 Both promoters of HNP1A are functional.
Primer extension with oligo A. This experiment was performed 
in a manner identical to that used in Fig.5, with the 
following modifications: 1) lOOng of 5'-end labelled oligo 
A (PRIMER) was used in each extension reaction. 2) 5pg of 
polyA+ RNA from CGL leukocytes (lane 1) or HL60P25 (lane 2) 
was substituted for the previous amounts used (10ug polyA+ 
and 50pg total cellular RNA, respectively) . The use of an 
increased amount of primer resulted in an increase in 
sensitivity such that a minor start-site of transcription in 
CGL leukocytes could clearly be detected (P2, arrowed) not 
apparent in the previous experiment (Fig.5). This species 
corresponds to initiation at a region 20-30 bases down­
stream of the distal TATA-like element shown in Fig.28. The 
main start-sites of transcription (PI) are rather hetero­
geneous and initiate 20-30 bases downstream of the proximal 
TATA-like element shown in Fig.28. DNA sequence ladders 
generated from Ml3 mpl8 were used for size estimation of the 
primer-extended material.
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DNAs. Although both HNP1A and HNPlB apparently both encode
HNP1, the clones are distinct as indicated in Fig. 27A. This 
will be discussed in Section 3.3.5.
3.3.4 Isolation of genomic clones for defensin HNP3
Since library screening had thus far isolated only HNP1- 
encoding genes, it remained to isolate genes encoding HNP3 
defensin. The knowledge that genes encoding HNP3 ought to
have a characteristic 1150bp Hae3 fragment at their 3’- coding 
regions due to their lacking a Hae3 site in their 3rd exons 
(Figs. 23, 24) aided rapid screening of clones from a new
library constructed from human leukocyte DNA. A partial
Sau3A library in EMBL3 of DNA from human leukocytes was 
constructed and screened (see Fig. 33) using the E2-E3 HNP3 
cDNA probe used previously (Fig. 27B).
Southern blots of three clones isolated from this library 
indicated that two of them encoded HNP3 (Figs. 34 and 35, lane 
6). One of these clones, HNP3B, was sequenced in the region 
of the 3rd exon and in this way shown directly to encode HNP3 
defensin (Figs. 32B, 37). Both genomic clones contain a
characteristic 1150 bp Hae3 fragment seen in human genomic 
DNAs (Fig. 31) and have their entire coding regions present on 
a 8-9 Kb BamHl fragment (Figs. 32A and B) as predicted rrom 
the result of the experiment shown in Fig.
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Fig. 31 HNP1 and HNP3 genes distinguished by 
Hae3 digestion and Southern blotting.
Approximately 0.5pg (rather more in the case of HNP3A) of 
the 8-9kb BamHl fragment of clones HNP1A, HNPlB, HNP3A and 
HNP3B were digested with Hae3, the products run on a 1.2% 
agarose gel and the gel blotted onto a Hybond-N membrane. 
The blot was then hybridized with a radiolabelled E2-E3 
defensin cDNA probe. Both HNP1 clones have a character­
istic 350/650bp fragment pairing detected with this probe, 
whilst the HNP3 clones have a characteristic 1150bp frag­
ment (see Figs.27B & 32B ) . In the cases of HNP1A 
and HNP3B this has been shown directly to be due to 
a single base change in the GGCC site (HNP1) giving a GGAC 
site (HNP3) . HNP3 clones also lack a GGCC site present in 
the second intron of the HNP1 clones as determined by 
restriction mapping (see Fig.32B) .
229
3.3.5 Two distinct: genes encode HNP3 mRNAs
Although both HNP3 clones were similar, they were not 
identical. Tig. 32A shows the restriction maps of these two 
clones. Identity of sites existed for a number of
restriction enzymes (Hind 3, Hinc 2 and EcoRl shown) mainly in 
and around the coding regions of the clones, with differences 
occuring outwith (5' to) this region. On the basis of one 
easily detected difference (Fig. 32D) in the Hind3 map
upstream of the presumptive first exon, these clones were
termed HNP3A (1450 bp El Hind3 fragment) and HNP3B (1300 bp El 
Hind3 fragment) as shown in Fig. 32A. Subsequent
reinvestigation of the two HNP1 clones isolated during the 
first library screening revealed that they too differed in 
their 5 ’ -regions and could also be distinguished by Hind3 
digestion due to a change analogous to that observed with the 
two HNP3 clones (Fig. 27A and 32D).
Returning to the HNP3 clones, using HNP3 cDNA 
oligonucleotides A, B, C and D (see Fig. 3) as hybridization 
probes to Southern blots of restriction enzyme digests of the 
HNP3A and HNP3B clones, their intron-exon structures were 
shown to be similar to that of the HNP1A gene. Thus both
clones contained three non-contiguous coding regions with a 
small upstream exon (El) present on a 500bp Hinc2-Hinc2 
fragment (Fig. 32A; B) separated from E2 by aft intron
( < 1.75kb in size) which in turn was separated from E3 
sequences by a smaller intron (Alkb in size) (data not shown).
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Fig.32 Characterization of HNP3 defensin genes.
A: Restriction maps.
Genomic clones HNP3A and HNP3B were isolated, along 
with a larger clone for HNP1A (Fig.36), as partial 
Sau3A genomic fragments (>12kb in size) cloned into 
bacteriophage lambda vector EMBL3 (Frischauf et al,
1983). For each of these 3 clones, a central 8-9kb 
BamHl fragment was isolated and restriction mapped 
with Hinc2, EcoRl and Hind3. The subscript A or J3 
refers to the position of the first Hind3 site up­
stream of exon 1 described in the text, used as a 
convention to distinguish the clones.
B: Coding regions of HNP3-encoding defensin genes.
The 3'-regions of the two HNP3 clones isolated are 
shown. Both clones were mapped at their 3'-ends 
(from the 3'-most Hae3 site in the E2 position of 
the HNP1A gene to the BamHl site at the 3'-end the 
8-9kb fragment on which the HNP3 genes reside) with Hae3. 
The map predicts a 1150bp Hae3 fragment detectable with 
the E2-E3 cDNA probe, which is observed (see Fig.31).
The HNP3B gene was partially sequenced by subclon­
ing a 3'-portion (a 2.7kb Hind3 fragment shown in 
Fig.35, lane 4 containing exon 3 and 1.5kb of 3'- 
sequence downstream of the BamHl site) into M13mpl8; 
sequencing primed with oligo D.
C and D: Southern blotting of defensin genomic clones.
C: BamHl; lpg of plasmids HNPlA/pUC8 and HNPlB/pUC8 and 
approximately 5pg of HNP3A/EMBL3 and HNP 3B/EMBL3 DNA 
were digested with BamHl, the products run on a 0.8% 
agarose gel, and the gel blotted onto a Hybond-N 
membrane. The blot was then hybridized with a radio­
labelled full-length HNP3 defensin cDNA probe.
D: Hind3; 0.5pg of the 8-9kb BamHl fragments of HNP1A, 
HNPlB, HNP3A and HNP3B were digested with Hind3, the 
products run on a 0.8% agarose gel, and the gel blotted 
onto a Hybond-N membrane. The blot was then hybridized 
with a radiolabelled HNP3 defensin El cDNA probe.
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Fig.33 Secondary plaque screening of HNP3 clones.
As described in Section 2.8.2 positive areas of 
hybridization from primary lambda EMBL3 screenings 
were replated at various tit res and plates containing 
50-100 lambda plaques screened using an E2-E3 HNP3 
cDNA radiolabelled probe. A: secondary screen iso­
lating HNP3A/EMBL3 clone (a single hybridizing plaque 
isolated and grown indicated by an arrow) . B: secondary 
screen isolating HNP3B/EMBL3 clone (a single hybridizing 
plaque isolated from this plate indicated by an arrow) . 
The other clone isolated from the primary EMBL3 library 
screen was similarly isolated through replating and 
rescreening (data not shown).
HNP3B HNP3A
234
HNP3A
HAE3 
1 2 3 4  5 6
I n
<<1150
m
Fig.34 Southern blot of HNP3A/EMBL3 clone.
Lambda clone HNP3A/EMBL3 DNA was prepared as described 
in Section 2.4.3 and lpg was digested with various 
restriction enzymes. The digestion products were run 
on an agarose gel and the gel blotted onto a Hybond-N 
membrane. The blot was then hybridized with a radio­
labelled E2-E3 HNP3 defensin cDNA probe. Lane 1, Sail; 
lane 2, BamHl/Sail; lane 3, EcoRl/Sall (star activity of 
EcoRl due to wrong buffer strength used, later shown to 
be a single 4.5kb fragment detected with this probe); 
lane 4, Hind3; lane 5, Pstl; lane 6, Hae3. This partial 
Sau3A genomic clone contains at least another 5.5Kb of 
sequence (Lane 1; genomic insert plus data net shown) 
more than the 8-9kb shown in Fig.32A.
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Fig.35 Southern blot of HNP3B/EMBL3 clone.
Lambda clone HNP3A/EMBL3 DNA was prepared as described in 
Section 2.4.3 and lpg was digested with various restriction 
enzymes. The digestion products were run on an agarose gel 
and the gel blotted onto a Hybond-N membrane. The blot was 
then hybridized with a radiolabelled E2-E3 HNP3 defensin 
cDNA probe. Lane 1, Sail; lane 2, BamHl/Sail; lane 3, 
EcoRl/Sall; lane 4, Hind3; lane 5, Pstl; lane 6; Hae3.
This partial Sau3A genomic clone contains 'at least another 
7.3kb of sequence (lane 1; genomic insert plus data not 
shown) more than the 8-9kb BamHl fragment shown in Fig.32A.
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3.3.6 Four distinct: defensin—encoding genes
Screening for HNP3-encoding genes also isolated another 
defensin—encoding clone (Fig. 36). On the basis of its
characteristic 350/650 bp Hae3 fragment pairing (Fig. 36, lane 
6) this clone encoded HNP1. Restriction mapping of the clone 
revealed that, in common with the other defensin-encoding 
genes, it too had its entire coding region contained on a 
8-9Kb BamHl fragment (data not shown and Fig. 36, lane 2). 
Furthermore, the restriction map of this fragment (with the 
restriction enzymes Hind 3, Hinc2 and EcoRl) indicated that it 
was indistinguishable from the previously isolated HNP1A clone 
(Fig. 21k).
Thus the screening of this partial Sau3A EMBL3 library, 
constructed from the DNA of one individual, resulted in the 
isolation of three distinct defensin-encoding genes, two 
enc oding HNP3, one encoding HNP1. This indicated that there 
could be at least three different defensin genes present in 
the genome of any one individual. Furthermore, a total of 
four different defensin genes had been isolated in total (see 
Figs. 27A; 32A). These four genes HNP1A, HNPlB, HNP3A and
HNP3B, although similar, are clearly distinct by restriction 
enzyme analysis of their 5’— non-coding regions (compare Hind 
3 maps Figs. 27B and 32A) and by the presence, in the cases of 
HNP1A and B, of two Hae3 sites absent in HNP3A ana B vcompare
Fig. 27B and Fig. 32B).
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Fig.36 Southern blot of HNP1A/EMBL3 clone.
Lambda clone HNP1A/EMBL3 DNA was isolated as 
described in Section 2.4.3 and lpg digested with var­
ious restriction enzymes. The digestion products were 
run on an agarose gel and the gel blotted, onto a Hybond- 
N membrane. The blot was then hybridized with a radio­
labelled E2-E3 HNP3 defensin cDNA probe. Lane 1,. Sail; 
lane 2, BamHl/Sail; lane 3,- EcoRl/Sail; lane 4, Hind3; 
lane 5, Pstl; lane 6, Hae3. This clone was isolated 
from the same library as HNP3A and HNP3E indicating that 
all 3 genes are present in the same individra]. If was 
isolated as a partial Sau3A fragment and cotca:.r.s 
at least another 5kb of sequence (lane 1; geronic in se rt 
plus data not shown) more than the G-9kh shov.rv in 
Fig.27A.
HNP1 HNP3
A C G T  A C  G T
Fig.37 Sequences of HNP1 and HNP 3 genes at Hae3 
polymorphic site.
A 2.6 Hinc2-BamHl fragment of clone HNP1A and a 2.7kb 
Hind3-Hind3 fragment (see Fig.35, lane 4) of clone 
HNP3B cloned into appropriately cut Ml 3 mpl8 were seq­
uenced through their E3 regions (see Fig.28) using oligo D 
(Fig.3) as a sequencing primer. The sequence obtained for 
HNP1A was identical to that of HNP3B apart, from one base 
change (C in HNP1A, A in HNP3B) indicated by an arrowhead 
at the relevant nucleotide. This change results in the 
presence of a Hae3 restriction enzyme site present in 
HNP1A that is absent in HNP3B and the encoding of dist­
inct defensin peptides.
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The question as to whether all these genes are functional 
remains unanswered. However, as revealed by the PCR
experiment shown in Fig. 40, at least two of the 
defensin-encoding genes must be actively transcribed.
3.3.7 Inheritance of defensin—encoding genes
Both the isolation of four distinct defensin-encoding 
genes (Section 3.3.6) and the analysis of the relative amounts 
of HNP 1 and HNP3 def ensin-encoding genes by Hae3 digestion of 
human DNAs (Section 3.3.1) implied that there were at least 
four defensin-encoding genes per diploid genome. Since two 
studies on the chromosomal localization of defensin genes 
(Wiedemann et al, 1989; Sparkes et al, 1989), had previously 
indicated that defensin genes were present only on chromosome 
8 (8p23 in the study of Sparkes et al, 1989) it seemed
reasonable to suppose that the genes were clustered. This is 
in fact known to be the case for the closely homologous rabbit 
defensin genes MCP1 and MCP2 which share with HNP1, for 
example, the same intron-exon organization and 86% homology in 
their 5T—untranslated regions (Ganz et al, 1989, discussed in
Section 4.3). The rabbit genes are tandemly duplicated and
are within 10 Kb of each other (Ganz et al, 1989).
A simple model for the organization of human defensin 
genes is that they too are tandemly duplicated (perhaps with 
the same separation between genes as with MCP1 and MCP2) ana 
that a number of alleles are present in the population, eac
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allele consisting of a tandem pair of defensin-encoding genes 
(for example HNP1-HNP1, HNP1-HNP3, HNP3-HNP3, see Fig. 38A). 
Accordingly, individuals containing, for example, only 
HNPl-encoding genes (eg. Fig. 24, lanes 4 and 5), since they 
have two copies of chromosome 8, would have two alleles each 
consisting of a pair of HNPl-encoding genes (Fig. 38A). A
prediction from this model is that since the recombination 
frequency between two defensin genes would be vanishingly 
small due to the small separation between two genes of a pair, 
inheritance of two copies of chromosome 8 should result in the 
inheritance of two pairs of def ensin-encoding genes, one pair 
derived from the mother, one pair from the father.
Fig. 38B shows that this is indeed the case. DNAs from 
a mother, father and two children were digested with Hae3 and 
a Southern blot probed with a E2-E3 cDNA probe which 
distinguishes HNP1 from HNP3 sequences. One parent (the
mother) was homozygous for HNP1 i.e. contained two alleles 
each consisting of a pair of HNPl-encoding genes. The other 
parent had a 2:2 ratio of HNP1:HNP3 genes. However, both 
children had a different pattern from either parent and 
contained a 3:1 ratio of HNP 1 : HNP 3 genes. By simple
Mendelian inheritance then they must have received a tandem 
pair of HNP1 genes (HNP1-HNP1 allele) from their mother and a 
mixed tandem pair (HNPI-HNP3 allele) from their father. 
Furthermore, if no recombination or gene conversion events 
occured in the father, this result also implies that his
c O of a HNP1-HNP3 allele rathergenotype consists of 2. copies Oj a
Fig.38 Inheritance of defensin-encoding genes.
A: Model for arrangement of de fens in-encoding genes.
In this model there are 4 de fens in-encoding genes 
per diploid cell. From the analysis of Hae3-cut 
human DNAs (see Fig.24) four distinct genotypes 
could be distinguished each having different relative 
amounts of HNP1-:HNP3- encoding seguences. Thus some 
individuals contained 4 HNP1- encoding sequences 
(4:0), some had 3 HNP1:1 HNP3 (3:1), some 2 HNP1:
2 HNP3 (2:2) and some 1 HNP1:3 HNP3 (1:3) . The model 
assumes that defensin genes are tandemly duplicated, 
as shown for the closely homologous rabbit defensins 
M2P1 and MCP2 (Ganz et al, 1989) with two copies 
contained on each chromosome 8, the sole location of 
defensin-encoding genes (Wiedemann et al, 1989; 
Sparkes et al, 1989) . For 2:2 HNP1:HNP3 ratios, two 
alternative configurations for the arrangement of 
defensin-encoding genes are possible and are shown. 
The model predicts that defensin genes should be in­
herited as a linked pair due to their proximity 
(< lOkb between M3P1 and M3P2) .
B: Inheritance of tandem pairs of defensin genes.
15jjg of genomic DNA from a mother, father and two 
children was digested with Hae3 and Southern blotted 
onto a Hybond-N membrane. The blot was then hybrid­
ized with a radiolabelled E2-E3 cDNA probe (see Fig. 
23) . This probe distinguishes HNP1- from HNP3- en­
coding sequences. The mother contained 4:0 HNP1:HNP3 
encoding sequences, the father 2:2 HNP1:HNP3 and the 
two children 3:1 HNP1:HNP3 ratios. According to the 
model both children received a HNP1-HNP1 tandem pair 
allele from their mother and a HNP1-HNP3 tandem pair 
allele from their father. This establishes their 
father as having a two copies of an allele with a 
HNP1-HNP3 tandem pair as his 2:2 HNP1:HNP3 con­
figuration.
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than one copy of an HNP1-HNP1 and one of a HNP3-HNP3, since 
neither of the children could have inherited either of these 
two alleles from their father (Fig. 38B).
This experiment then is confirmatory evidence of the 
model shown in Fig. 38A. However, it is not direct proof, 
which requires a knowledge of the long-range organization of 
the defensin genes by the cloning of a tandem pair of genes on 
lambda or cosmid clones. If the human defensin genes are in 
fact homologous to the genes for MCP1 and MCP2 isolated from 
rabbits and 10 Kb apart then with the genomic clones thus far 
isolated (HNP1A; two clones of 8Kb and approx 12Kb; HNPlB, 
8Kb; HNP3A, approx 13.5 Kb; HNP3B approx 15.3 Kb) it may be 
the case that two clones might overlap at their 3’- or 5’- 
ends. Whether this is the case is currently being addressed 
by restriction mapping of the larger genomic clones outwith 
the 8-9 Kb BamHl fragment previously mapped.
3.3.9 HNP1 and HNP3 defensin mRNAs can be distinguished utilizing 
PCR
Having established that individuals have different 
relative amounts of HNP1- and HNP3- encoding sequences it was 
decided to test whether this results in the expression of 
different relative amounts of HNP1 and hi*»P3 mhNA-s. As shown 
in Fig. 39, HNP1 and HNP3 mRNAs can be distinguished by virtue, 
of the single base difference between them resulting '-a -a., 
additional Hae3 site in HNP1 absent :.n . -.v
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Electro­
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Fig.39 Schematic representation of PCR experiment.
Defensin mRNAs present in RNA from HL60 cells or periph­
eral blood leukocytes of individuals can be amplified by 
PCR (Saiki et al, 1985) by first synthesizing cDNA primed 
by oligo D (1st Strand cDNA) and then amplifying using 
a combination of oligos B' and D (PCR) . The 27Qbp ampli­
fied fragments derived from both HNP1 and HNP3 mRNAs can 
then be distinguished from each other by digestion with 
Hae3 (Hae3 Site), since the HNP1-derived fragment contains 
a cutting site for this restriction enzyme and is digest­
ed giving two fragments of 90 and 130bp whereas the HNP3- 
derived fragment remains undigested since it lacks this 
site. Both the I30bp HNP 1-derived, fragment and the 27Qbp 
HNP3-derived fragment can be resolved by gel electrophor­
esis, Southern blotted and detected with an oligonucleo­
tide not used to amplify (oligo C).
245
HNP3 mRNAs can be amplified by PCR giving identically-sized 
double-stranded DNA fragments which, upon digestion with Hae3, 
can be distinguished on the basis of size. These fragments 
are easily detected by oligonucleotide hybridization using an 
end-labelled oligonucleotide (oligo C) not used to amplify.
3.3.10 Expression of defension mRNAs in individuals with different 
HNP genotypes
From three individuals (Fig. 40, lanes 2, 3 and 4, the 
same individuals as Fig. 24, lanes 5, 6 and 10) and from
HL60P25 cells (defensin-expression-positive), RNA and DNA were 
prepared. Fig. 40B shows a Southern blot of these DNAs
digested with Hae3 and probed with an E2-E3 cDNA probe. Lane 
1 is an individual (HL60P25 cells) with equal representation 
of HNP1- and HNP3- encoding sequences (2:2 ratio), whilst the 
individuals of lanes 3 and 4 both have 3:1 ratio of 
HNP1:HNP3. Lane 2 is an individual containing only
HNPl-encoding sequences (see Section 3.3.1 for an explanation 
of this interpretation). Fig. 40A shows the result of
amplifying defensin mRNAs present in the leukocytes of these 4 
cases. Three out of four samples amplified successfully each 
giving the expected 270 bp fragment (Fig. 40A UNCUT). 
Digestion of this fragment with Hae3 established how much of 
the total amount of this fragment is derived from each of the 
two defensin mRNAs (Fig.. 40A, Hae3 CUT).
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Fig.40 Variable expression of HNP1 and HNP3.
A: PCR Experiment.
0. 2pg polyA+ RNA from exponentially growing HL60P25 cells 
(lane 1) or lOpg total cellular RNA from the peripheral 
blood leukocytes of 3 leukaemia patients (lane 2, myelo­
fibrosis; lane 3, ANNL; lane 4, CGL) were amplified by PCR 
using oligos B' and D as described in Section 2.3.10. 
Amplified products were run on an agarose gel and a 
discrete 270bp band detected for the samples of lanes 1, 
and 4 purified and digested with Hae3 (Hae3 cut) or 
Hind3 ( to ensure complete digestion with another enzyme, 
data not shown) . Digestion products were run on a 1.5% 
agarose gel and the gel blotted onto Hybond-N. The blot 
was then hybridized with a 5'-end labelled oligo C. Lane 3 
failed to amplify in this experiment, probably due to the 
extremely low level of defensin mRNAs present in ANNL 
leukocytes ( Bimie et al. 1983 ) . In a sub­
sequent experiment (data not shown) defensin mRNAs were 
amplified successfully from this individual's leukocyte 
RNA, the result showing a pattern of expression of defen- 
sins identical to Fig.34A, lane 4 (Hae3 cut).
B: Southern Blotting of Genomic DNAs used in PCR 
Experiment.
DNA was extracted from exponentially growing HL60P25 cells 
(lane 1) or from the peripheral blood leukocytes of the 3 
individuals described in A (lanes 2, 3 and 4) as described 
in Section 2.4.1. lOug of DNAs digested with Hae3 were 
Southern blotted onto Hybond-N and the blot hybridized 
with a radiolabelled E2-E3 HNP3 defensin cDNA probe.
AUNCUT HAE III CUT
1 2 *  3  4  1 2* 3  4
2 7 0 b p
m '150bp
B
1 2* 3 4
||50bp>
650bp-i *  •  H
3 5 0 bp>
24 e
The main conclusion from this experiment was that the
individual hypothesized to contain only HNP1—encoding genes 
(Fig. 40B, Lane 2) only synthesized HNP1 mRNAs (Fig. 40A, lane 
2 UNCUT), lane 2 (Hae3 CUT). In contrast HL60P25 cells,
which contained both HNP1- and HNP3- encoding sequences (Fig. 
40B, lane 1) synthesized both HNP1 and HNP3 mRNAs 
(approximately 4-fold more HNP3 than HNP1). Interestingly,
an individual containing relatively more HNP1- than HNP3-
encoding sequences (Fig. 40B, lane 4) had a higher abundance 
of HNP1 mRNAs than an individual containing equal proportions 
of HNPl- and HNP3- encoding sequences (compare Fig. 40B, lanes 
1 and 4 and Fig. 40A, lanes 1 and 4 (Hae3 CUT)). This general 
result, that of increased abundance of a particular HNP mRNA 
in individuals containing more of that homologous HNP-encoding 
sequence, holds true for a number of other individuals 
analyzed (data not shown). However explanations other than 
their being a direct relationship between gene dosage and mRNA 
abundance exist which might explain this phenomenon and these 
will be discussed in Section 4.3.
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4. DISCUSSION
4.1 CHARACTERIZATION OF pCG14 cDNA
4.1.1 Isolation of pCG14 cDNA
The isolation of pCG14 (Wiedemann et al, 1983) and its 
subsequent characterization (this work, Section 3.1) was of 
interest from several stand-points. Firstly, the gene
encoding pCG14 was expressed in the leukocytes of CGL 
patients. As described in Section 1.5, CGL is a stem cell 
disease characterized by two phases: (i) a long chronic phase
in which unregulated myelopoiesis occurs due to a rapid 
expansion in the pool size of committed myeloid precursors 
(myeloblasts, promyelocytes and myelocytes primarily; 
Galbraith and Abu-Zahra, 1972; Moore et al, 1973; Goldman et_ 
al, 1980); and (ii) a shorter acute phase characterized by 
an arrest of leukocyte differentiation in which immature 
myeloid or lymphoid blast-like cells predominate both in bone 
marrow and in the circulation (Koeffler and Golde, 1981). 
Initially then, it was hoped that expression of the gene 
encoding pCG14 might be a useful molecular marker in the 
diagnosis of CGL. However, it was soon realized that pCG14 
gene expression was neither leukaemia-specific nor indeed 
absolutely CGL-specific (Daher et al, 1988).
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The finding that the gene encoding pCG14 was not 
expressed specifically as a cause or consequence of 
transformation in CGL, but was in fact expressed during normal 
bone-marrow-confined myelopoiesis (Birnie et al, 1984) first
indicated that pCG14 might encode a myeloid gene and that its 
isolation from CGL was a consequence of the large numbers of 
immature leukaeraic myeloid cells in the peripheral blood 
leukocytes of CGL patients. This was confirmed by Birnie et 
si (1984) and Wiedemann et al (1989) who showed that the gene 
encoding pCG14 was expressed in a differentiation 
stage-specific manner during myelopoiesis. Thus expression 
of the gene was shown to occur only in the neutrophilic 
myelocyte in normal bone marrow. During this stage of 
myelopoiesis, neut rophil-commit te d cells synthesize and 
assemble many of the key proteins found in granules which 
contribute to the functions of mature neutrophils. In the 
chronic phase of CGL, large numbers of these cells are 
produced and many end up in the peripheral blood. By using iri 
situ hybridization, the cell type expressing the pCG14 gene in 
CGL was shown to be morphologically indistinguishable from 
that expressing the gene during normal myelopoiesis i.e. the 
neutrophilic myelocyte (Wiedemann et al, 1989).
One of the first tasks undertaken (Section 3.1) was the 
complete sequencing of a PCG14 cDNA. Another cDNA clone, 
pCG32, apparently identical to pCGl4 where the clones 
overlapped (and subsequently also shown to encode HNP_> 
defensin by Hae3 restriction enzyme analysis (data not
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shown)), was also partially sequenced. Using a combination 
of primer extension, SI analysis and R M  sequencing, both 
cDNAs were shown to contain distinct foreign sequences at 
their 5 ’-ends, but were otherwise almost full-length. These 
foreign sequences were probably introduced during blunt—end 
ligation of cDNA fragments into the vector pAT153 (Wiedemann 
et al, 1983; Affara et al, 1981). The sequence of pCG14 did 
not match any sequence then present in databases and seemed to 
encode a cysteine-rich 94-amino acid protein. However, what 
this protein was and how it functioned in myeloid cells was 
unknown until the reports by Mars et al (1988) and Selsted et 
al (1985b) of the isolation and sequencing of (respectively) 
mrs and human defensins.
4.1.2 Isolation of mrs
Concurrent with the work described in Section 3.1, Mars 
et al (1988) reported the sequence of a cDNA they termed mrs 
shown to be homologous to pCG14. In the isolation of mrs, 
Mars et al (1985) used a similar approach to that of Wiedemann 
et al (1983) to isolate preferentially expressed genes in 
CGL. One clone (first termed C-A3, then mrs) was isolated 
and characterized which was found to represent an mRNA found 
at high abundance in chronic phase CGL leukocytes. In common 
with pCG14, no mrs gene expression was detectable in normal 
leukocytes or leukocytes from ANLL, ALL or CLL patients. In 
situ hybridization analysis indicated that this gene was also
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expressed at high levels in immature myeloid cells 
(promyelocytes and myelocytes) (Mars et al, 1987). The
sequence of mrs (Mars et al, 1988) indicated that it was
identical to pCG14 where the clones overlapped apart from one 
base (C in mrs, A in pCG14) and also encoded a cysteine-rich 
94-amino acid protein.
4.1.3 pCG14 and mrs encode defensins
The nascent polypeptides of pCG14 and mrs encode 
precursors of defensins HNP3 and HNP1, respectively, peptides 
involved in neutrophil antimicrobial killing (this work, 
Section 3.1.6; Selsted et al, 1985b; Wiedemann et al, 1989; 
Daher et al, 1988). These peptides are found at high
abundance in mature PMN and are discussed in Section 1.2.4. 
Both pCG14 and mrs cDNAs were also isolated by Daher et al
(1988) using an oligonucleotide probe representing defensin 
peptide sequences to probe an HL60 cDNA library. They showed 
that their cDNAs for HNP1 and HNP3 differed by a further base 
change in their 3’—untranslated regions (C in HNP1, T in HNP3) 
in a stretch of 3' sequence not cloned by Wiedemann et al
(1989) or Mars et al (1988), in addition to the coding change 
previously described. They too found that expression of
defensins was high in CGL leukocytes, but they also detected 
expression in some CLL leukaemias. However, using an
ant i-def ensin antibody this expression was localized to 
immature myeloid and not lymphoid cells (Daher et__al_, 1988).
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4.1.4 Chromosomal location of pars and pCG14 (HNP1 and 3) genes
The gene encoding mrs (HNP1 defensin) was first localized 
by Mars et al (1988) to the long arm of chromosome 8 
(8q21.1-23) using a combination of somatic cell hybrid 
analysis and in situ hybridization to metaphase chromosomes.
Using a similar approach, Wiedemann et al ( 1989) also
localized the gene encoding pCG14 to chromosome 8, but to the 
short arm rather than the long. Due to the almost 100% 
identity of the probes used in these two studies (mrs and 
pCG14 cDNAs differ by only one base) the different 
localization of the two genes is hard to explain since each 
probe should hybridize to both genes and therefore give two 
peaks of hybridization, one on each arm of chromosome 8, if 
the genes were indeed present on either arm of the 
chromosome. It seems more likely that in one of the studies 
the defensin gene(s) have been assigned to the wrong arm of 
chromosome 8. In support of the assignment of defensin
tm )
gene(s) to the short arm of chromosome 8, Sparkes et al have 
also localized mrs (HNPl) to the short arm of chromosome 8 
(8p23) using the twin methods of a mouse/human somatic cell 
hybrid panel and in situ hybridization to normal human 
metaphase chromosomes. In this study, only one strong peak 
of in situ hybridization on chromosome 8p23 was detected, 
suggesting that all defensin genes must be located in this 
region.
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4.1.5 Expression of pCG14 and pirs in vivo
The finding that both pCG14 and mrs are expressed in both 
normal and leukaeraic (CGL) myelocytes (Birnie et al , 1984;
Mars et al, 1985) is in accord with other work comparing
normal and leukaemic gene expression (see Section 1.4.3). 
Thus, in the majority of cases, the phenotypes and gene
expression of leukaemic cells are similar in many
characteristics to normal hematopoietic progenitors (Greaves 
et al, 1986). In this regard, it is interesting to note
that, in contrast to the expression of pCG14 (HNP3 defensin) 
during the chronic phase of CGL, expression during the acute
phase of the disease (blast crisis) is low or variable. Thus 
in the study of Birnie et al (1984) all (14/14) CGL patients 
in chronic phase contained defensin mRNAs in their peripheral 
blood leukocytes whilst only 1/3 patients in blast crisis
contained detectable defensin mRNAs. Similarly, Mars et al 
(1985) in a survey of CGL patients showed that 17/18 contained 
defensin mRNAs in their peripheral blood leukocytes and that 
this expression correlated with the presence of myelocytes in 
peripheral blood as evaluated by differential counts. 
Significantly, the one CGL patient in this study not 
containing detectable defensin mRNAs did not contain
myelocytes in his peripheral blood leukocytes. This study 
also investigated the presence of defensin mRNAs during blast 
crisis of CGL and produced results similar to that of Birnie 
et al (1984). Thus defensin gene expression daring blast
. • • -ui o/a individuals containing detectablecrisis was variable with z/4 individuals 6
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defensin mRNAs in their peripheral blood leukocytes (Mars et 
al^ , 1985). Interestingly, the two positive patients
peripheral blood contained myelocytes, whilst the two negative 
patients did not.
These results with blast crisis CGL are consistent with 
what is known about the differentiation stages of the 
leukaemic cells during this phase of CGL. The blast cells 
seen during the acute phase of CGL usually resemble 
myeloblasts seen in ANLL (Rosenthal et al, 1977); however in 
a number of cases they may have morphological and/or 
cytochemical features of lymphoblasts (Peterson et al, 197 6-). 
Since the normal window of differentiation of defensin gene 
expression occurs in more differentiated myeloid cells than 
myeloblasts, and expression is not found at all in the 
lymphoid lineage (Mars et al, 1987; Wiedemann et al, 1989), 
if one assumes that during blast crisis the majority of cells 
are one of these two types, the lack of/variable defensin 
gene expression observed can be understood. In the caffe of 
CGL blast crisis where defensin gene expression is detected, 
the presence of a small residual population of more mature 
myeloid cells around the myelocyte stage of differentiation 
accounts for the observed expression (Mars et al, 1985).
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4.2 DEFENSIN GENE EXPRESSION
4.2.1 Use of cell lines as model systems
Understanding the myriad changes in gene expression 
occuring daring lineage commitment and terminal maturation
occuring during normal heraatopoiesis is made difficult by both
the physical inaccessibility of the site of maturation (bone 
marrow for non-lymphoid lineages in humans) and the complex
number and organization of both hematopoietic and bone marrow
cell types as well as the underlying extracellular matrix.
At best, for example in the long-term bone marrow culture 
system of Dexter (see Section 1.1.5), if appropriate
maturation stages of a particular lineage can be identified, 
expression of particular markers can be evaluated using
specific monoclonal antibodies and the techniques of 
immunocytocheraistry. However, the underlying causes of
changes in the expression of such markers remain obscure using 
such culture systems.
Many investigators have turned to clonal cell lines 
capable of differentiation in vitro to answer questions 
relating to how individual or sets of genes are regulated 
during hematopoietic (or non-hematopoietic) differentiation. 
Amongst these are myogenic cell lines, embryonic lines,
neuronal cell lines and hematopoietic cell lines (Blau and 
Epstein, 1979; Strickland and Mahdavi, 1978; Marks and 
Rifkind, 1978; Temple and Raff, 1985; Patterson, 1978;
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Collins et al, 1977). An analysis of the changes which qcur 
during induced differentiation of these cell lines in vitro not 
only sheds light on the events leading up to terminal 
differentiation in the individual systems but can also be used 
to give a general overview of differentiation in all systems.
The main advantage of cell lines is that they allow the 
isolation of relatively pure clonal cell populations of
differentiated cells not available either in vivo or in
Dexter—type culture systems. As a result, these systems also 
enable maturation to be monitored easily as the 
differentiating cells are not surrounded by a background of 
other cell types or cells at markedly different 
differentiation stages. Cell lines which can be
differentiated also allow the process of commitment to 
differentiate to be studied since variant cell lines resistant 
to differentiation are available (Toksoz et al , 1982).
Moreover, large amounts of material for analysis, for example 
DNA, RNA and protein, are easily obtainable. Another
advantage of using hematopoietic cell lines to study 
differentiation in this system is that hematopoiesis in man 
has been well—studied and the cell biology of the different 
lineages well—characterized (Metcalf, 1971).
However, with few exceptions (see, for example, Dexter et
al, 1980; Greenberger et al^ , 1983; Hapel et— al_, 1981),
hematopoietic cell lines are derived from tumour cells and are 
therefore transformed and aberrant. Since aberrant gene
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expression is known to occur in transformed cells, it remains 
problematic whether, as a rule, control of gene expression may 
also be aberrant due to adaptation of the cells to tissue 
culture, and might therefore be expected to vary depending on 
how close culture conditions are to those encountered by the 
cells in vivo. Almost certainly for most cell lines, culture 
conditions do not reflect that of the natural in vivo 
microenvironment of the cell which may be required for normal 
growth and gene expression.
The inducing agents used to initiate differentiation of 
cell lines are often either highly non-physiological, such as 
DMSO, or are physiological agents used at concentrations far 
greater than that likely to be encountered by cells in vivo. 
These agents (with the probable exception of the CSFs 
sometimes used to effect hematopoietic differentiation in vivo 
(Koeffler, 1983)) are unlikely to reflect a normal 
differentiation signal. Furthermore, the mechanisms of
action of these agents remain, for the most part, obscure. 
Therefore it is unknown if induction of differentiation by 
chemical agents occurs by similar patterns of gene expression 
as those found in vivo. Cell lines are also immortal, with 
unlimited proliferative capacity, unlike normal cells. 
During induction of differentiation cell lines become 
committed to a specific course of differentiation. This is 
followed by a loss of immortality. Therefore many of the
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changes in gene expression observed during induction of 
differentiation may result from a shift from immortality to 
mortality, and need not necessarily represent "changes 
important in the cell’s differentiation programme*
4.2.2 Differentiation of HL60 cells as a model of myelopoiesis
The HL60 cell line affords several advantages as a model 
system in which to study differentiation. This cell line 
provides a continuous supply of apparently "maturation 
arrested" cells which can be cultured easily and indefinitely 
(Collins et al, 1977). The cells can be induced to
differentiate by readily available agents, and the progress of
differentiation can be monitored by easily measurable 
characteristics. The HL60 cell line is also a useful model 
for the study of maturation arrest itself in leukaemic
disorders. These cells provide an insight into the nature of 
leukaemic lesion(s) and are therefore useful as a means of 
analyzing the changes between normal and transformed cells. 
It is interesting to note that the drugs which are most 
effective in the treatment of patients with ANLL, such as
anthracyclines, are also potent inducers of HL60 cell 
differentiation (Schwartz and Sartorelli, 1981). It can be
speculated that the effectiveness of these drugs may be due,
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in part, to their ability to promote leukaemic cell 
differentiation as well as direct cytotoxic effect on rapidly 
proliferating malignant cells.
Uninduced HL60 cell cultures are somewhat heterogeneous, 
consisting of 90% promyelocytic cells with 10— 15% more mature 
cells of both the granulocyte and monocyte/macrophage lineages 
(Collins et al, 1977). Following addition of the inducing
agent to the growth medium, during the differentiation 
process, the cell population becomes more heterogeneous. The 
whole HL60 cell population appears to undergo a programmed 
differentiation, such that 3-5 days following the addition of 
inducing agent most cells resemble mature cells of either the 
granulocyte or monocyte/macrophage lineage depending on the 
inducing agent used. However, during the course of treatment 
with inducing agents, cells can be found distributed 
throughout the stages of the myeloid cell lineages leading to 
mature granulocytes or monocytes (Boyd and Metcalf, 1984). 
Thus intermediates between promyelocytes and granulocytes 
during induction with DMSO or retinoic acid and monocytic 
intermediates during TPA induction can be detected in culture 
(Mitchell, 1987). The cell morphologies closely reflect the 
morphologies observed during in vivo differentiation of 
myeloid cells. At the completion of differentiation,
however, the majority of cells resemble mature, terminally 
differentiated myeloid cells (Breitman et_al, 1980; Boyd and 
Metcalf, 1984).
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Heterogeneity of an HL60 cell population during the 
course of differentiation may be the result of lack of
synchrony between cells both in the position of individual 
cells in the cell cycle and also in the stage of
differentiation of each cell at the time the inducing agent 
was added. This may result in variation in the timing of the 
appearance of overt differentiation between individual cells. 
Therefore, when interpreting data pertaining to 
differentiation of HL60 cells the proportion of fully
differentiated cells has to be determined and the fact that a 
proportion of cells will always be relatively undifferentiated 
has to be noted (see Section 4.2.5).
4.2.3 Mechanisms of regulation of gene expression
The control of defensin gene expression, in common with 
other non-housekeeping eukaryotic genes, might be expected to 
be a complex affair both in vivo and during in vitro
differentiation of HL60 cells. Currently accepted models to
explain the regulation of gene expression in both eukaryotes
and prokaryotes are essentially similar (Ptashne, 1986) with 
the overriding control of gene expression in both types of
organism exerted at the t ransciptional level. Thus, the
first level of control of gene expression is generally exerted
at the transcriptional level.
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For both prokaryotes and eukaryotes the basic mechanisms 
that lead to gene activation or inactivation involve 
interaction of specific cis-acting regulatory elements in the 
DNA with trans-acting factors, which include the enzymatic 
machinery of transcription, although in eukaryotes these steps 
are inherently more elaborate than in prokaryotes, reflecting 
the relatively greater size and complexity of the eukaryotic 
genome.
So far as eukaryotic gene expression is concerned, the 
pathway of mRNA biogenesis involves several steps, all of 
which potentially offer the cell points at which gene 
expression may be regulated. These steps include
transcriptional initiation, elongation and termination, RNA 
capping, 3 ’ processing of the primary transcript, 
polyadenylat ion, splicing, nucleo-cytoplasmic transport and 
cytoplasmic stability. There is considerable evidence that 
most, if not all, of these options are used in eukaryotic 
cells. Genes for which transcriptionolinitiation, elongation 
or termination is exploited for regulation of gene expression 
are said' to be under transcriptional control, while those 
genes for which other steps are used for control of gene 
expression are under post-transcriptional control.
Transcriptional control of eukaryotic genes has 
rtoardina
fec<UVtd the most attention /\ possible levels of control of 
gene expression, Many of the cis acting sequences
responsible for normal and inducible transcription as well as
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the trans acting factors both general and specific;responsible
Ha/e Wh
for gene activation^ isolated and partially characterized 
(Maniatis et— al^ , 1987). Although eukaryotic cells possess 
three classes (1, 2 and 3) of RNA polymerase, it is almost
exclusively pol2 which trancribes genes encoding proteins. 
Evidence from in vitro transcription of cloned protein-coding 
genes indicates that RNA polymerase 2 initiates transcription 
at the mRNA cap site (Breathnach and Chambon, 1981). A 
conserved AT-rich element (TATA box), generally located 25-30 
bases from this site (Darnell, 1982), was first shown to be 
involved in regulating gene expression by directing the 
transcriptional machinery to the correct site for initiation 
by RNA polymerase 2 (Nevins, 1983). Two Similar elements are 
present upstream of the HNP1A defensin gene at appropriate 
positions to mediate transcriptional initiation from two sites 
approximately 60 nucleotides apart (Section 3.3.3).
Many other sequences have since been characterized which 
serve to modulate transcription of certain genes. Enhancer 
elements (Khoury and Gruss, 1983), themselves constructed from 
smaller sequence elements termed enhanffons (Ondek et al, 
1988), steroid hormone receptor binding sites (Beato, 1989; 
Evans, 1988), metal responsive regulatory elements (Karin et 
al, 1985) and heat-shock transcriptional regulatory elements 
(Pelham, 1984) are examples of such cis-acting transcriptional 
control sequences all under the influence of various 
trans-acting proteins some of which themselves are tissue or 
differentiation-stage specific (Scheidereit et a^ , 1988).
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A more recently described control of transcription occurs 
during transcriptional elongation itself. For both the c-myc 
(Bentley and Groudine, 1986; Eick and Bornkaram, 1986) and the 
c-my_b (Bender et al , 1987) proto-oncogenes, this novel mode of 
intragenic control has been shown to operate. For the c—myc 
gene, a specific sequence at the end of exon 1 has been shown 
to be responsible for premature termination or pausing of 
elongation (Bentley and Groudine, 1988). This mechanism of 
control may be most appropriate for genes whose control must 
be tightly coupled to cellular processes such as proliferation 
and differentiation.
Termination of transcription has been found to occur at a 
defined site in genes transcribed by RNA polymerase 2 
(Manderious and Chen-Kiang, 1984). The 3’-end of most
primary transcripts is generated by 3’ processing of the 
nascent transcript (Birnstiel et al 1985). This process 
potentially affords a point of control of gene expression 
since differential termination of transcription can generate a 
number of different mRNAs. This sort of mechanism has been 
described' for transcripts of adenovirus genes (Darnell, 1982) 
and for regulation of expression of the secreted and 
membrane-bound forms of the immunoglobulin ji-merabrane protein 
(Early et al, 1980).
The process of mRNA polyadenylation accompanies cleavage 
of the nascent transcript to form the 3'-end of the mRNA 
(Birnstiel et al, 1985). A conserved sequence AAUAAA has
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been identified 10-30 nucleotides upstream of the polyA 
addition site at the 3'-end of polyA - containing transcripts, 
and this sequence may direct or regulate mRNA cleavage and 
polyadenylation (Birnstiel et al, 1985). This sequence is
also found at the 3 '-end of the HNP1A gene (see Fig. 28) as 
might be expected since HNP1 mRNAs are polyadenylated (Daher 
et__al^ , 1988). Experiments showing a decrease in stability 
on removing the polyA tail from globin mRNA after injection 
into HeLa cells (Huez et al, 1981), have highlighted the
importance of a polyA tail to mRNA stability.
Although the initial events of mRNA biogenesis occur
rapidly, further processing of the precursor RNA is a slower
event (Nevins, 1979). Most higher eurkaryotic transcripts
undergo splicing to remove intron sequences to yield mature
mRNAs. Splicing reactions are directed by splice site
signals at the intron/exon junctions (Breathnach and Charabon, 
1981) and may be facilitated by formation of lariat RNA 
intermediates (Keller, 1984). The HNP1A gene characterized 
in Section 3.3.3 contains three exons and two introns both of 
which must be spliced out to produce a functional HNP1 mRNA. 
For the HNP1A gene, the splicing signals at the intron/exon 
junction correspond well to consensus splicing signal 
sequences proposed by Mount (1982). Splicing control is 
common in eukaryotic genes with more than one mature 
transcript often being derived from the one gene in different 
tissues (Lewin, 1985a).
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Transcript export from the nucleus to polysomes 
represents another possible level Oi control of gene 
expression. How such a control might operate is unknown, 
nor is it known whether such a process is active or passive. 
Results to date, however, suggest that only mature mRNAs enter 
the cytoplasm (Nevins, 1979). Since it seems that there is 
sequence-specific selection of transcripts for transport 
(Jacobs and Birnie, 1982; Babich et al, 1983; Fulton et al, 
1985), this step in the pathway of gene expression may afford 
an important control point.
Lastly, the rates of cytoplasmic mRNA turnover in 
eukaryotes vary widely and this is often a factor in the 
control of expression of particular genes. The half-lifes of 
some mRNAs span several hours or even days (Singer and Penman, 
1973; Volloch and Houseman, 1981). Some mRNAs, however, 
such as those encoding interferon (Raj and Pitha, 1981), 
GM-CSF (Shaw and Kamen, 1986), c-myc and c-fos (Greenberg et 
al, 1986) are relatively unstable, with a half-life in the
range of 30 min or less. Moreover, in response to
physiological and pharmacological stimuli, preferential 
stabilization (Guyett et al, 1979; Brock and Shapiro, 1983,
Raghow et al, 1987) or destabilization (Hamalainen et al,
1985; Dani et al, 1985; Raghow et al, 1986) of specific
mRNAs has been demonstrated.
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4.2.4 Changes in defensin gene expression during granulopoiesis
Induction of HL60 cells along the granulocytic lineage by 
treatment with DMSO leads to a biphasic down—regulation of 
defensin gene expression (Section 3.2.1). Thus uninduced 
HL 60P25 cells used in the experiments described in that
section synthesized defensin mRNAs (both HNP1 and HNP3, as
evaluated by PCR amplification and Hae3 digestion), whilst 
cells which had been induced to differentiate for 72 hours had 
ceased to synthesize detectable defensin mRNAs. This
down-regulation of defensin gene expression was not gradual as 
might perhaps be expected if defensin gene expression was 
strictly linked to the process of differentiation, since 
defensin mRNA abundance did not correlate linearly with the 
proportion of mature granulocytes appearing in culture 
(Section 3.2.1). Rather, defensin gene expression was
rapidly down—regulated, then re-elevated before a second, 
slower down-regulation which seemed to correlate with the
differentiation process. The kinetics of this change in
expression is similar to that seen for the change in abundance 
of c—myc mRNAs when murine erythroleukaeraia cells are induced 
to differentiate to mature erythroid cells by treatment with 
HMBA or DMSO (Lachman and Skoultchi, 1984). Thus, during
the induced differentiation of these cells a 5 to 15 -fold 
drop in c-myc mRNA levels occurs within 1 to 2 hours of 
treatment. The c-myc mRNA level then recovers to
pretreatraent levels by 12 to 18 hours and then continues to 
fall off gradually as terminally differentiated cells
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accumulate. The striking similarity between this regulation 
and the regulation of defensin gene expression suggests that 
similar mechanisms of control of gene expression may be 
operating for both genes.
In contrast to treatment of HL60 cells with DMSO, 
treatment with retinoic acid does not lead to a 
down-regulat ion of defensin gene expression. Rather a f$U 
up-regulation 32 hours after treatment is 
observed which, after 5 days of treatment, has returned to 
pre-induction levels. Thus, although the cells apparently 
differentiate normally to mature granulocyte-like cells (65% 
NBT-positive by day 5 of treatment), albeit to a lesser extent 
than with DMSO (85% NBT-positive by day 5 of treatment), 
defensin gene expression is maintained and indeed transiently 
increased during the course of induced differentiation.
However, for DMSO at least two distinct events would seem 
to be occuring. The initial down-regulat ion and subsequent 
re—elevation of expression may well be simply a result of DMSO 
treatment' and not linked in any direct way to differentiation 
of the cells. DMSO is a bipolar molecule with a high
dielectric constant which has an enormous effect on 
permeability of membranes. Phase transition temperatures of 
phospholipids are increased by DMSO treatment causing reduced 
fluidity and increased membrane stability. However, the
mechanism(s) through which DMSO operates to induce 
differentiation are obscure. One possibility is that changes
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in membrane permeability could enhance differentiation by 
altering the binding of certain factors (perhaps those 
described by Sachs (1987)) which normally initiate 
differentiation.
The striking similarity in the kinetics of c-myc 
regulation during Friend cell differentiation and defensin 
gene expression during HL60 cell differentiation induced by 
DMSO may be instructive and shed some light on how DMSO alters 
gene expression. Like c-myc in Friend cells, defensin gene 
expression is rapidly down-regulated following the addition of 
DMSO to HL60 cells in a manner not directly linked to 
differentiation. Moreover, it is known that for other cell 
lines DMSO can lead to a rapid mRNA destabilization of c-myc 
in the absence of differentiation. For example, Darling et^  
al (1989) have shown that this occurs in several diverse cell 
lines (K562 (myeloid;) Daudi and Raji (Burkitt lymphoma 
lines); CEM (T-cell lymphoblastoid cells) and L1210 (mouse 
lymphoma line)). If, as seems to be the case, the mechanism 
of this decrease in abundance of c-myc mRNA is 
post-transcriptional, then for c-myc (and also defensin) it 
seems also to be reversible, such that mRNA levels are 
re-elevated 4-12 after treatment (this work, Section 3.2.1 
Lachman and Skoultchi, 1984; Darling et al, 1989). This
re-elevation of c-myc mRNA levels seems to be absent or 
greatly attentuated in HL60 cells induced to differentiate by 
treatment with DMSO (Siebenlist et al, 1988) where the rapid
decrease of c-myc mRNA abundance is not reversible and
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probably occurs via an increase in transcriptional pausing at 
the end of exon 1 of the c-myc gene (Bentley and Groudine, 
1986; Eick and Bornkamm, 1986; Siebenlist et al, 1988).
The third facet of defensin gene expression during 
DMSO-induced HL60 differentiation is a down-regulation of gene 
expression which seems to parallel the differentiation 
process. If retinoic acid and DMSO induce differentiation of 
HL60 cells in different ways, then despite a population shift 
of HL60 cells through the myelocyte stage of differentiation 
(where the defensin genes are normally expressed) then, in 
contrast with retinoic acid-induced differentiation, gene 
expression would not seem to be up-regulated after DMSO 
treatment of HL60 cells.
In summary then, the differences in defensin gene
regulation between retinoic acid- and DMSO-induced 
differentiation may be as a result of two factors: (i) DMSO
inducing a higher proportion of HL60 cells to mature 
non-expressing granulocyte-like cells; (ii) both agents
effecting differentiation and co-ordinate gene expression in 
different ways. For retinoic acid it is possible that
additionally it may act directly to increase defensin gene
expression and thereby overcome the normal down-regulation of 
gene expression occuring with differentiation. Retinoids are 
derivatives of vitamin A, a hormone demonstrated to be 
required for normal vision, reproduction as well as 
maintenance of differentiated epithelium and mucous secretion
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in the whole animal (Goodman, 1984). It is also thought that 
retinoids play a basic role in control of differentiation and 
can suppress the malignant phenotype (Lotman, 1980) and may 
exert a hormone-like control of either or both of 
proliferation or differentiation (Sporn and Roberts, 1984). 
Retinoic acid can increase gene expression acting via specific 
nuclear receptors which bind the hormone and increase the rate 
of transcriptional initiation of retinoic acid-responsive 
genes (de The et al, 1987; Petkovich et al, 1987; Brand et^  
al, 1988). It is possible, then, that defensin genes may be 
directly responsive to this hormonal effect of retinoic acid 
independently of the indirect effect of induced HL60 
differentiation promoted by the agent.
4.2.7 Comparison of indite ing agents
The reason for this difference in regulation of defensin 
gene expression in response to different inducing agents is 
not known. At first sight it would appear to be unlikely 
that the small difference in the induction capacity of 
retinoic acid and DMSO could result in such entirely different 
regulations of defensin gene expression. Some workers have 
directly compared the efficacies of retinoic acid and DMSO at 
inducing HL60 cells to differentiate with conflicting 
results. Tsifsoglou and Robinson (1985) have reported that 
retinoic acid is apparently more effective at inducing HL60 
cells to terminally differentiate to granulocytes than DMSO. 
However, Skubitz et al (1982) have observed that DMSO-induced
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HL60 cells have a greater receptor activity for formylated 
peptides (a granulocyte marker) than retinoic acid-induced 
HL60 cells. Similarly, a report by Breitraan and Keene
(1982), demonstrated that calcium ionophore— activated 
production of leukotrienes (another marker of mature 
granulocytes) is greater in DMSO- than retinoic acid-induced 
cells. In contrast, Hemmi et al (1982) demonstrated that 
retinoic acid-induced HL60 cells appeared morphologically more 
mature at an earlier stage during induction than DMSO-induced 
HL60 cells. However, the HL60 cells used in this work
(HL60P25) reproducibly could be induced to differentiate to a 
greater extent with DMSO than with retinoic acid, using the 
ability of the cells to reduce NBT (Section 2.2.4) as an assay 
for terminally differentiated cells. In conclusion, there 
appears to be great variation in the extent of differentiation 
of HL60 cells with different inducing agents used in 
different laboratories. Since the concentrations of the
inducing agents used are all very similar,it seems reasonable 
to suppose that these inconsistencies result from differences 
in the HL60 sublines from various laboratories and/or 
differences in cell culture technique.
Many different HL60 sublines have been isolated which 
display varying degrees of resistance to induced 
differentiation (Gallagher et al, 1985). However, the
mechanisra(s) responsible for such resistance remain obscure. 
In this regard it is possible that the maintenance of defensin 
gene expression during retinoic acid—induced differentiation
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may be due to the presence in the HL60P25 line of a population 
of cells incapable of responding to retinoic acid. A second 
possibility is that retinoic acid may only induce HL60 cells 
partly along the granulocytic lineage. It is known that
during initiation of retinoic acid-induced differentiation 
HL60P25 cells are not synchronous in relation to phase of the 
cell cycle (Mitchell, 1987) and possibly stage of 
differentiation, either of which could result in some cells 
responding more quickly to the induction stimulus than 
others. Therefore, at the end of a 5-day retinoic acid
induction period those cells which responded early in the 
treatment period would display mature cell characteristics 
whilst those cells which were later in responding would still 
be at an early stage on the granulocytic differentiation 
pathway and hence w o uld retain u n i n d u c e d  cell 
characteristics. Interestingly, with the HL60P25 line,
Mitchell (1987) also observed following 5 days of incubation 
with retinoic acid 50- 60% of cells resembling granulocytes
both morphologically and biochemically. However, 30-40% of 
the cells still resembled uninduced HL60 cells or 
myelocytes. In this study, cell proliferation could still be 
observed in the HL60 cell culture after 5 days of retinoic 
acid treatment, supporting the notion that a significant 
proportion of the cells remained undifferentiated. 
Moreover, 5 day retinoic acid-induced HL60 cells invariably 
appeared less mature morphologically than 5 day DMSO-induced 
HL60 cells.
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One hypothesis, then, for the difference between DMSO and 
retinoic acid on the regulation of defensin gene expression in 
HL60 cells might be that if indeed retinoic acid leads to a 
culture of cells containing 30-40% of defensin-expression- 
positive immature cells then significant overall expression of 
defensin might still be seen by day 5 of treatment. 
Furthermore, the increase in defensin gene expression observed 
by 32 hours of incubation of retinoic acid may be real and 
reflect increased expression of defensin genes as a 
significant proportion of HL60 cells become differentiated to 
myelocyte-like cells, the cell type of highest defensin gene 
expression in vivo (Wiedemann et al, 1989; Mars et a l ,
1987). In vivo the average transit time from promyelocyte to 
myelocyte in man is 40-50 hours (Bainton, 1977) which agrees 
well with the timing seen of highest defensin gene expression 
during retinoic acid-induced HL60 differentiation. The
slower decrease in abundance of defensin mRNAs observed by day 
5 of treatment with retinoic acid may then represent a further 
shift in the population of cells to metamyelocyte and 
band-like cells for the majority of cells in culture with a 
concomitant down-regulation of defensin gene expression 
similar to that observed in vivo.
4.2.6 Control of defensin gene expression
Of a number of hematopoietic cell lines investigated 
(Section 3.2.6) only one HL60 cell line expressed human 
defens ins. Since both HNP1 and HNP3 mRNAs were found in
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HL60P25 cells (Section 3.3.9), both types of genes must
therefore have been transcribed. Defensin genes are normally
located on chromosome 8, only one copy of which is found in 
HL60 cells (Gallagher et al, 1979). InterestjV)^/^ in Southern 
blots of HL60 cells DNA digested with Hae3, direct comparison 
with identical quantities of DNA suggest that although an 
equal ratio of HNP1- to HNP3 - sequences is present there is
about 1/2 the autoradiographic signal intensity of a normal
2:2 pattern DNA (data not shown). This result should be 
treated with caution until a more quantitative test is carried 
out (for example DNA dot-blot hybridization comparing defensin 
genes to a control gene present at two copies/diploid cell in 
HL60 cells and another cell type). However, if correct it is 
of some interest since it implies that HL60 cells contain one 
HNP1 gene and one HNP3 gene, both of which seem to be actively 
transcribed. Interestingly, the relative abundance of the 
two types of defensin mRNA in HL60 cells was not equal; HNP3 
mRNAs seemed to be 3-4 fold more abundant than HNP1 mRNAs. 
The reason for this is not clear. One possibility is that 
HNP3 and HNP1 mRNAs may have inherently different 
stabilities. How might this occur? Two possibilities
present themselves. One possibility is that either or both 
of the two base changes between the two mRNAs (one in the 
3 ’-coding region, one in the 3 T-non-coding region (Section 
4.1.3)) filaj serve to stabilize HNP3 relative to HNP1 mRNA. 
Alternatively, a significant increase in the length of polyA 
tail of HNP3 mRNA may enhance its stability relative to HNP1 
mRNA as has been described for tubulin mRNA abundance during 
the cell cycle (Green and Dove, 1988).
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A more likely explanation, though, is that the genes
encoding HNP1 and HNP3 were transcribed at different rates in
HL60 cells. How this might have been effected will require a
direct comparison of the expression of HNP1 and HNP3 genes. 
This could be investigated using the isolated genomic clones 
for HNP1 and 3 described in Section 3.3. Certainly, the
limited restriction analysis of the 4 isolated defensin genes 
(Section 3.3) indicated that differences exist between the two
isolated HNP1 or HNP3 genes as well as between HNP1 and HNP3
genes in their 5 1-regulatory regions which may be responsible 
for different levels of expression.
During induced differentiation of HL60 cells only the
overall regulation of defensin gene expression was 
investigated. Since both HNP1 and HNP3 genes would seem to 
be independently regulated in uninduced HL60P25 cells as
indicated by the different mRNA abundances of HNP1 and 3, it
is possible that they were also independently regulated during 
differentiation. This question could be addressed, should a 
defensin-expressing HL60 cell line become available, using a 
PCR-based approach rather than Northern blotting to 
distinguish HNP1 from HNP3 mRNAs during differentiation. An 
analysis of the results of Section 3.2 must therefore be 
viewed as results of expression of both HNP1 and HNP3 genes.
As revealed by actinomycin D treatment of HL60 cells, 
defensin mRNAs seem to be relatively stable. Interestingly, 
a rapid transient increase in the level of defensin mRNAs
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occurred shortly (30 min) after actinomycin D treatment
(Section 3.2.2). The reason for this induction is unknown 
since actinomycin D is best known as a potent inhibitor of
transcription. A comparison of the effect of the protein 
synthesis inhibitor cycloheximide on c-myc RNA levels may be 
instructive. In this case, cycloheximide treatment of cells 
leads to a super-induction of c-myc gene expression during 
mitogenic stimulation of lymphocytes (Kelly et al , 1983). In 
this case a labile negative regulator protein was invoked to 
explain the effect of a protein synthesis inhibitor on c-myc 
gene expression. However, both the extreme rapidity and
transience of the effect on defensin gene expression would 
argue against such a protein regulator being involved. How 
actinomycin D might rapidly and transiently increase defensin 
gene expression as seems to be the case may merit future
studies.
Nuclear run-on experiments with uninduced HL60P25 cells 
indicated that defensin genes are transcribed at a low level 
in these cells (Section 3.2.2). Again with this technique, 
transcription of the HNP1 gene was not distinguished from the 
HNP3 gene. However such an analysis, even if technically 
possible, would have been difficult to perform due to the low 
level of transcription seen in HL60P25 cells. Most probably 
the down-regulation of defensin gene expression seen during 
the latter part of DMSO-induced HL60 differentiation reflects 
a decrease in the transcription of defensin genes, but this 
awaits direct proof.
281
4.2.7 Loss of defensin gene expression
The loss of defeasin gene expression on reculture at a
later date of a new batch of frozen and rethawed HL60P25
cells, HL60P25(1) (Section 3.2.5), is one of the more puzzling
results in the work described in Section 3.2. It seems that
the defensin genes are still retained in HL60P25(1) (data not
shown) and therefore the loss of defensin gene expression is
not simply due to a gross deletion of defensin sequences.
There are, however, other possible reasons for the observed
loss of defensin gene expression. The first possibility is
that in the intervening period between experiments with
HL60P25 and HL60P25(1) some aspect of cell culture was
changed. For both medium and serum used to culture the cells
this is unlikely since the same manufacturer (Gibco) was used
for both medium and serum in both sets of experiments.
However, differences between batches of either of these two
constituents cannot be ruled out as a variation between
{
culture conditions. Alternatively, growth of a culture of 
HL60P25(1) may have selected for a clone of cells not 
expressing defensin genes. This is a distinct possibility 
bearing in mind that there is no positive selection for HL60 
cells expressing defensins since the peptides have no 
documented role in cell viability or proliferation (see 
Section 1.2.4-6).
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Any mechanism pertaining to lack of expressing must, 
however, account for the loss of expression of both (or 
possibly 4) defensin genes in HL60 cells, since the different 
levels of gene expression of HNP1 and 3 indicate that they are 
independently regulated. Investigation of the raethylation
status of the defensin genes in HL60P25(1) may help to rule 
out gene inactivation via methylation as the mechanism of loss 
of defensin gene expression (Jackson and Felsenfeld, 1985).
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4.3 CHARACTERIZATION OF DEFENSIN GENES
4.3.1 Hae3 restriction analysis of human DNAs indicates the presence
of at least 4 defeasin genes/diploid cell
The occurence of a single coding change between defensin 
cDNAs encoding HNP1 and HNP3 (this work, Section 3.3.1; Daher 
et al 1988) and the realization that this was a possible way 
to distinguish HNP1 from HNP3 genes (this work, Section 
3.3.1), by virtue of the presence or absence of a cutting site 
for the Hae3 restriction enzyme, provided the first insight 
into the structure and copy number of human defensin genes 
(Section 3.3.1). Thus prior to any knowledge of the fine 
structure of defensin genes, individuals could be shown to 
contain variable relative amounts of HNP1 and HNP3 genes and a 
hypothesis proposed in which individuals contained a total of 
4 defensin genes, two per chromosome 8.
In a total of 32 human DNAs analyzed, individuals could 
be placed into one of four groups, depending on their relative 
amounts of HNP1 and HNP3 genes. Thus some individuals (16%) 
contained only HNP1 genes, about twice this number (31%) 
contained three HNP1 genes and one HNP3 gene, most individuals 
(41%) contained two HNP1 and two HNP3 genes whilst a small 
number (12%) contained one HNP1 gene and three HNP3 genes. 
Interestingly, no individuals were found out of a total of 32 
analyzed that contained only HNP3 genes.
284
The strength of an analysis of defensin genotypes using 
the Hae3 restriction enzyme to distinguish HNP1 from HNP3 
genes was firmly underscored by the demonstration (Section 
3.3.7) that defensin genes are inherited in pairs. Thus it 
could be shown that a parent containing only HNP1 genes passed 
on one pair of these to each of two offspring in a manner 
consistent with the hypothesis that human defensin genes are 
closely linked as a tandem pair and therefore co-inherited.
A more extensive analysis using DNAs from a large family 
tree or several families, however, is required to prove the 
generality of this inheritance.
4.3.2 Characterization of an HNP1 defensin gene
The first defensin genes isolated from human DNA 
libraries encoded HNP1 defensin. The two genes were isolated 
from two individuals and shown by restriction analysis to have 
distinct 5 f-regulatory sequences but great similarity in their 
coding regions (Section 3.3.2). On the basis of one easily 
detected Hind3 polymorphism the genes were termed A or B and 
the HNP1A gene investigated in detail.
The HNP1A was found to be split into three exons 
separated by two introns. Exon 1 of the HNP1 gene was found 
to be non-coding, with exons 2 and 3 encoding the nascent HNP1 
defensin precursor. Both by Hae3 restriction enzyme analysis 
and by sequencing, the gene was shown to encode HNP1.
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Sequencing of 239 bp of the upstream region of the HNP1A 
gene revealed the presence of two promoters containing 
> both of which seem to be functional since 
they serve to initiate transcription 30 bases downstream (PI 
and P2 transcripts). The proximal promoter PI is the
stronger of the two and serves to initiate transcription over 
a 2 or 3 nucleotide region (Section 3.3.3). The reason for 
the presence of two promoters is unknown but it is also a 
characteristic of the rabbit defensin genes MCPl and MCP2 
(Ganz et al, 1989). At least for MCP2, both TATA boxes may
also be functional as suggested by the existence of two 
classes of cDNA clones with 5 T-termini positioned 
appropriately by the two promoters (Ganz et al, 1989).
Continuing the analogy with rabbit MCP defensin genes, 
HNP1 shares the same intron-exon organization as the rabbit 
genes, although the sizes of the rabbit MCP introns are 
somewhat smaller (500 bp and 600 bp) than the equivalent HNP1A 
introns (1500 bp and 650 bp). Like HNP1A, the first exon of 
the rabbit MCP genes is non-coding, with exons 2 and 3 
encoding the MCP precursor protein. Interestingly, a
comparison of MCPl or MCP2 cDNAs with those encoding HNP1 or 3 
(Ganz et al, 1989), shows a 61%-64% overall homology between
the sequences. Moreover, a 110 nucleotide region of 86% 
homology occurs which includes the 5 ’-untranslated region 
(exon 1 of HNP1A or MCPl and 2) and 73 nucleotides of HNP1A 
exon 2 (encoding 20-residues of the defensin precursor). The 
hydrophobicity of this 20-residue peptide has prompted some
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authors to suggest that it represents a signal sequence which 
is cleaved during proteolytic processing to produce mature 
defensin peptides (Daher et al, 1988; Ganz et al, 1989).
If this is correct it implies that at least two processing 
events must occur during the maturation of defensin peptides: 
(i) removal of a signal peptide and; (ii) removal of a 
residual 44 residues to give the mature HNP1 or HNP3 
peptide. If a myeloid cell line expressing defensins could 
be found, the occurence of such processing steps could be 
tested by both pulse-labelling and pulse-chase experiments 
utilizing the anti-defensin antiserum used in Section 3.1.7 to 
immunoprecipitate defensin precursors. Whatever the function 
of the first 20 residues of the defensin precursor, its 
sequence conservation between HNP and MCP precursors suggests 
that it is required for the production of both human and 
rabbit defensins.
4.3.3 Isolation of 4 different defensin genes
Subsequent to the isolation of the two different HNP1 
genes, three more defensin genes were isolated by screening a 
single genomic library (Sections 3.3.4 and 3.3.5). One of
these was shown by restriction mapping to be indistinguishable 
from the previously isolated HNP1A gene, the other two by Hae3 
restriction enzyme analysis shown to encode HNP3.
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The two HNP3 genes were restriction mapped and shown to 
have distinct 5'-regulatory regions but great similarity in 
their coding reglflns. Interestingly, the two genes had the 
same upstream Hind3 polymorphism as the two HNP1 genes and 
were thus also termed A or B. As yet the two genes encoding 
HNP3 have not been analyzed in as much detail as the HNP1A 
gene. However, both genes lack a second 3 f Hae3 site present 
in their putative second introns compared to HNP1 genes as 
well as the Hae3 site which results from their encoding
HNP3. Of special interest will be the promoters of HNP3 
genes where a comparison with HNP1 genes will shed light on 
how the two genes are expressed at different levels (Section 
4.2.6).
If, as seems to be the case by analogy with rabbit MCPl
and 2 genes, human defensin genes are tandemly duplicated, it
is of interest how they might be organized. For the four 
defensin genes isolated it is presently unknown which genes
are allelic (i.e. present at equivalent positions on different 
copies of the same chromosome) and which non-allelic (i.e. 
present at different positions on the same chromosome). 
Stated this way allelic genes would be expected to be more 
alike than non-allelic genes. To satisfactorily answer this 
question, a more complete sequence analysis of the four 
defensin genes would be required.
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4.3.4 HNP genotype influences relative abundance of HNP1 and 3 mRNAs
A number of important issues are raised by the finding of 
different HNP genotypes amongst individuals (Section 3.3.1). 
The first issue is how variable relative amounts of HNP1 and 
HNP3 genes affect the relative abundances of HNP1 and 3 
mRNAs. This issue was addressed in Section 3.3.9 using a 
PCR-based approach and Hae3 digestion to distinguish HNP1 from 
HNP3 mRNAs. Interestingly, it was found that an individual 
containing only HNP1 genes expressed only HNP1 mRNAS. Thus a 
small percentage (16%) of individuals might be expected to 
only express HNP1 peptides. Furthermore, it was found that 
individuals containing relatively more HNP1 genes expressed 
relatively more HNP1 mRNAs. However, a measure of caution
should be expressed about this latter interpretation. In the 
experiment described in Section 3.3.9, RNA for determination 
of the relative abundance of HNP1 and HNP3 mRNAs, with the 
exception of that derived from HL60 cells, was derived from 
mixed populations of leukocytes for which data on the relative 
expression of HNP1 and HNP3 genes is not available. Thus it 
can be imagined that increased expression of the HNP1 genes, 
for example, may be a consequence of the particular leukocyte 
population chosen and not be directly related to the relative 
amount of HNP1 compared to HNP3 genes if the HNP1 gene was 
expressed at a higher level in such a leukocyte population.
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A second issue arising from this result and the results 
of Section 3.3.1 concerns the biological consequences, if any, 
of expressing only one defensin peptide (in the case of HNP1 
homozygotes) or relatively more HNP3 than HNP1 peptide (in the 
case of individuals containing 1:3 ratios of HNP1:HNP3 
genes). As detailed in Section 1.2.5, in several different 
assays investigating the relative activities of defensin 
peptides, HNP1 has been shown to have greatest activity, HNP2
less and HNP3 least or none (Ganz et al, 1985; Lehrer et al,
1988b; Territo et al, 1989). Simplistically, one might
expect individuals expressing only HNP1 peptides not to be 
disadvantaged whilst individuals expressing only HNP3 
peptides may be. However this analysis ij3 simplistic and 
does not take into account the HNP2 peptide which is almost as 
active as HNP1 and may be derived from either or both of HNP1 
or 3. If HNP2 defensin can be derived from HNP3, then the 
presence of relatively more HNP3 genes might not be expected 
to be disadvantageous. In this regard, it is of interest to 
know why HNP3 genes occur at all since HNP1 genes would seem 
to provide adequate protection in the form of HNP1 (and HNP2?) 
peptides.' If a coding change converting an HNP1 to an HNP3 
gene was genetically neutral one might expect several other
changes in the coding and non-coding structural regions of 
defensin genes, which is not found. It would seem therefore 
that the HNP3 genotype has been fixed and must be of some
purpose. Just what functions the HNP3 peptide can perform, 
however, remain to be established.
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4.4.5 Hypothesis for the evolution of HNP1 and HNP3 genes
The above argument presupposes that HNP3 genes are 
derived from HNP1 genes. Is there any evidence for this? 
The occurence of homozygotes containing only HNP1 genes and 
the relative infrequency of individuals containing 1:3 ratios 
of HNP1:HNP3 genes is consistent with the ancestral defensin 
gene being of the HNP1 type. Fig. 41 shows a model of how 
the present HNP genotypes may have arisen. The first event
in such a scheme is that of gene duplication. Such an event 
is common in eukaryotes with many genes, for example, the 
interferons and globins, occuring in clusters deriving 
initially from gene duplication (Lewin, 1985b). Following 
duplication, at least one of the genes is free to collect 
mutations some of which may become fixed. In the case of 
defensin genes, one such mutation which may have become fixed 
was that converting an HNP1 to an HNP3 gene. Such a change 
can create chromosomes containing an HNP1-HNP3 tandem pair. 
How might one then create a chromosome with an HNP3-HNP3 
tandem pair, seen in a small number of individuals? For 
genes occuring in clusters some interesting molecular 
mechanisms operate both to spread mutations and to homogenize 
gene sequences, the result being a process called concerted 
evolution (Lewin, 1985b; Hartl and Clarke, 1989). A good
comparison is with the human globin genes (Maniatis, 1980). 
For example, humans have duplicated <X-globin genes encoding 
identical proteins and there is only a single amino acid 
difference between the two human 15 -globin proteins. How do
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POINT MUTATION 
^  3
M/
GENE CONVERSION/ 
UNEQUAL CROSSING-OVER 
3
Fig.41 Hypothesized evolution of defensin genes.
There are two varieties of human defensin genes (HNP1 and 
HNP3) . On the basis of the present allele frequencies of 
tandem pairs of defensin genes (i.e. HNP1-HNP1, HNP1-HNP3, 
HNP3- HNP3), it is hypothesized that the ancestral defensin 
gene was of the HNP1 type. Subsequent duplication of this 
gene led to the presence of tandem pairs of HNP1 genes 
(DUPLICATION) . One gene of the tandem pair was free to 
collect mutations, one of which (the nucleotide substitution 
C->A converting HNP1 to HNP3) became fixed (POINT MUTATION) . 
To bring about the relatively rare HNP3-HNP3 tandem pair 
allele it is hypothesized that either gene conversion or 
two or more rounds of unequal crossing-over converted a 
HNP1-HNP3 allele into a HNP3-HNP3 allele (GENE CONVERSION/ 
UNEQUAL CROSSING-OVER).
292
these sequences remain so similar if one accepts that both are 
not under selective pressure in order to produce enough 
functional protein? Two general types of mechanism which 
maintain identity of gene sequences are gene conversion and 
unequal crossing-over (Hartl and Clarke, 1989). Gene
conversion is a process whereby nucleotide pairing between two 
sufficiently homologous genes is accompanied by the loss of 
all or part of the nucleotide sequence in one gene and its 
replacement by a replica of the nucleotide sequence of the 
other gene. Formally, the result is that the sequence in one 
gene converts the sequence in the other gene to be exactly 
like itself. An example of the frequency of such conversion 
may be the presence of a particular p-thalasseraia nonsense 
mutation (p-globin gene p39(CAG-TAG))which £S present on nine 
different j5-thalassemia chromosomes in a Sardinian population 
(Pirastu et al, 1987).
Concerted evolution can also occur by means of unequal 
crossing-over. In tandem gene families, misaligned pairing 
of the genes during meiosis can occur and crossing-over 
results in gametes that can have either an increase or a 
decrease in copy number. Thus, a subsequent crossing-over 
can either correct the copy number or increase it further. 
Formally, the final result is genetically equivalent to gene 
conversion because the nucleotide sequences of some members of 
the raultigene family have been replaced with the nucleotide 
sequences of other members. At the same time that unequal 
crossing-over increases the variance in copy number, it acts 
to homogenize the members of the family.
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By comparing the sequences of defensin genes one should 
be able to judge whether they are indeed subject to concerted 
evolution. If they are, one should not see the accumulation 
of silent site substitutions between them because the 
homogenization process applies to these as well as to the 
replacement sites. However, apparent spreading of the HNP3 
base change to both copies of the defensin gene present on one 
chromosome suggests that such mechanisms of concerted 
evolution may have acted on defensin genes in the past.
With the rather small number of individuals (12%) 
containing an allele with an HNP3-HNP3 tandem pair the absence 
of individuals (out of 32 tested) with an HNP3 homozygous 
genotype becomes easier to understand. Thus if this
proportion of individuals is representative of the frequency 
of the HNP3-HNP3 allele, one would expect the frequency of 
HNP3 homozygotes to be in the region of 1/270 (i.e. 1/4 X 0.12 
X 0.12) and thus be unlikely to be present in the small sample 
size (32) of individuals analyzed.
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